
<html lang="en"     class="pb-page"  data-request-id="7b81a550-352c-4644-91e8-996e4b5242ee"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2017.60.issue-13;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.7b00316"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site" /></meta><meta name="dc.Creator" content="Marcel  Günther" /></meta><meta name="dc.Creator" content="Jonas  Lategahn" /></meta><meta name="dc.Creator" content="Michael  Juchum" /></meta><meta name="dc.Creator" content="Eva  Döring" /></meta><meta name="dc.Creator" content="Marina  Keul" /></meta><meta name="dc.Creator" content="Julian  Engel" /></meta><meta name="dc.Creator" content="Hannah L.  Tumbrink" /></meta><meta name="dc.Creator" content="Daniel  Rauh" /></meta><meta name="dc.Creator" content="Stefan  Laufer" /></meta><meta name="dc.Description" content="Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer. Acquired resistance compromises the clinical efficacy of EGFR inh..." /></meta><meta name="Description" content="Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer. Acquired resistance compromises the clinical efficacy of EGFR inh..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 21, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00316" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00316" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00316" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00316" /></link>
        
    
    

<title>Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00316" /></meta><meta property="og:title" content="Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0019.jpeg" /></meta><meta property="og:description" content="Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer. Acquired resistance compromises the clinical efficacy of EGFR inhibitors during long-term treatment. The recently discovered EGFR-C797S mutation causes resistance against third-generation EGFR inhibitors. Here we present a rational approach based on extending the inhibition profile of a p38 MAP kinase inhibitor toward mutant EGFR inhibition. We used a privileged scaffold with proven cellular potency as well as in vivo efficacy and low toxicity. Guided by molecular modeling, we synthesized and studied the structure–activity relationship of 40 compounds against clinically relevant EGFR mutants. We successfully improved the cellular EGFR inhibition down to the low nanomolar range with covalently binding inhibitors against a gefitinib resistant T790M mutant cell line. We identified additional noncovalent interactions, which allowed us to develop metabolically stable inhibitors with high activities against the osimertinib resistant L858R/T790M/C797S mutant." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00316"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00316">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00316&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00316&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00316&amp;href=/doi/10.1021/acs.jmedchem.7b00316" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 5613-5637</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00282" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00338" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marcel++G%C3%BCnther">Marcel Günther</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jonas++Lategahn">Jonas Lategahn</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Juchum">Michael Juchum</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eva++D%C3%B6ring">Eva Döring</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marina++Keul">Marina Keul</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julian++Engel">Julian Engel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hannah+L.++Tumbrink">Hannah L. Tumbrink</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Rauh">Daniel Rauh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-1970-7642" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Laufer">Stefan Laufer</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-6952-1486" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Institute of Pharmaceutical Sciences, Pharmaceutical and Medicinal Chemistry, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Straße 4a, 44227 Dortmund, Germany</span></div><div class="corresp-info"><strong>*</strong>Phone: (+49)7071-2972459. Fax: (+49)7071-295037. E-mail: <a href="/cdn-cgi/l/email-protection#f487809192959ada989581929186b4819a9dd9808191969d9a93919ada9091"><span class="__cf_email__" data-cfemail="2556514043444b0b49445043405765504b4c08515040474c4b42404b0b4140">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00316&amp;href=/doi/10.1021%2Facs.jmedchem.7b00316" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 5613–5637</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 12, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 February 2017</li><li><span class="item_label"><b>Published</b> online</span>21 June 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 July 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00316" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00316</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5613%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMarcel%2BG%25C3%25BCnther%252C%2BJonas%2BLategahn%252C%2BMichael%2BJuchum%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D13%26contentID%3Dacs.jmedchem.7b00316%26title%3DTrisubstituted%2BPyridinylimidazoles%2Bas%2BPotent%2BInhibitors%2Bof%2Bthe%2BClinically%2BResistant%2BL858R%252FT790M%252FC797S%2BEGFR%2BMutant%253A%2BTargeting%2Bof%2BBoth%2BHydrophobic%2BRegions%2Band%2Bthe%2BPhosphate%2BBinding%2BSite%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5637%26publicationDate%3DJuly%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00316"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6199</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">49</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00316" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Marcel&quot;,&quot;last_name&quot;:&quot;Günther&quot;},{&quot;first_name&quot;:&quot;Jonas&quot;,&quot;last_name&quot;:&quot;Lategahn&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Juchum&quot;},{&quot;first_name&quot;:&quot;Eva&quot;,&quot;last_name&quot;:&quot;Döring&quot;},{&quot;first_name&quot;:&quot;Marina&quot;,&quot;last_name&quot;:&quot;Keul&quot;},{&quot;first_name&quot;:&quot;Julian&quot;,&quot;last_name&quot;:&quot;Engel&quot;},{&quot;first_name&quot;:&quot;Hannah&quot;,&quot;last_name&quot;:&quot;L. Tumbrink&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Rauh&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Laufer&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;21&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;5613-5637&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00316&quot;},&quot;abstract&quot;:&quot;Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer. Acquired resistance compromises the clinical efficacy of EGFR inhibitors during long-term treatment. The recently discovered EGFR-C797S mutation causes resistance against third-generation EGFR inhibitors. Here we present a rational approach based on extending the inhibition profile of a p38 MAP kinase inhibitor toward mutant EGFR inhibition. We used a privileged scaffold with proven cellular potency as well as in vivo efficacy and low toxicity. Guided by molecular modeling, we synthesized and studied the structure–activity relationship of 40 compounds against clinically relevant EGFR mutants. We successfully improved the cellular EGFR inhibition down to the low nanomolar range with covalently binding inhibitors against a gefitinib resistant T790M mutant cell line. We identified additional noncovalent interactions, which allowed us to develop metabolically stable inhibitors with h&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00316&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00316" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00316&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00316" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00316&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00316" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00316&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00316&amp;href=/doi/10.1021/acs.jmedchem.7b00316" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00316" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00316" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00316%26sid%3Dliteratum%253Aachs%26pmid%3D28603991%26genre%3Darticle%26aulast%3DG%25C3%25BCnther%26date%3D2017%26atitle%3DTrisubstituted%2BPyridinylimidazoles%2Bas%2BPotent%2BInhibitors%2Bof%2Bthe%2BClinically%2BResistant%2BL858R%252FT790M%252FC797S%2BEGFR%2BMutant%253A%2BTargeting%2Bof%2BBoth%2BHydrophobic%2BRegions%2Band%2Bthe%2BPhosphate%2BBinding%2BSite%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D13%26spage%3D5613%26epage%3D5637%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (5)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292253" title="Imidazoles">Imidazoles</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/jmcmar.2017.60.issue-13/20170713/jmcmar.2017.60.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer. Acquired resistance compromises the clinical efficacy of EGFR inhibitors during long-term treatment. The recently discovered EGFR-C797S mutation causes resistance against third-generation EGFR inhibitors. Here we present a rational approach based on extending the inhibition profile of a p38 MAP kinase inhibitor toward mutant EGFR inhibition. We used a privileged scaffold with proven cellular potency as well as in vivo efficacy and low toxicity. Guided by molecular modeling, we synthesized and studied the structure–activity relationship of 40 compounds against clinically relevant EGFR mutants. We successfully improved the cellular EGFR inhibition down to the low nanomolar range with covalently binding inhibitors against a gefitinib resistant T790M mutant cell line. We identified additional noncovalent interactions, which allowed us to develop metabolically stable inhibitors with high activities against the osimertinib resistant L858R/T790M/C797S mutant.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67666" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67666" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The epidermal growth factor receptor (EGFR), a member of the ERBB receptor tyrosine kinase family, is a transmembrane protein modulating cell growth, proliferation, migration, and cell survival.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Pathologically increased EGFR activity is closely linked to tumorigenesis and tumor cell growth in general and has been identified as a key driver for the onset and progression of non-small cell lung cancer (NSCLC) in particular.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Mutations in the EGFR kinase domain that cause an increased and ligand-independent catalytic activity, so-called activating mutations, have been identified as oncogenic drivers for NSCLC.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> These activating mutations ultimately lead to an “oncogene addiction”, meaning the survival of these particular tumor cells is highly dependent on the EGFR signaling. Thus, blockage of the EGFR signaling with either tyrosine kinase inhibitors (TKIs) or monoclonal antibodies (mAb) is a validated principal to inhibit cell growth in EGFR mutant NSCLC. Several activating mutations have been identified in patients, however, the majority of patients harbor a single-point mutation in exon 21, the L858R mutation or the exon 19 deletion, del746_A750.<a onclick="showRef(event, 'ref2 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref4">(2, 4)</a> Patients bearing one of these activating mutations generally respond well (50–80%) to a therapy based on first-generation EGFR inhibitors (gefitinib or erlotinib), and these responders show significant tumor shrinkage in the clinic (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> Suddenly, patients who have initially responded well to a TKI therapy develop secondary drug resistances during long-term treatment.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In approximately 60% of cases, the secondary mutation T790M has been identified in resistant patients.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> First-generation EGFR inhibitors show low inhibitory activity for this mutant as well as for the double-mutant L858R/T790M, which indicates that this so-called gatekeeper mutation is the most abundant cause for tumor relapse in patients who initially responded well to first-generation EGFR inhibitors. T790M has mainly two effects: significantly increased binding affinity of ATP to this mutant protein and the increased spatial requirement of methionine, compared to threonine, causes steric clashes with the 3-chloro-4-fluoroaniline residue of gefitinib.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Second-generation EGFR inhibitors, e.g., afatinib, have been designed to overcome T790M resistance by a covalent interaction with the protein.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> Thus, these compounds bear acrylamide moieties as Michael acceptors that can undergo Michael addition reactions with the thiol group of a noncatalytic cysteine (Cys797). This additional covalent interaction restores inhibitory activity while increasing target residence time. Both effects result in significant tumor growth inhibition in preclinical settings. However, the clinical efficacy of second-generation EGFR inhibitors was unsatisfying. Because second-generation EGFR inhibitors are nonselective with respect to EGFR mutant inhibition, they are potent cellular EGFR wild-type (wt) inhibitors as well. As a consequence, these inhibitors showed dose limiting toxic side effects which have been directly linked to wt inhibition, resulting in low tolerable, subtherapeutic concentrations in the clinic.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> Third-generation EGFR inhibitors, e.g., osimertinib<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> or <i>N</i>-(3-((5-chloro-2-((2-methoxy-4-(4-methyl-1-piperazinyl)phenyl)amino)-4-pyrimidinyl)oxy)phenyl)-2-propenamide, <b>85</b> (WZ4002<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a>), have been designed to overcome T790M resistance by (i) employing novel scaffolds, while (ii) sparing the wild-type to circumvent toxic side effects and (iii) covalent alkylation of the reactive cysteine.<a onclick="showRef(event, 'ref15 ref17'); return false;" href="javascript:void(0);" class="ref ref15 ref17">(15, 17)</a> Because third-generation EGFR inhibitors activity is merely based on their covalent interaction with the protein, these compounds are highly vulnerable for a Cys797 mutation. Because this amino acid is noncatalytic and not conserved, it is not surprising that a C797S mutation has been identified to be one of the key drivers for osimertinib resistance in the clinic.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> We previously reported a small series of EGFR inhibitors based on a trisubstituted imidazole core as potent inhibitors that retain activity toward the cysteine mutant EGFR variant.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In contrast to third-generation EGFR inhibitors, our compounds occupy a hydrophobic region (HR I) in the back of the ATP binding pocket, whose access is limited by the respective gatekeeper residue. As shown by Engel, Becker, et al., additional interactions between compounds and the ATP binding site reduce dependence on the covalent interaction for inhibitory activities and in consequence yields efficiency against EGFR-C797S.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Following this concept, we herein present insights into the SAR of trisubstituted pyridinylimidazoles as EGFR inhibitors. With the help of modular and flexible organic synthetic strategies, we gained a deep understanding of a variety of substituents in different positions of this structure class. Following an iterative process from molecular modeling over synthesis to biological testing and back, allowed us to find an ideal attachment point for a Michael acceptor, able to inhibit the enzymatic activity of EGFR-L858R/T790M in an irreversible manner. We studied the influence of aromatic and aliphatic groups that can occupy HR I, aromatic residues occupying HR II, and different H-bond donors as well as acceptors that increase the inhibitory activity by interactions with the phosphate binding site (PB). In sum, the additional interactions mentioned above separate our newly synthesized compounds from third-generation inhibitors in terms of interaction profile and result in effective inhibition of the osimertinib-resistant L858R/T790M/C797S EGFR mutant variant.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0001.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. First-, second-, and third-generation EGFR inhibitors and their binding modes: (A) Two-dimensional binding mode of osimertinib found in the X-ray structure compared to pyridinylimidazoles based on our molecular model. HR, hydrophobic region; PB, phosphate binding site; PFG, pocket-filling group. (B) Difference between the dihedral angle of gefitinib and a vicinally substituted imidazole. (C) Generations of EGFR inhibitors occupying the ATP binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70027" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70027" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Rational Design of EGFR Inhibitors</h3><div class="NLM_p">Starting from lead compound <b>1</b>,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> we performed a rational design approach guided by molecular modeling. Docking studies predicted a bidentate hinge binding motif between the 2-aminopyridine moiety of compound <b>1</b> and Met793 when docked into an X-ray structure of EGFR-L858R/T790M (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Moreover, in this predicted binding mode, the 4-fluorophenyl residue extended deep into HR I, occupying this hydrophobic pocket. The phenyl ring of the aniline moiety was located in HR II. Because lead compound <b>1</b> bears a small methyl residue attached to the sulfur in the imidazole C2 position, it does not interact with the PB in our docking studies. On the basis of this model, we first studied possible substituents in the imidazole C2 position to interact with the PB, thus increasing the inhibitory activity of the resulting compounds.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0002.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Proposed three-dimensional (left) and two-dimensional (right) binding modes of lead compound <b>1</b> in PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>. Hydrogen bond acceptors are depicted as red arrows and hydrogen bond donors as green arrows. Hydrophobic interactions are depicted as yellow spheres (3D model) or yellow brackets (2D model).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">We synthesized compounds bearing different substituents at the imidazole C2 position, keeping the aniline moiety at the pyridine C2 position unchanged. To evaluate the possibility for polar interactions with the phosphate-binding site and to study the structure–activity relationship (SAR), we initially synthesized several derivatives with the capability to form additional hydrogen bonds, both as acceptors as well as donors.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Our docking model revealed a distance of 7.5 Å between the sulfur atom of lead compound <b>1</b> and the sulfur atom of Cys797 with an angle of roughly 90° based on the imidazole carbon–sulfur bond (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Hence, we investigated the possibility of attaching a Michael acceptor via a suitable linker to the imidazole C2 position in order to form a covalent bond with the reactive Cys797 side chain (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>a), resulting in compounds (<b>6a</b> and <b>7</b>–<b>9</b>). To direct the reactive Michael acceptor in close proximity to the cysteine, suitable geometries and distances of an aliphatic linker were of utmost importance. We varied linker lengths as well as three-dimensional geometries by the introduction of rigidized cyclic alkyl linkers (<b>14</b>–<b>16</b>). By the application of covalent docking algorithms (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>), we identified the 3 position of the aniline ring of lead compound <b>1</b> to be a suitable attachment point for a Michael acceptor as well and synthesized the respective compounds (<b>17</b>–<b>31</b>). The incorporation of a reactive Michael acceptor at this attachment point displayed a conformationally less flexible geometry, thus arranging the reactive group in a rigidized manner toward Cys797. The concept of reducing conformational flexibility has been shown previously to result in improved inhibitory activity.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a> We studied the influence of the acrylamides on the inhibitory activity by comparison with the reversible analogues, the respective propionamides. To investigate the role of residues occupying HR I, we synthesized compounds bearing various alkyl or aryl residues in the imidazole C4 position, having different polarities as well as growing spatial requirements (<b>23</b>–<b>30</b>). Our findings led us to combine the most promising partial structures in a hybrid compound (<b>31a</b>). In previous studies, we examined whether the sulfur atom could be substituted with a carbon atom without any significant change in activity.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> With this approach, we synthesized one compound bearing all four interaction patterns: a Michael acceptor targeting Cys797, a bidentate hinge binding to Met793, aromatic residues occupying HR II as well as HR I, and a polar side chain interacting with the phosphate binding site.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">Compounds <b>1</b>–<b>13</b> were synthesized according to our previously reported synthetic route<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> by applying minor changes and optimizations (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Thus, the corresponding commercially available benzoic acid esters were condensed with 2-fluoro-4-picoline using NaHMDS as a strong non-nucleophilic base in good yields. Subsequent nitrosation with sodium nitrite in glacial acetic acid followed by reduction with zinc dust under acidic conditions yielded α-aminoketones <b>38a</b>–<b>c</b> as the corresponding hydrochloride salts after workup. Cyclization with potassium thiocyanate in refluxing DMF resulted in thiones <b>39a</b>–<b>c</b> in excellent yields. Key intermediates <b>40a</b>–<b>c</b> were synthesized by means of nucleophilic aromatic substitution reactions with aniline under acidic conditions in refluxing NMP in good yields. Compounds <b>1</b>–<b>4</b> and <b>10</b>–<b>11</b> were synthesized by the application of nucleophilic substitution reactions by employing the corresponding alkyl halides and K<sub>2</sub>CO<sub>3</sub> as base in refluxing THF. To introduce aliphatic linkers to attach either a Michael acceptor as the corresponding acrylamide or the generic propionyl amide, imidazole thiones <b>40a</b>–<b>c</b> were decorated with aliphatic amines protected as phthalimides under similar conditions. Compounds <b>41a</b>–<b>d</b> were subsequently deprotected via hydrazinolysis using hydrazine hydrate in EtOH at elevated temperature to give primary amines <b>5</b> and <b>12</b> in decent yields. Amide couplings of <b>5</b>, <b>12</b>, and <b>42e</b>,<b>f</b> with the corresponding carboxylic acids were conducted using TBTU and DIPEA in THF to obtain <b>6a</b>–<b>9</b> and <b>13</b> in moderate yields.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Trisubstituted Imidazoles (<b>1</b>–<b>13</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaHMDS, THF, 0 °C to rt, 65–79%. (ii) NaNO<sub>2</sub>, HOAc, 10 °C, 84–97%. (iii) Zn dust, HOAc, 10 °C, 78–85%. (iv) KSCN, DMF, reflux, 73–84%. (v) aniline, NMP, conc HCl<sub>aq</sub>, reflux, 63–88%. (vi) alkyl halide, K<sub>2</sub>CO<sub>3</sub>, THF, reflux, 48–79%. (vii) (<i>n</i> = 2), <i>N</i>-(2-bromoethyl)phthalimide, K<sub>2</sub>CO<sub>3</sub>, THF, reflux; (<i>n</i> = 3), <i>N</i>-(3-Iodopropyl)phthalimide, K<sub>2</sub>CO<sub>3</sub>, THF, reflux, 57–81%. (viii) Hydrazine hydrate, EtOH, 70 °C, 55–65%. (ix) Carboxylic acid, TBTU, DIPEA, THF, 27–63%.</p></p></figure><div class="NLM_p">Cyclic alkyl linkers <b>45a</b>,<b>b</b> and <b>49</b> were synthesized according to <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Commercially available enantiomerically pure (<i>R</i>)- or (<i>S</i>)-proline was Boc-protected and subjected to reduction with borane in THF, leading to the corresponding alcohols <b>44a</b>,<b>b</b>. The following bromination was achieved under Appel conditions using triphenylphosphine and carbon tetrabromide in THF, giving <b>45a</b>,<b>b</b> in good yields.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Final compounds <b>14</b> and <b>15</b> were synthesized by nucleophilic substitution reactions of <b>45a</b>,<b>b</b> with <b>40a</b>, followed by Boc-deprotection under acidic conditions and subsequent amide coupling with acrylic acid in acceptable yields. Boc protection of 3-hydroxypyrrolidine (racemic mixture) yielded intermediate <b>48</b> that was transformed into the corresponding bromide <b>49</b> via Appel reaction using triphenylphosphine and CBr<sub>4</sub> in good yields.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Again, we attached this cyclic side chain to the imidazole thione <b>40a</b> by nucleophilic substitution reaction under similar conditions as mentioned above. Deprotection followed by amide bond formation yielded final compound <b>16</b> as racemic mixture.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Trisubstituted Imidazoles with Cyclic Alkyl Linkers (<b>14</b>–<b>16</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) BH<sub>3</sub>*THF, THF, 0 °C 62–65%; (ii) PPh<sub>3</sub>, CBr<sub>4</sub>, rt, 65–71%; (iii) <b>36a</b>, K<sub>2</sub>CO<sub>3</sub>, THF, reflux, 76–80%; (iv) TFA, DCM, rt, 81–88%; (v) acrylic acid, TBTU, DIPEA, THF, 28–37%; (vi) Boc<sub>2</sub>O, neat, rt; DMAP, 90%; (vii) PPh<sub>3</sub>, CBr<sub>4</sub>,THF, 0 °C to rt, 62%; (viii) <b>36a</b>, K<sub>2</sub>CO<sub>3</sub>, THF, reflux, 84%.</p></p></figure><div class="NLM_p">Because we were not able to produce analogues of <b>40a</b>–<b>c</b> using substituted anilines for a nucleophilic aromatic substitution with thiones <b>39a</b>–<b>c</b>, we established a different synthetic route according to <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> based on a Suzuki cross coupling approach.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> First, we α-brominated commercially available ketones with bromine in methylene chloride (for aromatic ketones) or methanol (for aliphatic ketones) to yield <b>52a</b>–<b>j</b>. For the <i>S</i>-methyl series, we next cyclized these α-bromoketones with <i>S</i>-methyl isothiourea hemisulfate under mild basic conditions to give <b>53a</b>,<b>c</b>–<b>j</b> in acceptable yields. The following SEM protection initially yielded both corresponding regioisomeres. The regioisomeric mixtures were converted to the less sterically demanding isomer by stirring with a catalytic amount of SEM chloride in acetonitrile at elevated temperature in good yields.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Electrophilic bromination with NBS in acetonitrile at −30 °C yielded key intermediates <b>55a</b>,<b>c</b>–<b>j</b>, which were subjected to a high yielding Suzuki cross coupling reaction with an <i>N</i>-protected 2-amino-pyridine-4-boronic acid ester under optimized conditions. After deprotection of the amino pyridines <b>56a</b>,<b>c</b>–<b>j</b>, the free amines <b>57a</b>,<b>c</b>–<b>j</b> were obtained in good yields. The subsequent Pd catalyzed aryl amination with predecorated <i>m</i>-bromoanilines gave precursors <b>58a</b>–<b>j</b> and <b>59</b>–<b>63</b> that were deprotected under acidic conditions using TFA to obtain final compounds <b>17a</b>–<b>b</b> and <b>19</b>–<b>30</b> in moderate to excellent yields.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>17a</b>,<b>b</b> and <b>19a</b>–<b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Br<sub>2</sub>, DCM or MeOH, rt, 64–95%; (ii) <i>S</i>-methylisothiourea hemisulfate salt, NaHCO<sub>3</sub>,THF/H<sub>2</sub>O, reflux, 15–65%; (iii) NaH, SEM-Cl, THF, −15 °C, quant; (iv) SEM-Cl (5 mol %), MeCN, 80 °C, 50–91%; (v) NBS, MeCN, −30 °C, 21–90%; (vi) corresponding boronic acid or acid ester, Pd(OAc)<sub>2</sub>/XPhos or Pd<sub>2</sub>(dba)<sub>3</sub>/(<i>t</i>-Bu)<sub>3</sub>P*HBF<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane/H<sub>2</sub>O, reflux, 54–91%; (vii) 5 M NaOH<sub>aq</sub>, MeOH, 60 °C, 63–92% or NH<sub>2</sub>OH, DIPEA, ethanol, rt 53–63% or TFA, DCM, rt 88–99%; (viii) (hetero)aryl bromide, Brettphos Pd G1, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/<i>t</i>-BuOH, 130 °C, 61–91%; (ix) TFA, DCM, rt, 55–86%.</p></p></figure><div class="NLM_p">For the synthesis of compound <b>18</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>), α-bromoketone <b>52b</b> was converted to the corresponding α-aminoketone <b>64</b> via Delépine reaction and subsequently cyclized with potassium thiocyanate under acidic conditions to give imidazole thione <b>65</b> in good yield. We obtained the <i>N</i>-protected intermediate <b>66</b> by means of nucleophilic substitution of <i>N</i>-(2-bromoethyl)phthalimide under basic conditions. <i>N</i>-Protection of the imidazole core gave the SEM protected precursor <b>67</b>, which was converted to the free aliphatic amine <b>68</b> by hydrazinolysis in excellent yield. Amide bond formation was performed by utilizing propionic acid, TBTU, and DIPEA in THF to obtain the corresponding amide <b>69</b> in excellent yield. Subsequent electrophilic bromination of the imidazole core followed by a one-pot, two-step tandem borylation Suzuki cross coupling reaction<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> with 4-bromo-2-(2,5-dimethyl-1<i>H</i>-pyrrol-1-yl)pyridine gave the dimethylpyrrole protected aminopyridine <b>71</b> in acceptable yield. Under very controlled conditions, the dimethylpyrrole protective group could be cleaved in good yield without hydrolysis of the aliphatic amide by the use of hydroxylamine hydrochloride at 45 °C under neutral conditions. Subsequent Pd catalyzed arylamination followed by acidic SEM deprotection gave the final compound <b>18</b> in acceptable yield.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0008.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Br<sub>2</sub>, DCM, rt, 90%; (ii) urotropine, CHCl<sub>3</sub>, 50 °C, then conc HCl<sub>aq</sub>, EtOH, rt, 99% (over two steps); (iii) KSCN, AcOH, reflux, 50%; (iv) <i>N</i>-(2-bromoethyl)phthalimide, K<sub>2</sub>CO<sub>3</sub>, THF, reflux, 80%; (v) NaH, SEM-Cl, DMF, rt, 84%; (vi) N<sub>2</sub>H<sub>4</sub>*H<sub>2</sub>O, EtOH, 50 °C, 85%; (vii) propionic acid, TBTU, DIPEA, THF, rt, 91%; (viii) NBS, DMF, rt, 98%; (ix) 4-bromo-2-(2,5-dimethyl-1<i>H</i>-pyrrol-1-yl)pyridine, bis(pinacolato)diboron, KOAc, Pd(OAc)<sub>2</sub>, XPhos, K<sub>3</sub>PO<sub>4</sub>, 40%; (x) NH<sub>2</sub>OH*HCl, trimethylamine, EtOH/H<sub>2</sub>O, 45 °C, 37%; (xi) <i>N</i>-(3-bromophenyl)acrylamide, Cs<sub>2</sub>CO<sub>3</sub>, Brettphos Pd G1, 1,4-dioxane/<i>t</i>-BuOH, 51%; (xii) TFA, DCM, rt, 73%.</p></p></figure><div class="NLM_p">Compounds <b>32</b>–<b>35</b> were synthesized via Pd catalyzed arylamination with the appropriate bromoarenes followed by acidic SEM deprotection with TFA in DCM (<a class="ref internalNav" href="#sch6" aria-label="Scheme 5">Scheme 5</a>).</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0009.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>32</b>–<b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Cs<sub>2</sub>CO<sub>3</sub>, Brettphos Pd G1, 1,4-dioxane/<i>t</i>-BuOH, 78–92%; (ii) TFA, DCM, 50–93%.</p></p></figure><div class="NLM_p">Compounds <b>31a</b>,<b>b</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 6">Scheme 6</a>) were synthesized starting from commercially available <i>p</i>-fluoroacetophenone, which was converted to keto aldehyde <b>76</b> using selenium dioxide in a mixture of 1,4-dioxane and water under refluxing conditions in good yield. Cyclization with O-TIPS protected aldehyde <b>78</b> and ammonium acetate resulted in imidazole <b>79</b> in moderate yield. <i>N</i>-Protection of the imidazole core with SEM chloride followed by electrophilic bromination with NBS led to key intermediate <b>81</b> in good yields. Again, we used our previously optimized Suzuki cross coupling reaction with <i>N</i>-acetyl protected 2-aminopyridine-4-boronic acid pinacol ester for the C–C bond formation to obtain intermediate <b>82</b> in good yield. Subsequent Pd catalyzed arylamination with predecorated <i>m</i>-bromoanilines gave the SEM-protected precursors <b>84a</b>,<b>b</b> in decent yields. The final SEM deprotection was achieved under acidic conditions (TFA in DCM) to give compounds <b>31a</b>,<b>b</b> in moderate yields.</div><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0010.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>31a</b> and <b>31b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) SeO<sub>2</sub>, 1,4-dioxane/H2O, reflux, 73%; (ii) NaH, TIPSCl, THF, 0 °C to rt, quant; (iii) C<sub>2</sub>O<sub>2</sub>Cl<sub>2</sub>, DMSO, DCM, −78 °C to rt, 62%; (iv) NH<sub>4</sub>OAc, MeOH, rt, 51%; (v) NaH, SEMCl, DMF, 0 °C to rt, 64%; (vi) NBS, MeCN, 0 °C to rt, 86%; (vii) <i>N</i>-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetamide, X-Phos/Pd(OAc)<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane/H<sub>2</sub>O, 60 °C, 75%; (viii) 5 N NaOH(aq), 1,4-dioxane/MeOH, 60 °C, 63%; (ix) substituted 3-bromoaniline, BrettPhos Pd G I, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/<i>t</i>-BuOH, 120 °C, 62% (acrylamide)/74% (propionyl chloride); (x) TFA,DCM, rt, 41% (acryloylamide)/ 56% (propionylamide).</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Biological Evaluation</h3><div class="NLM_p">To evaluate the effect of substituents extending into the phosphate binding site, we characterized compounds <b>1</b>–<b>5</b> and <b>11</b>–<b>12</b> in an activity based enzyme assay against EGFR-wt, -L858R, as well as -L858R/T790M. We found increased activities against EGFR-L858R/T790M for compounds bearing an ethylene linker with a terminal heteroatom. Compound <b>2</b>, bearing a dimethyl amide group in this position showed a slight gain of activity (81 nM) as well as <b>3</b> (83 nM), which is decorated with a hydroxyethyl group. The primary amine <b>5</b> showed an IC<sub>50</sub> value of 29 nM, which displayed a 4-fold improvement of inhibitory activity when compared with compound <b>1</b> (130 nM). However, the morpholine moiety of <b>4</b> with an IC<sub>50</sub> value of 1246 nM against EGFR-L858R/T790M was not tolerated. Amides <b>6a</b>, <b>6b</b>, and <b>7</b> were well tolerated and showed IC<sub>50</sub> values of 38, 52, and 29 nM, respectively. The introduction of an acrylamide resulted in a slightly higher IC<sub>50</sub> value for <b>6a</b> in the L858R/T790M assay when compared with the free amine <b>5</b>. In addition, the reversible counterpart <b>6b</b> showed only a minor decrease of activity with an IC<sub>50</sub> value of 52 nM. Supported by kinetic characterization, we identified <b>6a</b> to be a weak covalent inhibitor of EGFR-L858R/T790M with a slow covalent binding rate of 0.09 min<sup>–1</sup> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). When the amide was diminished to the corresponding ketone (<b>10</b>), we observed a dramatic loss of inhibitory activity (1328 nM). The ideal distance between hydrogen bond donors or acceptors to address the phosphate binding site appeared to be an ethylene linker, while the increased chain lengths of <b>11</b>, <b>12</b>, and <b>13</b> showed a marked decrease of activity displayed by IC<sub>50</sub> values of 746, 240, and 321 nM, respectively.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Determination of Inhibitory Activities against EGFR Wild-Type (wt), L858R, and L858R/T790M Mutants (Series I)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0011.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0013.gif" alt="" id="fx2" /></img><div></div></div><div class="NLM_p">Our concepts to rigidize alkyl linkers (<b>14</b>–<b>16</b>) by cyclization did not result in higher inhibitory activities. For <b>9</b>, the most potent compound in this series, we observed an IC<sub>50</sub> value of 18 nM in the double-mutant EGFR L858R/T790M enzyme assay. With <b>7</b>, we showed that the 4-fluoro substituent did not influence the biological activities. However, the additional 3-CF<sub>3</sub> group of <b>8</b> was not tolerated and led to a dramatic decrease of activity (IC<sub>50</sub> value = 646 nM).</div><div class="NLM_p"><a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a> shows the different proposed binding modes of <b>6a</b> modeled into an X-ray crystal structure of the L858R/T790M mutant applying covalent docking (A) and induced-fit docking (B). As depicted in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>, the additional hydrogen bond of <b>6a</b> with the Asp855 side chain of the DFG motif stabilizes the flexible linker chain into an orientation directed away from Cys797. This results in a higher inhibitory activity in general but prevents a covalent interaction of the Michael acceptor. It is noteworthy that both docking poses yielded high docking scores and showed identical hinge binding patterns.</div><figure id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0003.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Different outcomes of modeling studies of <b>6a</b> using covalent docking (A) and induced-fit docking (B) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>). Covalent docking indicates a bond formation with Cys797 and bidentate hinge binding, while induced-fit docking indicates an additional hydrogen bond to Asp855, preventing the Michael acceptor from covalent binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, we attached the reactive Michael acceptor to the hinge binding pyridine core via arylamination. We assumed that this approach toward a less flexible geometry would give a better preorientation of the Michael acceptor in close proximity to Cys797. Our initial approach included the decoration of the aniline residue of <b>1</b> in the <i>meta</i> position with a suitable Michael acceptor. We anticipated that polar interactions would not direct the Michael acceptor-bearing group away from Cys797 in this series. With this approach, we were able to synthesize covalent inhibitors of EGFR mutants that showed subnanomolar IC<sub>50</sub> values against all three kinase variants (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). <b>17a</b> showed high inhibitory activities in the isolated enzyme assay of EGFR wild-type and the L858R mutant with IC<sub>50</sub> values below 1 nM and an IC<sub>50</sub> value of 3.3 nM when tested against the double-mutant L858R/T790M. However, the reversible analogue <b>17b</b> showed a loss of inhibitory activities for all three kinases, indicating covalent binding mode of <b>17a</b>. To further look into this, both compounds were incubated with EGFR-T790M and the mixture analyzed by mass spectrometry. Compound <b>17a</b> showed an increase in mass as compared to a DMSO treated control sample, corresponding to covalent alkylation of the kinase. In contrast, we did not observe covalent labeling for the reversible counterpart <b>17b</b> in this setting (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_001.pdb" class="ext-link">Figure S1</a>). We next decorated the phenylenediamine moiety of <b>17a</b> with an additional methoxy group in the <i>ortho</i> position as a gentle steric hindrance for the free torsion of the N–C bond. We expected that the methoxy group would direct the benzene ring, carrying the Michael acceptor into a greater out-of-plane conformation, providing a highly targeted orientation of the Michael acceptor toward Cys797. On the basis of this rational concept, we were able to generate <b>19a</b>, a highly potent EGFR inhibitor displaying IC<sub>50</sub> values below 1 nM against all three kinase variants. The covalent bond formation with EGFR-T790M was again shown by means of MS analysis (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_001.pdb" class="ext-link">Figure S1</a>), and we furthermore characterized the binding kinetics. The rate of covalent bond formation was determined to be moderate, with a <i>k</i><sub>inact</sub> = 0.16 min<sup>–1</sup> in the context of EGFR-L858R/T790M, but we observed high reversible binding as represented by the <i>K</i><sub>i</sub> value of 1.2 nM (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Compound <b>19b</b>, the reversible analogue, displayed subnanomolar IC<sub>50</sub> values in the wild-type EGFR as well as in the L858R assay but failed to overcome T790M resistance, as indicated by an IC<sub>50</sub> value of 5.0 nM in the L858R/T790M assay. However, although <b>19b</b> is a reversible binder, this compound showed high inhibitory activities in all three kinase assays. These findings support our initial hypothesis that addressing the hydrophobic regions of EGFR can yield potent reversible L858R/T790M inhibitors.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Determination of Inhibitory Activities against EGFR Wild-Type (wt), L858R, and L858R/T790M (Series 2)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0014.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0015.gif" alt="" id="fx4" /></img><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Determination of Kinetic Parameters <i>K</i><sub>i</sub>, <i>k</i><sub>inact</sub>, and <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> for <b>6a</b>, <b>19a</b>, <b>31a</b>, and osimertinib</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">EGFR</th><th class="colsep0 rowsep0" align="center" char="±"><i>K</i><sub>i</sub> [nM]</th><th class="colsep0 rowsep0" align="center" char="±"><i>k</i><sub>inact</sub> [min<sup>–1</sup>]</th><th class="colsep0 rowsep0" align="center" char="±"><i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> [μM<sup>–1</sup> s<sup>–1</sup>]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="center">wt</td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">0.09 ± 0.004</td><td class="colsep0 rowsep0" align="char" char="±">0.94 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">L858R</td><td class="colsep0 rowsep0" align="char" char="±">0.38 ± 0.00</td><td class="colsep0 rowsep0" align="char" char="±">0.04 ± 0.00</td><td class="colsep0 rowsep0" align="char" char="±">0.58 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">L858R/T790M</td><td class="colsep0 rowsep0" align="char" char="±">6.0 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">0.09 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.25 ± 0.00</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">      </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19a</b></td><td class="colsep0 rowsep0" align="center">wt</td><td class="colsep0 rowsep0" align="char" char="±">0.35 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.16 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">L858R</td><td class="colsep0 rowsep0" align="char" char="±">0.10 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.03 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">L858R/T790M</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">0.16 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31a</b></td><td class="colsep0 rowsep0" align="center">wt</td><td class="colsep0 rowsep0" align="char" char="±">0.07 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">0.16 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">L858R</td><td class="colsep0 rowsep0" align="char" char="±">0.03 ± 0.003</td><td class="colsep0 rowsep0" align="char" char="±">0.10 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">13 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">L858R/T790M</td><td class="colsep0 rowsep0" align="char" char="±">0.10 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.13 ± 0.003</td><td class="colsep0 rowsep0" align="char" char="±">11 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">osimertinib</td><td class="colsep0 rowsep0" align="center">wt</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 2.3</td><td class="colsep0 rowsep0" align="char" char="±">0.43 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">0.52 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">L858R</td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">0.30 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">L858R/T790M</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">0.33 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">3.8 ± 0.4</td></tr></tbody></table></div></div><div class="NLM_p">To study the influence of the 4-fluorophenyl moiety in more detail, we synthesized compounds with various substituents in the imidazole 4-position (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). To determine the SARs and the possibility of reduction of molecular size, we decorated the imidazole scaffold with several aromatic as well as aliphatic moieties with increasing sizes, hydrophobicity, and steric demands. We kept the optimized methoxy aniline acrylamide of <b>19a</b> in this series unchanged to retain the geometry for a covalent interaction that produced highly active compounds in series 3 (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). The exchange of the 4-fluorophenyl moiety with thiophene (<b>24</b>) and even with naphthalene (<b>23</b>) was well tolerated and led to compounds with high activities in all three tested enzyme assays. Compound <b>25a</b>, which lacks a substituent in this position, showed high inhibitory activities with an IC<sub>50</sub> value of 8.6 nM against the L858R/T790M mutant. However, the influence of the acrylamide on the inhibitory activity was much more pronounced for this compound. Thus, the reversible counterpart <b>25b</b> showed a tremendous loss of activity. This result indicated the crucial role of the aromatic residue in <b>19b</b> in this position, leading to high inhibitory activities independent of the covalent interaction of the acrylamide. Aliphatic residues showed an increasing trend of activity with growing ring size and spatial requirements. Hence, we observed an IC<sub>50</sub> value of 4.5 nM against the L858R/T790M mutant for <b>29</b>, bearing a cyclopentyl group in this position. However, the sterically more demanding <i>tert</i>-butyl group was not tolerated. In general, we could not obtain high activities for compounds bearing aromatic residues by substitution with alkyl moieties even though the most potent compound in this series, <b>29</b>, showed a single-digit IC<sub>50</sub> value in the L858R/T790M double-mutant enzyme assay. Combining the identified crucial features for efficient inhibiton, targeting the hydrophobic region next to the gatekeeper side chain as well as the phosphate binding site yielded compounds <b>31a</b>,<b>b</b>. The covalent compound <b>31a</b>, as well as the reversible counterpart <b>31b</b> showed intense inhibition in the biochemical setting of below 1 nM, substantiating this approach. Because the reversible counterpart <b>31b</b> showed no drop of activity when compared with the irreversible inhibitor <b>31a</b>, T790M resistance could be mainly overcome by reversible binding affinities. This was further strengthened by a very low <i>K</i><sub>i</sub> value of 0.10 nM determined in EGFR-L858R/T790M, while the rate of covalent bond formation was 0.13 min<sup>–1</sup>. Thus, the high activity of <b>31a</b>, decorated with a hydroxypropyl substituent in the imidazole 2-position, was less dependent on a covalent interaction and mutation of Cys797 should not lead to resistances against this inhibitor. As depicted in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, our modeling studies of <b>31a</b> with EGFR-T790M predicted a bidentate hinge binding of the aminopyridine and hydrophobic interactions of the fluorophenyl moiety, the aniline ring and the pyridine ring. Additionally, a polar contact between the terminal hydroxyl group of <b>31a</b> with the Asp855 side chain could be seen.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Determination of Inhibitory Activities against EGFR Wild-Type (wt), L858R, and L858R/T790M (Series 3)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0016.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0012.gif" alt="" id="fx6" /></img><div></div></div><figure id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0004.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Left: Three-dimensional binding mode of <b>31a</b> in a docking study with EGFR T790M (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>). Right: Pharmacophore model produced with the computer software ligandscout 4.11. Hydrogen bond acceptors are depicted as green arrows; hydrogen bond donors are depicted as red arrows. Hydrophobic interactions are depicted as yellow spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Determination of Inhibitory Activities against EGFR wt, L858R, and L858R/T790M (Series 4)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0017.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0018.gif" alt="" id="fx8" /></img><div></div></div><div class="NLM_p last">Most of our synthesized compounds showed very low aqueous solubility, thus we introduced solubilizing groups at the acrylamide-bearing aniline ring to increase aqueous solubility (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Both compounds <b>34</b> and <b>35</b> were barely soluble in a physiological phosphate buffer but showed high activities in the tested enzyme assays. Because substituents in this position are exposed to the solvent according to our docking model (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>), we expected derivatization to be highly tolerated.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Cellular Evaluation</h3><div class="NLM_p">To further investigate the potential for growth inhibition of the new sets of pyridinylimidazoles, we tested all compounds against the gefitinib-resistant H1975 cell line as well as against A431, derived from metastatic lung cancer cells (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). While the gefitinib-resistant H1975 cell line harbors the L858R and the T790M mutation, A431 cells overexpress wild-type EGFR. Growth inhibition of the A431 cell line is an indicator for wild-type inhibition-associated toxic side effects of the tested compounds.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Cellular Growth Inhibition Data of Synthesized Compounds in A431 and H1975 Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">NSCLC cell lines EC<sub>50</sub> [μM]</th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">NSCLC cell lines EC<sub>50</sub> [μM]</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">A431 wt</th><th class="colsep0 rowsep0" align="center" char="±">H1975 L858R/T790M</th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">A431 wt</th><th class="colsep0 rowsep0" align="center" char="±">H1975 L858R/T790M</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char="±">11 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 6</td><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char="±">18 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 5</td><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="char" char="±">14 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">3.4 ± 1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char="±">11 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 5</td><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="char" char="±">24 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">23 ± 8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char="±">10 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 2</td><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="char" char="±">3.0 ± 2.0</td><td class="colsep0 rowsep0" align="char" char="±"><b>0.38 ± 0.15</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="char" char="±">11 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 1.1</td><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="char" char="±">7.4 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±"><b>0.084 ± 0.008</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6a</b></td><td class="colsep0 rowsep0" align="char" char="±">12 ± 5</td><td class="colsep0 rowsep0" align="char" char="±">2.4 ± 0.7</td><td class="colsep0 rowsep0" align="left"><b>25a</b></td><td class="colsep0 rowsep0" align="char" char="±">4.1 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="char" char="±">16 ± 7</td><td class="colsep0 rowsep0" align="char" char="±">9.7 ± 1.1</td><td class="colsep0 rowsep0" align="left"><b>25b</b></td><td class="colsep0 rowsep0" align="char" char="±">13 ± 4</td><td class="colsep0 rowsep0" align="center" char="±">>30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="char" char="±">11 ± 5</td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 1.9</td><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="char" char="±">9.7 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">4.1 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="char" char="±">11 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.2</td><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="char" char="±">8.0 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="char" char="±">6.6 ± 1.9</td><td class="colsep0 rowsep0" align="char" char="±">5.1 ± 1.1</td><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="char" char="±">8.9 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="char" char="±">12 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 3</td><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="char" char="±">7.8 ± 2.8</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char="±">17 ± 5</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 4</td><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="char" char="±">20 ± 7</td><td class="colsep0 rowsep0" align="char" char="±">18 ± 8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="char" char="±">7.4 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">8.4 ± 2.6</td><td class="colsep0 rowsep0" align="left"><b>31a</b></td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±"><b>0.4 ± 0.2</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.2</td><td class="colsep0 rowsep0" align="left"><b>31b</b></td><td class="colsep0 rowsep0" align="char" char="±">17 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="char" char="±">6.9 ± 2.0</td><td class="colsep0 rowsep0" align="char" char="±">3.4 ± 0.4</td><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="char" char="±">19 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">30 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="char" char="±">8.8 ± 2.6</td><td class="colsep0 rowsep0" align="char" char="±">4.7 ± 0.8</td><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="char" char="±">7.8 ± 2.0</td><td class="colsep0 rowsep0" align="char" char="±">13 ± 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="char" char="±">17 ± 5</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 1</td><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17a</b></td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±"><b>0.19 ± 0.04</b></td><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17b</b></td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.5</td><td class="colsep0 rowsep0" align="left">gefitinib</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">11 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 0.4</td><td class="colsep0 rowsep0" align="left">afatinib</td><td class="colsep0 rowsep0" align="char" char="±">0.6 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">0.7 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19a</b></td><td class="colsep0 rowsep0" align="char" char="±">4.1 ± 2.8</td><td class="colsep0 rowsep0" align="center" char="±"><b><0.014</b></td><td class="colsep0 rowsep0" align="left"><b>85</b></td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">0.1 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19b</b></td><td class="colsep0 rowsep0" align="char" char="±">7.7 ± 4.9</td><td class="colsep0 rowsep0" align="char" char="±">4.3 ± 1.4</td><td class="colsep0 rowsep0" align="left">osimertinib</td><td class="colsep0 rowsep0" align="char" char="±">0.7 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">0.019 ± 0.009</td></tr></tbody></table></div></div><div class="NLM_p last">With compounds of series 1 (<b>2</b>–<b>16</b>), we were able to markedly improve the cellular activity against the gefitinib-resistant H1975 cell line (EGFR-L858R/T790M) down to the low micromolar range. Thus, <b>13</b> showed a 17-fold gain in activity when compared with <b>1</b>. However, this compound showed no selectivity over wild-type in this cellular setting. For <b>9</b>, which showed an IC<sub>50</sub> value of 18 nM in the isolated enzyme assay, we determined an EC<sub>50</sub> value of >5 μM. We determined moderate activity (2.4 μM) for <b>6a</b> against the H1975 cell line with a high selectivity over A431 (12 μM). Interestingly, <b>7</b> and <b>8</b> showed similar EC<sub>50</sub> values in this cellular setting even though we determined a 22-fold lower IC<sub>50</sub> value for <b>8</b> in the isolated enzyme assay. High activity in the H1975 (L858R/T790M) growth inhibition assay could be observed for <b>19a</b>, showing an EC<sub>50</sub> value of <0.014 μM. Even though this compound showed an equal inhibition of EGFR-wt in the biochemical assays, we determined high selectivity over the A431 cell line (4.1 μM). Notably, compound <b>19a</b> showed comparable inhibitory activity and an improved selectivity profile over wt in this cellular setting as compared to the gold standard osimertinib. The reversible counterpart <b>19b</b> showed only poor activity (4 μM) in the cellular assay, indicating the crucial role of the irreversible inhibition in terms of cellular activity. The lack of the methoxy group in <b>17a</b> resulted in a 10-fold higher EC<sub>50</sub> value of 0.19 μM as compared to <b>19a</b>. The substitution of the 4-fluoro phenyl ring with aliphatic residues (<b>25</b>–<b>30</b>) resulted in a dramatic loss of cellular activity in general. The presence of aliphatic groups may contribute to lower inhibitory activities as well as reduced cell permeability of these compounds, but this line of thought was not further investigated. Among the compounds with a solubilizing group, we observed only moderate activity of about 1 μM in H1975 cells, which could probably be further optimized by repositioning of the methylpiperazine moiety.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Biochemical Evaluation against Osimertinib-Resistant EGFR-L858R/T790M/C797S Variant</h3><div class="NLM_p">Because we observed a high reversible binding character of our compounds as reflected in the <i>K</i><sub>i</sub> value of 1.2 nM for compound <b>19a</b> and 0.10 nM for compound <b>31a</b>, and because some of our reversible binding compounds (especially <b>31b</b>) showed high inhibitory activities in the L858R/T790M assay, we assumed that they might inhibit a cysteine mutated EGFR variant as well (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). To verify this hypothesis, we tested selected compounds in an activity based radiolabeled <sup>33</sup>P(ATP) EGFR-L858R/T790M/C797S triple-mutant kinase assay. This particular EGFR mutation is the leading cause for osimertinib resistance, as observed in the clinical setting, and besides an allosteric inhibitor,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> no highly active compounds for this target have been reported in the literature even though they represent a high unmet need.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Determination of Inhibitory Activities against EGFR L858R/T790M and L858R/T790M/C797S</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">EGFR IC<sub>50</sub> [nM]</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">L858R/T790M</th><th class="colsep0 rowsep0" align="center">L858R/T790M/C797S<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17a</b></td><td class="colsep0 rowsep0" align="center">3.3 ± 1.5</td><td class="colsep0 rowsep0" align="center">nd</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17b</b></td><td class="colsep0 rowsep0" align="center">93 ± 37</td><td class="colsep0 rowsep0" align="center">223</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19a</b></td><td class="colsep0 rowsep0" align="center"><1</td><td class="colsep0 rowsep0" align="center">90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19b</b></td><td class="colsep0 rowsep0" align="center">5.0 ± 0.9</td><td class="colsep0 rowsep0" align="center">167</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="center"><1</td><td class="colsep0 rowsep0" align="center">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="center"><1</td><td class="colsep0 rowsep0" align="center">53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31a</b></td><td class="colsep0 rowsep0" align="center"><1</td><td class="colsep0 rowsep0" align="center">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31b</b></td><td class="colsep0 rowsep0" align="center"><1</td><td class="colsep0 rowsep0" align="center">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>85</b></td><td class="colsep0 rowsep0" align="center"><1</td><td class="colsep0 rowsep0" align="center">2053</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">osimertinib</td><td class="colsep0 rowsep0" align="center"><1</td><td class="colsep0 rowsep0" align="center">278</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are measured as duplicates in a single experiment.</p></div></div></div><div class="NLM_p last">Indeed, compound <b>19a</b> revealed a considerable activity of 90 nM, which could be further improved by the introduction of solubilizing groups, as compounds <b>34</b> and <b>35</b> showed increased activities with IC<sub>50</sub> values of 11 and 53 nM, respectively. The incorporation of solubilizing groups did not significantly increase the aqueous solubility, but these compounds benefited from this substitution in terms of L858R/T790M/C797S inhibition. Hybrid compounds <b>31a</b> and <b>31b</b> that can form additional interactions with the phosphate binding site, namely with the aspartate side chain of the DFG motif, showed high inhibitory activities in the single-digit nanomolar range (8 and 7 nM, respectively). We next determined the metabolic stability of <b>19a</b>, <b>31a</b>, and <b>34</b> in human liver microsomes (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_001.pdb" class="ext-link">Figure S2</a>). All three compounds seemed to be metabolically stable and showed 23% (<b>19a</b>), 9% (<b>31a</b>), and 27% (<b>34</b>) degradation after 240 min of incubation time. Compound <b>19a</b> showed a good kinome selectivity profile with a selectivity score of 0.039 (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_001.pdb" class="ext-link">Table S1</a>). We determined the inhibitory activities for <b>19a</b>, <b>31a</b>, and <b>34</b> against p38-α. All three compounds showed high inhibitory activities in the low double-digit nanomolar range (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_001.pdb" class="ext-link">Table S2</a>). However, additional p38 inhibition might be beneficial because upregulation of this kinase is also involved in lung cancer cells.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> We further used the latest version of ZINC15 database to virtually test all final compounds for structural elements representing pan-assay interference compounds (PAINS). We did not get any PAIN hit from this database search.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34050" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34050" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Even though three generations of EGFR inhibitors have been approved for the treatment of nonsmall cell lung cancer and the inhibition of the EGFR signaling has been validated as a target, the efficacy of this therapy is still compromised by somatic mutations. First-generation EGFR inhibitor resistance is mainly caused by the single amino acid exchange T790M. Third-generation inhibitors irreversibly inhibit this mutated enzyme and take into account that wild-type inhibition leads to toxic side effects. These considerations led to the development and approval of the therapeutically effective and wild-type sparing inhibitor osimertinib. However, the recently discovered single amino acid exchange C797S offsets the possibility of irreversibly inhibiting this mutant enzyme. In consequence, osimertinib loses most of its activity and becomes ineffective during long-term treatment. We synthesized a set of diverse trisubstituted imidazoles to first examine the structure–activity relationships. To develop compounds that bear multiple noncovalent polar and hydrophobic interactions with several regions within the ATP binding site, we studied all three substitution sites of the imidazole core, guided by molecular modeling. Additionally, a suitable attachment point for a Michael acceptor to irreversibly inhibit EGFR was identified. Next, we merged beneficial structural elements and developed inhibitors that irreversibly target the gefitinib-resistant EGFR L858R/T790M mutant and reversibly inhibit EGFR L858R/T790M/C797S. We recently developed compound <b>19a</b> with a cellular EC<sub>50</sub> value of <14 nM against EGFR-L858R/T790M assay and a high selectivity of ∼300-fold over the wild-type.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> With our concept, we developed compounds <b>31a</b> and <b>31b</b>, with improved inhibitory activity against the EGFR-L858R/T790M/C797S triple mutant. Our concept allowed us to produce compounds with single-digit nanomolar IC<sub>50</sub> values. In sum, our new class of EGFR inhibitors together with this rational approach to inhibit EGFR-L858R/T790M/C797S may stimulate the development of either improved trisubstituted imidazoles as therapeutic drug candidates or probes and the transfer of our design approach to other structural classes of EGFR inhibitors.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14207" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14207" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Activity-Based Assay for IC<sub>50</sub> Determination and Kinetic Characterization</h3><div class="NLM_p">IC<sub>50</sub> determinations for EGFR and its mutants (Carna Biosciences, lot13CBS-0005K for EGFR-wt; Carna, lot13CBS-0537B for EGFR-L858R; Carna, lot12CBS-0765B for EGFR-L858R/T790M) were performed with the HTRF KinEASE-TK assay from Cisbio according to the manufacturer’s instructions. Briefly, the amount of EGFR in each reaction well was set to 0.60 ng of EGFR-wt (0.67 nM), 0.10 ng of EGFR-L858R (0.11 nM), or 0.07 ng of EGFR-T790M/L858R (0.08 nM), respectively. An artificial substrate peptide (TK-substrate from Cisbio) was phosphorylated by EGFR. After completion of the reaction (reaction times: 25 min for wt, 15 min for L858R, and 20 min for T790M/L858R), the reaction was stopped by addition of buffer containing EDTA as well as an antiphosphotyrosine antibody labeled with europium cryptate and streptavidin labeled with the fluorophore XL665. FRET between europium cryptate and XL665 was measured after an additional hour of incubation to quantify the phosphorylation of the substrate peptide. ATP concentrations were set at their respective <i>K</i><sub>m</sub> values (9.5 μM for EGFR-wt, 9 μM for EGFR-L858R, and 4 μM for EGFR-L858R/T790M), while a substrate concentration of 1 μM, 225 nM, and 200 nM, respectively, was used. Kinase and inhibitor were preincubated for 30 min before the reaction was started by addition of ATP and substrate peptide. An EnVision multimode plate reader (PerkinElmer) was used to measure the fluorescence of the samples at 620 nm (Eu-labeled antibody) and 665 nm (XL665 labeled streptavidin) 50 μs after excitation at 320 nm. The quotient of both intensities for reactions made with eight different inhibitor concentrations was then analyzed using the Quattro Software Suite for IC<sub>50</sub> determination. Each reaction was performed in duplicate, and at least three independent determinations of each IC<sub>50</sub> were made. Inhibition data against EGFR-L858R/T790M/C797S were conducted at Reaction Biology Corporation via a commercial radiolabeled<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a>P(ATP) kinase assay. IC<sub>50</sub> values were measured in duplicate at five different concentration with 10-fold dilution steps starting from 1 μM. Staurosoprine was tested as control compound in singlicate at 10 different concentrations with a 4-fold dilution starting at 20 μM. A detailed description of the assay format is given in the literature<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> or at the vendor’s Web site: <a href="http://www.reactionbiology.com/webapps/site/Kinase_Assay_Protocol.aspx" class="extLink">http://www.reactionbiology.com/webapps/site/Kinase_Assay_Protocol.aspx</a>.</div><div class="NLM_p last">For kinetic characterization (<i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub>), the inhibitors were incubated with EGFR-wt, -L858R or -L858R/T790M, respectively, over different periods of time (2–90 min), whereas durations of enzymatic and stop reactions were kept constant as stated above. A 6-fold dilution series (eight data points per IC<sub>50</sub> curve) starting at 20 μM final compound concentrations was applied. Compound dilutions were generated using the acoustic dispensing system “ECHO 520 Liquid Handler” from Labcyte (Sunnyvale, California, USA) and the according dose–response software “Echo Dose–Response v1.5.4”. Calculated IC<sub>50</sub> values were plotted versus incubation time and data was fit as described in the literature to determine <i>k</i><sub>inact</sub> and <i>K</i><sub>i</sub>.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Mass Spectrometry Experiments</h3><div class="NLM_p last">We used the drug-resistant mutant variant of EGFR (EGFR-T790M) for MS experiments. We incubated a mixture of 52 μM of protein with 100 μM of inhibitor in buffer (25 mM TRIS, 250 mM NaCl, 10% glycerol, 1 mM TCEP, pH 8) on ice for 1 h. We analyzed the aliquots by mass spectrometry using a Finnigan LCQ Advantage Max mass spectrometer from Thermo. Deconvolution and visualization were performed using MagTran.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Cell Culture</h3><div class="NLM_p">A431 and H1975 cells were obtained from the American Type Culture Collection (ATCC). A431 cells were cultured in DMEM high glucose media (Life Technologies, Germany), and H1975 cells were cultured in RPMI media (Life Technologies, Germany), both containing <span class="smallcaps smallerCapital">l</span>-glutamine, and were supplemented with 10% FBS (GE Healthcare, Austria) and 1% PenStrep (Life Technologies, Germany) in a humidified incubator at 37 °C and 5% CO<sub>2</sub>.</div><div class="NLM_p last">Cell line authentication has been performed last in October 2014 by STR profiling of 16 alleles.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Viability Assay</h3><div class="NLM_p last">Cells were seeded at cell numbers that ensure linearity and optimal signal intensity (150–300 cells/well, 25 μL) and cultured for 24 h in serum- and antibiotics-containing media in humidified chambers at 37 °C/5% CO<sub>2</sub>. The cells were treated with EGFR inhibitors in serial dilutions (14 nM to 30 μM) with DMSO and staurosporine as control and incubated for 96 h. Compound dilutions were generated using the acoustic dispensing system “ECHO 520 liquid handler” from Labcyte (Sunnyvale, California, USA) and the according dose–response software “Echo Dose–Response v1.5.4”. Afterward, viability studies were carried out using CellTiterGlo assay (Promega, USA) that is a homogeneous method of determining the number of viable cells in culture. It is based on quantification of ATP, indicating the presence of metabolically active cells. For these studies, CellTiterGlo reagent was prepared according to the instructions of the kit and diluted 1:1 with the complete growth medium suitable for the corresponding cell line. Thereon, reagent and assay plates were equilibrated at room temperature for 20 min. Equal volumes of the reagent were added to the volume of culture medium present in each well (25 μL). The plates were shaked for 2 min on an orbital shaker to induce cell lysis. The microplates were then incubated at room temperature for 20 min for stabilization of the luminescent signal. Following incubation, the luminescence was recorded on a EnVision microplate reader (PerkinElmer) using 500 ms integration time. The data was then analyzed using the Quattro Software Suite for EC<sub>50</sub> determination. As quality control, the <i>Z</i>′-factor was calculated from 16 positive and negative control values. Only assay results showing a <i>Z</i>′-factor ≥0.5 were used for further analysis. All experimental points were measured in duplicates for each plate and were replicated in at least two plates.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Chemistry</h3><div class="NLM_p">All reagents and solvents used for synthesis or chromatography were purchased from Sigma-Aldrich, Acros, CombiBlocks, or Fluorochem and used without further purification unless otherwise noted. NMR spectra were measured with a Bruker Avance 200 or a Bruker Avance 400. Spectra were calibrated by using the residual undeuterated solvent peaks. Chemical shifts (δ) are indicated in parts per million (ppm). Not obvious signals are indicated as multiplets (m) or broad singlets (bs). Mass experiments were performed either by DC-MS (ESI) (Advion Expression CMS) or FAB-MS (Mass Spectrometry Department, Institute of Organic Chemistry, Eberhard Karls Universität Tübingen). ESITOF-HRMS data were obtained from the Mass Spectrometry Department, Institute of Organic Chemistry, Eberhard-Karls-University Tübingen. TLC was performed with fluorescent silica gel 60 F<sub>254</sub> plates (Merck). Spots were visualized via UV illumination at 254 nm/366 nm or with a suitable stain. Automated column chromatography was performed with Davisil LC60A 20–45 μm silica from Grace Davison using glass or plastic coloumns with a VWR LaFlash or Interchim Puriflash XS420 with integrated UV detectors and fraction collectors. The purity of tested compounds was determined via reverse phase high performance liquid chromatography on Hewlett-Packard HP 1090/1100 series II LC equipped with a UV diode array detector (DAD, detection at 230 and 254 nm). The purity of all final compounds was ≥95%. The chromatographic separation was performed with a Phenomenex Luna 5 μ C8 column (150 mm × 4.6 mm, 5 μm) as stationary phase at 35 °C oven temperature with an injection volume of 5 μL and a flow rate of 1.5 mL/min. Solvents: 0.01 M KH<sub>2</sub>PO<sub>4</sub>, pH 2.3 (solvent A) and methanol (solvent B). Method A: 40% B to 85% B in 8 min, 85% B for 5 min, 85% to 40% B in 1 min, 40% B for 2 min, stop time 16 min. Method B: 60% B to 10% B in 10 min, 10% B for 13 min, 10% B to 60% B in 1 min, stop time 24 min. All docking experiments were performed with Glide Docking and Covalent Docking of the Schrödinger Suite software package. The presented docking results were the highest ranked poses after scoring. For visualization and generation of pharmacophore models, the PyMOL Molecular Graphics System, version 1.3 Schrödinger, LLC, was used. Docking studies: For all docking experiments, the X-ray structure of T790M mutated EGFR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>) in complex with AEE788 was used with Maestro 10.4 from Schroedinger. The protein structure was directly loaded into Maestro, and all water molecules, ligands, and nonprotein atoms were removed. Ligands were drawn in ChemDraw and prepared using the “ligprep” plugin of Maestro. The protein structure was prepared using the “Protein Preparation Wizard”. Compounds without a covalent tag were docked using the “Ligand Docking” plugin of Glide in Maestro with XP Precision and without any constraints or further modification from default settings. Compounds bearing a covalent tag were docked using the “Covalent Docking” plugin of Glide included in Maestro. A:Cys797 was selected as reactive residue, and the position of AEE788 was selected as the box center. “Michael addition” was set as the reaction type. Docking was performed without any constraints using “Pose Prediction” docking mode (XP) without any further modifications of the default settings. For detailed syntheses and characterization of all intermediates not shown below, see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_001.pdb" class="ext-link">Supporting Information</a>.</div><div id="sec4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> General Procedure A</h4><div class="NLM_p last">A solution of sodium bis(trimethylsilyl)amide 2 M (2 equiv) in THF was diluted with dry THF to a final concentration of 0.5 mol/L and cooled to 0 °C. To the cooled solution, 2-fluoro-4-methylpyridine (1 equiv) was added via cannula under vigorous stirring. The resulting brownish solution was stirred for 45 min at 0 °C, after which the appropriate substituted benzoic acid ester (1.2 equiv) was rapidly added via cannula under ice bath cooling. The mixture was allowed to warm up to room temperature over 45 min and subsequently poured into 2 M aq HCl (15 equiv) carefully. The resulting biphasic mixture was transferred into a separation funnel, and the organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to yield intermediates <b>32a</b>–<b>c</b> as white solids.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> General Procedure B</h4><div class="NLM_p last">Substituted phenylethan-1-ones obtained from general procedure A (1 equiv) were dissolved in glacial acetic acid under vigorous stirring. The reaction mixture was carefully cooled to 10 °C. To the cooled solution, sodium nitrite (3 equiv) dissolved in water (3.5 mol/L) was added dropwise over 30 min via cannula. The reaction mixture was allowed to slowly warm up to room temperature and stirred for additional 90 min. After complete consumption of the starting materials (TLC), the reaction was quenched by the addition of ice-cold water. The resulting suspension was stirred for an additional hour under cooling and the product subsequently isolated by filtration. The analytically pure product was dried in vacuum overnight.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> General Procedure C</h4><div class="NLM_p last">Oxime (1 equiv) obtained from general procedure B was suspended in glacial acetic acid and vigorously sonicated to yield a clear solution. The mixture was carefully cooled to 0 °C under rapid stirring. Zinc dust (1.5 equiv) was added in one portion. The reaction mixture was stirred until complete consumption of the starting material (HPLC monitoring). The resulting suspension was filtered, and the solid was thoroughly washed with isopropyl alcohol. The filtrate was concentrated in vacuum to give an oily residue. The crude product was dissolved in ethyl acetate and cooled to −10 °C, and the pure amine was precipitated as the corresponding hydrochloric salts by passing HCl gas through this solution. The product was isolated by filtration and washed with cooled ethyl acetate.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> General Procedure D</h4><div class="NLM_p last">α-Aminoketone (1 equiv) obtained from general procedure C was dissolved in dry DMF. Potassium thiocyanate (2.5 equiv) was added to this solution and the mixture heated to reflux until HPLC indicated complete consumption of the starting material (usually 40 min). The reaction mixture was cooled to room temperature and quenched by the addition of ice/water. Vigorous stirring under cooling led to precipitation of the product that was isolated by filtration and thoroughly washed with water. The crude product was purified via silica flash chromatography.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> General Procedure E</h4><div class="NLM_p last">The appropriate thione (1 equiv) obtained from general procedure D was dissolved in <i>N</i>-methylpyrrolidine. Under vigorous stirring, concentrated aq HCl (4 equiv) was added at room temperature. The reaction mixture was refluxed for 30 min. Aniline (10 equiv) was added to the refluxing mixture dropwise. After complete addition, the reaction mixture was heated under reflux for further 90 min, after which the reaction mixture was cooled to room temperature. The resulting dark solution was added dropwise to a cooled satd NH<sub>4</sub>Cl solution. The crude product precipitated and was isolated by filtration and washed with satd NH<sub>4</sub>Cl solution. Purification was performed via recrystallization or silica flash chromatography</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> General Procedure F</h4><div class="NLM_p last">The appropriate alkyl halide (1.2 equiv), appropriate thione (1.0 equiv), and K<sub>2</sub>CO<sub>3</sub> (1.2eq ) were suspended in dry THF. The mixture was stirred vigorously and heated under reflux conditions until HPLC indicated complete consumption of the starting material. After cooling to room temperature, the solvent was evaporated. The residue was suspended in water, neutralized with NH<sub>4</sub>Cl, and the crude product extracted three times with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent removed under reduced pressure. The crude material was purified via silica flash chromatography.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> General Procedure G</h4><div class="NLM_p last">The appropriate phthalimide (1 equiv) obtained from general procedure F was dissolved in ethanol. Then 80% hydrazine hydrate (5 equiv) was added with stirring. The reaction mixture was stirred under reflux conditions until HPLC indicated complete consumption of the starting material. The solvents were removed under reduced pressure, and the white residue was taken up in water. The product was extracted with EtOAc three times. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent removed by rotary evaporation. The crude product was purified via basic silica flash chromatography.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> General Procedure H</h4><div class="NLM_p last">The Boc protected intermediate was dissolved in dry DCM. TFA was added under vigorous stirring at room temperature to reach a final acid concentration of 20%. The reaction mixture was stirred until TLC indicated complete consumption of the starting material (usually 60 min). All volatiles were removed via rotary evaporation. The residue was taken up in water, neutralized with NaHCO<sub>3</sub>, and extracted three times with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent removed by rotary evaporation. The crude product was purified via basic silica flash chromatography.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> General Procedure I</h4><div class="NLM_p last">The appropriate primary or secondary amine (1 equiv) obtained from general procedure G or H was suspended in dry THF. To the stirred solution was added the appropriate carboxylic acid (1 equiv) and DIPEA (2 equiv) followed by TBTU (1.1 equiv). The reaction mixture was stirred until HPLC indicated complete consumption of the starting material. The reaction was quenched by the addition of satd NH<sub>4</sub>Cl solution and extracted three times with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent removed by rotary evaporation. The crude product was purified via silica flash chromatography</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> General Procedure J</h4><div class="NLM_p last">The appropriate commercial available nonracemic acid <b>38a</b>,<b>b</b> (1 equiv) was dissolved in dry THF (3 mL/mmol) and cooled to 0 °C. BH<sub>3</sub>*THF (2.5 equiv) was added dropwise to the vigorously stirring solution at 0 °C. The ice bath was removed after complete addition, and the reaction mixture was stirred overnight. The reaction was quenched by the slow addition of Rochelle’s salt (saturated aqueous solution). The aqueous phase was extracted thrice with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvents evaporated to yield the title compound that was used in the next step without further purification.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> General Procedure K</h4><div class="NLM_p last">Triphenylphosphine (1.5 equiv) dissolved in dry DCM (5 mL/mmol) was added dropwise to a cooled solution of the appropriate alcohol (1.0 equiv) and CBr<sub>4</sub> (1.5 equiv) in dry DCM (5 mL/mmol). After complete addition, the ice bath was removed and the reaction mixture was stirred overnight. The resulting suspension was filtered over Celite, and the filtrate was concentrated by rotary evaporation. The crude product was purified by silica flash chromatography.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> General Procedure L</h4><div id="sec4_17_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> Method A: Aliphatic Ketones</h5><div class="NLM_p last">The appropriate ketone (1 equiv) was dissolved in dry MeOH (2 mL/mmol). The solution was cooled under stirring to 0 °C. Bromine (1 equiv) was added fast in one portion under vigorous stirring, and the resulting dark solution was stirred overnight allowing to reach room temperature slowly. The reaction was quenched by the addition of water and sodium sulfite. The colorless solution was extracted three times with diethyl ether. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent removed by rotary evaporation. The crude product was used directly in the next step without further purification.</div></div><div id="sec4_17_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> Method B: Aromatic Ketones</h5><div class="NLM_p last">The appropriate ketone (1 equiv) was dissolved in dry DCM. Bromine (1 equiv) was added dropwise at room temperature under vigorous stirring. After complete addition, the mixture was stirred for additional 30 min at room temperature until decolorization. After addition of water and sodium sulfite, the mixture was exracted three times with diethyl ether. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent removed by rotary evaporation. The crude product was used directly in the next step without further purification</div></div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> General Procedure M</h4><div class="NLM_p last"><i>S</i>-Methyl isothiourea hemisulfate (1 equiv) was suspended in a mixture of THF/water (4:1). Under vigorous stirring, NaHCO<sub>3</sub> (2.0 equiv) was added at room temperature. The reaction mixture was heated under reflux for 15 min. The appropriate α-haloketone (1.0 equiv) dissolved in THF was added dropwise to the refluxing suspension. The mixture was heated for additional 30 min, while the color changed from pale yellow to dark red. After cooling to room temperature, the reaction mixture was filtered and the filtrate concentrated to dryness under reduced pressure. The dark residue was suspended in water and the pH adjusted to 8. The mixture was extracted five times with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent removed by rotary evaporation. The product was purified via gradient silica flash chromatography</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> General Procedure N</h4><div class="NLM_p last">The appropriate imidazole (1 equiv) obtained from general procedure M was dissolved in dry THF and cooled to −15 °C using an ice–acetone bath. Then 60% sodium hydride (1.1 equiv) was added portionwise. The resulting suspension was allowed to warm up to room temperature. After stirring for 30 min at room temperature, the suspension was again cooled to −15 °C and SEM-Cl (1.0 equiv) was added dropwise. After HPLC indicated complete consumption of the starting material (usually 30 min), the reaction was quenched by the addition of brine and EtOAc. The organic layer was washed with satd NH<sub>4</sub>Cl solution followed by brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the volatiles removed under reduced pressure, yielding a regioisomeric mixture of product. This crude mixture was dissolved in dry MeCN (0.3M). A catalytic amount (5 mol %) of SEM-Cl was added to the solution, which was stirred at 70 °C overnight. After cooling to room temperature, the volatiles were removed by rotary evaporation. The residue was taken up on Celite and subjected to purification via silica flash chromatography.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> General Procedure O</h4><div class="NLM_p last">SEM protected imidazole (1.0 equiv) obtained from general procedure N was dissolved in dry MeCN (0.1M). The resulting solution or suspension was cooled to −30 °C. NBS (1.05 equiv) dissolved in MeCN (0.5 M) was added dropwise to the vigorous stirring cooled solution. The reaction mixture was stirred at −30 °C until HPLC indicated complete consumption of the starting material (usually 15 min). The reaction was quenched at −30 °C by addition of saturated sodium sulfite solution and brine. The mixture was extracted three times with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvent removed by rotary evaporation. The product was purified via gradient silica flash chromatography.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> General Procedure P</h4><div id="sec4_21_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> Method A</h5><div class="NLM_p last">5-Bromoimidazole (1 equiv) obtained from general procedure O was suspended in degassed 1-4-dioxane (3 mL/mmol). A previously degassed aqueous solution of K<sub>3</sub>PO<sub>4</sub> (1 M, 4 equiv) was added under vigorous stirring. The reaction mixture was carefully degassed under vacuum and backfilled with argon. Pd(OAc)<sub>2</sub> (2.5 mol %) and XPhos (5 mol %) were added under an argon flow, and the mixture was heated to reflux. The appropriate pyridine boronic acid ester (2.2 equiv) was added to the refluxing reaction mixture in small portions over 30 min. After complete addition, the biphasic dark solution was heated under reflux for an additional 60 min. The resulting suspension was cooled to room temperature, quenched by the addition of a saturated NH<sub>4</sub>Cl solution, and extracted three times with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvents removed by rotary evaporation. The product was purified via gradient silica flash chromatography.</div></div><div id="sec4_21_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> Method B</h5><div class="NLM_p last">5-Bromoimidazole (1 equiv) obtained from general procedure O and the appropriate pyridine boronic acid ester (1.3 equiv) and K<sub>3</sub>PO<sub>4</sub> (3 equiv) were suspended in degassed 1-4-dioxane (3 mL/mmol). Pd<sub>2</sub>(dba)<sub>3</sub> (5 mol %) and (<i>t</i>-Bu)<sub>3</sub>P*HBF<sub>4</sub> (5 mol %) were added, and the mixture was stirred under argon for 5 min. Previously degassed water (1.5 mL/mmol) was added under vigorous stirring. The reaction mixture was carefully degassed under vacuum and backfilled with argon. After complete addition, the biphasic solution was stirred at 40 °C until total consumption of the starting material (usually overnight). The resulting suspension was cooled to room temperature, quenched by the addition of a saturated NH<sub>4</sub>Cl solution, and extracted three times with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvents removed by rotary evaporation. The product was purified via gradient silica flash chromatography.</div></div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> General Procedure Q</h4><div class="NLM_p last">The appropriate acetamide (1.0 equiv) obtained from general procedure N was dissolved in methanol (20 mL/mmol). A solution of 5 M aqueous NaOH (25 equiv) was added to the vigorously stirred solution via canula at room temperature. The reaction was stirred at room temperature until TLC indicated complete consumption of the starting material (usually 5–7 h). The mixture was neutralized with saturated aqueous NH<sub>4</sub>Cl. Methanol was removed via rotary evaporation and the residue suspended in water. The aqueous phase was extracted three times with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvents removed by rotary evaporation. The product was purified via gradient silica flash chromatography.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> General Procedure R</h4><div class="NLM_p last">The appropriate dimethylpyrrole protected 2-aminopyridine (1 equiv) obtained from general procedure P was dissolved in a mixture of ethanol/water (2:1; 5 mL/mmol). To the vigorously stirred solution, hydroxylamine hydrochloride (6 equiv) followed by DIPEA (6 equiv) was added at room temperature. The reaction vessel was sealed with a rubber septum and carefully heated to 65 °C until TLC indicated complete conversion of the starting material (usually 48 h). The reaction mixture was cooled to room temperature and the solvents removed under reduced pressure. The resulting residue was taken up in saturated aqueous NaHCO<sub>3</sub> solution and extracted three times with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvents removed by rotary evaporation. The product was purified via gradient silica flash chromatography.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> General Procedure S</h4><div class="NLM_p last">The appropriate Boc protected 2-aminopyridine (1 equiv) obtained from general procedure P was dissolved in 5% TFA in dry DCM (2 mL/mmol). The resulting solution was stirred at room temperature until total consumption of the starting material (usually overnight). The reaction was quenched by the addition of a saturated aqueous NaHCO<sub>3</sub> solution and extracted three times with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvents removed by rotary evaporation. The product was purified via gradient silica flash chromatography.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> General Procedure T</h4><div class="NLM_p last">The appropriate 2-aminopyridine (1.0 equiv) obtained from general procedures Q, R, or S was dissolved in a mixture of dry 1,4-dioxane and <i>tert</i>-butyl alcohol (4:1) to give a final concentration of 0.1 mol/L based on the starting material. The appropriate substituted bromo(hetero)arene (1.2 equiv) was added to the reaction mixture under vigorous stirring followed by cesium carbonate (5.0 equiv). The resulting suspension was carefully degassed under vacuum and backfilling with argon. Brettphos Pd G1 (2.5 mol %) was added under a flow of argon to the reaction mixture. The suspension was heated under reflux until TLC indicated complete consumption of the starting material (usually 30–60 min). After cooling to room temperature, the solvents were removed by rotary evaporation. The residue was either taken up on Celite and purified by gradient silica flash chromatography or directly subjected to deprotection.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> General Procedure U</h4><div class="NLM_p last">The appropriate SEM-protected precursor (1.0 equiv) was dissolved or suspended in 20% TFA in dry DCM (3 mL/mmol). The mixture was stirred overnight or until HPLC indicated complete consumption of the starting material. All volatiles were removed via rotary evaporation, and the residue was dissolved in EtOAc. This solution was poured into a saturated aqueous NaHCO<sub>3</sub> solution and extracted three times with EtOAc. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the solvents removed by rotary evaporation. The product was purified via gradient silica flash chromatography.</div></div><div id="sec4_26_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 2-((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)thio)-<i>N</i>,<i>N</i>-dimethylacetamide (<b>2</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>36a</b> and 2-chloro-<i>N</i>,<i>N</i>-dimethylacetamide according to general procedure F and obtained as an pale-yellow solid after gradient silica flash chromatography (hexane → hexane/EtOAc 3:1) in 79% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.75 (s, 1H), 8.99 (d, 1H), 8.21–7.91 (m, 1H), 7.61–7.43 (m, 4H), 7.37–7.12 (m, 4H), 7.05 (s, 1H), 6.90–6.79 (m, 1H)m 6.75–6.68 (m, 1H), 4.20 (s, 2H), 3.04 (s, 3H), 2.85 (s, 3H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.6, 161.9 (d, <i>J</i> = 247 Hz), 156.6, 147.7, 143.2, 142.0, 140.6, 135.1, 131.0 (d, <i>J</i> = 8.5 Hz), 128.9, 127.1, 120.7, 118.4, 118.4, 116.2 (d, <i>J</i> = 21 Hz), 112.5, 107.5, 37.5, 35.6. HRMS (ESI): exact mass calculated for C<sub>24</sub>H<sub>22</sub>FN<sub>5</sub>OS [M + H]<sup>+</sup>, 448.16019. Found: 448.16046.</div></div><div id="sec4_26_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 2-((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)thio)ethan-1-ol (<b>3</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>36a</b> and 2-iodoethanol according to general procedure F and obtained as an off-white solid after gradient silica flash chromatography (hexane → hexane/EtOAc 2:1) in 67% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.72 (s, 1H), 8.99 (s, 1H), 8.23–7.87 (m, 1H), 7.64–7.42 (m, 4H), 7.37–7.01 (m, 5H), 6.84 (t, <i>J</i> = 7.2 Hz, 1H), 6.71 (d, <i>J</i> = 5.4 Hz, 1H), 5.09 (s, 1H), 3.77–3.60 (m, 2H), 3.21 (t, <i>J</i> = 6.5 Hz, 2H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 162.1 (d, <i>J</i> = 246 Hz), 156.6, 148.2, 147.6, 143.2, 142.1, 141.3, 135.1, 131.1 (d, <i>J</i> = 8.3 Hz), 128.8, 127.1, 120.6, 118.4, 116.1 (d, <i>J</i> = 22 Hz), 112.5, 107.7, 60.9, 35.6. HRMS (ESI): exact mass calculated for C<sub>22</sub>H<sub>19</sub>FN<sub>4</sub>OS [M + H]<sup>+</sup>, 407.13364. Found: 407.13358.</div></div><div id="sec4_26_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 4-(4-(4-Fluorophenyl)-2-((2-morpholinoethyl)thio)-1<i>H</i>-imidazol-5-yl)-<i>N</i>-phenylpyridin-2-amine (<b>4</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>36a</b> and 4-(2-chloroethyl)morpholin hydrochloride salt according to general procedure F but using 2 equiv of K<sub>2</sub>CO<sub>3</sub> and obtained as an off-white solid after gradient silica flash chromatography (hexane → hexane/EtOAc 3:1) in 73% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 11.12–12.20 (bs, 2H) 8.00 (d, <i>J</i> = 5.4 Hz, 1H), 7.50–7.33 (m, 2H), 7.29–6.81 (m, 11H), 3.55–3.43 (m, 4H), 3.09 (t, <i>J</i> = 5.8 Hz, 2H), 2.84–2.72 (m, 2H), 2.54–2.42 (m, 4H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 162.6 (d, <i>J</i> = 249 Hz), 156.1, 148.1, 142.3, 141.8, 140.0, 130.6 (d, <i>J</i> = 8.0 Hz), 129.0, 127.7, 122.7, 120.2, 115.9 (d, <i>J</i> = 22 Hz), 113.1, 105.2, 66.1, 60.4, 53.5, 30.2. HRMS (ESI): exact mass calculated for C<sub>26</sub>H<sub>26</sub>FN<sub>5</sub>OS [M + H]<sup>+</sup>, 476.19149. Found: 476.19240.</div></div><div id="sec4_26_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 4-(2-((2-Aminoethyl)thio)-4-(4-fluorophenyl)-1<i>H</i>-imidazol-5-yl)-<i>N</i>-phenylpyridin-2-amine (<b>5</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>37a</b> according to general procedure G and obtained as a white solid after silica flash chromatography (hexane/MeOH/NH<sub>3</sub> 90:8:2) in 60% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.99 (bs, 1H), 8.04 (d, <i>J</i> = 5.3 Hz, 1H), 7.66–7.45 (m, 4H), 7.38–7.14 (m, 4H), 6.99 (s, 1H), 6.85 (t, <i>J</i> = 7.3 Hz, 1H), 6.71 (d, <i>J</i> = 5.4 Hz, 1H), 5.50 (m, 3H), 3.11 (t, <i>J</i> = 6.3 Hz, 2H), 2.87 (t, <i>J</i> = 6.3 Hz, 2H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.7 (d, <i>J</i> = 245 Hz), 156.2, 147.5, 141.7, 141.6, 141.5, 141.4, 132.8, 131.9, 130.2 (d, <i>J</i> = 8.2 Hz), 128.5, 120.3, 118.0, 115.6 (d, <i>J</i> = 22 Hz), 112.2, 107.3, 42.0, 36.3. HRMS (ESI): exact mass calculated for C<sub>22</sub>H<sub>21</sub>FN<sub>5</sub>S [M + H]<sup>+</sup>, 406.14962. Found: 406.14898.</div></div><div id="sec4_26_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> <i>N</i>-(2-((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)thio)ethyl)acrylamide (<b>6a</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5</b> and acrylic acid according to general procedure I and obtained as an off-white solid after gradient silica flash chromatography (DCM → DCM/iPrOH 5%) in 27% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.77 (s, 1H), 9.16–8.75 (m, 1H), 8.42 (s, 1H), 8.22–7.87 (m, 1H), 7.54 (s, 4H), 7.41–7.01 (m, 5H), 6.95–6.64 (m, 2H), 6.36–5.93 (m, 2H), 5.72–5.47 (m, 1H), 3.54–3.40 (m, 2H), 3.28–3.14 (m, 2H). <sup>1</sup>H NMR (200 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.02 (d, <i>J</i> = 5.4 Hz, 1H), 7.56–7.40 (m, 2H), 7.32–7.09 (m, 6H), 7.01–6.76 (m, 3H), 6.25–6.10 (m, 2H), 5.71–5.53 (m, 1H), 3.56 (t, <i>J</i> = 6.5 Hz, 2H), 3.20 (t, <i>J</i> = 6.5 Hz, 2H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.1, 162.2 (d, <i>J</i> = 245 Hz), 156.5, 147.6, 143.2, 142.1, 140.6, 139.2, 135.3, 131.9, 131.0 (d, <i>J</i> = 8.5 Hz), 130.1, 128.8, 125.7, 120.6, 118.3, 116.2 (d, <i>J</i> = 22 Hz), 112.5, 107.6, 65.3, 32.4. HRMS (ESI): exact mass calculated for C<sub>25</sub>H<sub>23</sub>FN<sub>5</sub>OS [M + H]<sup>+</sup>, 460.16019. Found: 460.16089.</div></div><div id="sec4_26_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i>-(2-((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)thio)ethyl)propionamide (<b>6b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5</b> and propionic acid according to general procedure I and obtained as a pale-yellow solid after gradient silica flash chromatography (DCM → DCM/iPrOH 5%) in 63% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i> + MeOH-<i>d</i><sub>4</sub>) δ 8.08–7.93 (m, 1H), 7.51–7.37 (m, 2H), 7.24–7.02 (m, 6H), 7.01–6.75 (m, 2H), 3.45 (t, <i>J</i> = 6.4 Hz, 2H), 3.10 (t, <i>J</i> = 6.3 Hz, 2H), 2.18 (q, <i>J</i> = 7.6 Hz, 2H), 1.10 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i> + MeOH-<i>d</i><sub>4</sub>) δ 176.9, 163.6 (d, <i>J</i> = 248 Hz), 157.4, 148.6, 148.4, 141.4, 141.3, 141.2, 131.2 (d, <i>J</i> = 8.2 Hz), 129.6, 123.1, 120.9, 116.5 (d, <i>J</i> = 22 Hz), 113.6, 110.5, 107.5, 49.9, 40.1, 34.6, 30.0, 10.3. HRMS (ESI): exact mass calculated for C<sub>25</sub>H<sub>24</sub>FN<sub>5</sub>OS [M + H]<sup>+</sup>, 462,17584. Found: 462.17620.</div></div><div id="sec4_26_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>N</i>-(2-((4-Phenyl-5-(2-(phenylamino)pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)thio)ethyl)acrylamide (<b>7</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>37f</b> and acrylic acid according to general procedure I and obtained as an off-white solid after gradient silica flash chromatography (DCM → DCM/iPrOH 5%) in 31% yield. <sup>1</sup>H NMR (200 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.07–7.89 (m, 1H), 7.56–7.34 (m, 6H), 7.34–7.11 (m, 4H), 7.07–6.77 (m, 3H), 6.33–6.10 (m, 2H), 5.70–5.53 (m, 1H), 3.56 (t, <i>J</i> = 6.5 Hz, 2H), 3.20 (t, <i>J</i> = 6.5 Hz, 2H). <sup>13</sup>C NMR (50 MHz, MeOH-<i>d</i><sub>4</sub>) δ 166.8, 156.1, 146.5, 142.6, 140.5, 140.3, 131.0, 130.3, 128.5, 128.4, 128.1, 128.0, 125.4, 124.4, 123.2, 121.8, 119.5, 112.6, 107.0, 39.3, 33.1. HRMS (ESI): exact mass calculated for C<sub>25</sub>H<sub>23</sub>N<sub>5</sub>OS [M + H]<sup>+</sup>, 442.16961. Found: 442.17010.</div></div><div id="sec4_26_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>N</i>-(2-((4-(4-Fluoro-3-(trifluoromethyl)phenyl)-5-(2-(phenylamino)pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)thio)ethyl)acrylamide (<b>8</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>37e</b> and acrylic acid according to general procedure I and obtained as a yellow solid after gradient silica flash chromatography (hexane → hexane/EtOAc 2:1) in 48% yield. <sup>1</sup>H NMR (200 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.07 (s, 1H), 7.84–7.77 (m, 1H), 7.75–7.66 (m, 1H), 7.42–7.14 (m, 5H), 7.03–6.89 (m, 1H), 6.87–6.73 (m, 2H), 6.25–6.11 (m, 2H), 5.69–5.52 (m, 1H), 3.57 (t, <i>J</i> = 6.4 Hz, 2H), 3.23 (t, <i>J</i> = 6.5 Hz, 2H). HRMS (ESI): exact mass calculated for C<sub>26</sub>H<sub>21</sub>F<sub>4</sub>N<sub>5</sub>OS [M + H]<sup>+</sup>, 528.14757. Found: 528.14798.</div></div><div id="sec4_26_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (<i>E</i>)-4-(Dimethylamino)-<i>N</i>-(2-((4-(4-fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)thio)ethyl)but-2-enamide (<b>9</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>5</b> and (<i>E</i>)-3-carboxy-<i>N</i>,<i>N</i>-dimethylprop-2-en-1-aminium chloride according to general procedure H but using 3 equiv DIPEA and obtained as a white solid after basic silica flash chromatography (EtOAc/MeOH/NH<sub>3</sub> 90:8:2) in 50% yield. <sup>1</sup>H NMR (200 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.01 (d, <i>J</i> = 5.4 Hz, 1H), 7.59–7.35 (m, 2H), 7.36–7.09 (m, 6H), 7.00–6.78 (m, 3H), 6.77–6.63 (m, 1H), 6.11–5.94 (m, 1H), 3.56 (t, <i>J</i> = 6.4 Hz, 2H), 3.20 (t, <i>J</i> = 6.4 Hz, 2H), 3.08 (dd, <i>J</i> = 6.7, 1.4 Hz, 2H), 2.25 (s, 6H). <sup>13</sup>C NMR (50 MHz, MeOH-<i>d</i><sub>4</sub>) δ 167.8, 164.1 (d, <i>J</i> = 247 Hz), 157.9, 152.9, 148.8, 143.2, 142.1, 139.9, 131.7 (d, <i>J</i> = 8.2 Hz), 129.9, 129.2, 128.0, 123.1, 122.6, 122.6, 120.9, 116.8 (d, <i>J</i> = 22 Hz), 114.0, 108.3, 60.8, 45.1, 41.0, 34.5. HRMS (ESI): exact mass calculated for: C<sub>28</sub>H<sub>29</sub>FN<sub>6</sub>OS [M + H]<sup>+</sup>, 517.21803. Found: 517.21836.</div></div><div id="sec4_26_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 5-((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)thio)pentan-2-one (<b>10</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>36a</b> and 5-bromopentan-2-one according to general procedure F and obtained as an off-white solid after gradient silica flash chromatography (DCM → DCM/iPrOH 2.5%) in 76% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 11.68 (s, 1H), 8.01 (d, <i>J</i> = 5.4 Hz, 1H), 7.50–7.36 (m, 2H), 7.29–6.82 (m, 10H), 2.97 (t, <i>J</i> = 7.2 Hz, 2H), 2.59 (t, <i>J</i> = 6.5 Hz, 2H), 2.13 (s, 3H), 2.04–1.87 (m, 2H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 209.5, 159.9 (d, <i>J</i> = 249 Hz), 156.1, 148.1, 141.2, 139.9, 134.3, 130.2 (d, <i>J</i> = 8.0 Hz), 129.0, 122.7, 120.2, 115.6 (d, <i>J</i> = 21 Hz), 113.1, 111.4, 105.4, 41.7, 32.9, 30.0, 23.7. HRMS (ESI): exact mass calculated for C<sub>25</sub>H<sub>23</sub>FN<sub>4</sub>OS [M + H]<sup>+</sup>, 447.16494. Found: 447.16577.</div></div><div id="sec4_26_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 3-((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)thio)propanenitrile (<b>11</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>36a</b> and 3-bromopropionitrile according to general procedure F and obtained as a pale-yellow solid after gradient silica flash chromatography (DCM → DCM/iPrOH 2.5%) in 48% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>/MeOH-<i>d</i><sub>4</sub>) δ 8.37 (d, <i>J</i> = 5.5 Hz, 1H), 7.91–7.72 (m, 2H), 7.65–7.13 (m, 10H), 3.66 (t, <i>J</i> = 6.9 Hz, 2H), 3.24 (t, <i>J</i> = 6.9 Hz, 2H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 162.4 (d, <i>J</i> = 248 Hz), 156.1, 147.4, 139.8, 138.9, 135.0, 130.2 (d, <i>J</i> = 8.2 Hz), 128.7, 122.5, 120.1, 117.9, 115.5 (d, <i>J</i> = 22 Hz), 112.7, 106.0, 29.3, 18.5. HRMS (ESI): exact mass calculated for C<sub>23</sub>H<sub>18</sub>FN<sub>5</sub>S [M + H]<sup>+</sup>, 416.13397. Found: 416.13438.</div></div><div id="sec4_26_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 4-(2-((3-Aminopropyl)thio)-4-(4-fluorophenyl)-1<i>H</i>-imidazol-5-yl)-<i>N</i>-phenylpyridin-2-amine (<b>12</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>37b</b> according to general procedure G and obtained as a white solid after silica flash chromatography (hexane/MeOH/NH<sub>3</sub> 90:8:2) in 55% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.03 (s, 1H), 8.02 (d, <i>J</i> = 5.4 Hz, 1H), 7.74–7.41 (m, 4H), 7.39–7.08 (m, 4H), 7.00 (s, 1H), 6.83 (t, <i>J</i> = 7.3 Hz, 1H), 6.70 (d, <i>J</i> = 5.4 Hz, 1H), 6.46 (m, 3H), 3.17 (t, <i>J</i> = 6.8 Hz, 2H), 2.77 (t, <i>J</i> = 6.8 Hz, 2H), 1.92–1.72 (m, 2H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.0 (d, <i>J</i> = 246 Hz), 156.6, 147.7, 142.1, 133.3, 132.3, 130.5 (d, <i>J</i> = 8.2 Hz), 129.0, 128.9, 128.8, 120.6, 118.4, 115.9 (d, <i>J</i> = 22 Hz), 115.7, 112.6, 107.7, 39.7, 31.4, 30.4. HRMS (ESI): exact mass calculated for C<sub>23</sub>H<sub>22</sub>FN<sub>5</sub>S [M + H]<sup>+</sup>, 420.16527. Found: 420.16556.</div></div><div id="sec4_26_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>N</i>-(3-((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)thio)propyl)acrylamide (<b>13</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>12</b> and acrylic acid according to general procedure I and obtained as pale-yellow solid after gradient silica flash chromatography (DCM → DCM/iPrOH 5%) in 32% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.74 (s, 1H), 8.99 (s, 1H), 8.49–7.91 (m, 4H), 7.63–7.44 (m, 4H), 7.38–6.99 (m, 3H), 6.84 (t, <i>J</i> = 7.2 Hz, 1H), 6.71 (d, <i>J</i> = 5.4 Hz, 1H), 6.31–5.96 (m, 2H), 5.66–5.48 (m, 1H), 3.33–3.20 (m, 2H), 3.13 (t, <i>J</i> = 7.1 Hz, 2H), 1.94–1.73 (m, 2H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.0, 162.2 (d, <i>J</i> = 244 Hz), 156.5, 147.6, 143.3, 142.0, 141.0, 135.2, 132.1, 131.0 (d, <i>J</i> = 8.2 Hz), 130.0, 128.9, 127.1, 125.4, 120.7, 118.4, 116.1 (d, <i>J</i> = 21 Hz) 112.6, 107.7, 37.7, 30.7, 29.8. HRMS (ESI): exact mass calculated for C<sub>26</sub>H<sub>24</sub>FN<sub>5</sub>OS [M + H]<sup>+</sup>, 474,17584. Found: 474.17501.</div></div><div id="sec4_26_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (<i>R</i>)-1-(2-(((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)thio)methyl)pyrrolidin-1-yl)prop-2-en-1-one (<b>14</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>42a</b> and acrylic acid according to general procedure I and obtained as a white solid after gradient silica flash chromatography (DCM → DCM/EtOH 5%) in 31% yield. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 7.94 (t, <i>J</i> = 5.9 Hz, 1H), 7.52–7.35 (m, 2H), 7.27–6.98 (m, 6H), 6.97–6.61 (m, 3H), 6.35 (dd, <i>J</i> = 16.9, 10.4 Hz, 1H), 6.11 (td, <i>J</i> = 16.4, 2.1 Hz, 1H), 5.53 (dd, <i>J</i> = 10.4, 2.1 Hz, 1H), 3.63–3.55 (m, 1H), 3.55–3.43 (m, 1H), 3.39–3.20 (m, 4H), 2.16–1.80 (m, 3H). <sup>13</sup>C NMR (100 MHz, MeOH-<i>d</i><sub>4</sub>) δ 164.9, 162.2 (d, <i>J</i> = 246 Hz), 156.0, 146.7, 140.2, 129.8 (d, <i>J</i> = 8.2 Hz), 128.1, 128.0, 126.7, 126.4, 121.4, 121.3, 119.2, 119.2, 114.9, 114.7 (d, <i>J</i> = 22 Hz), 112.2, 106.4, 106.1, 57.3, 45.5, 34.7, 27.9, 23.0. HRMS (ESI): exact mass calculated for C<sub>28</sub>H<sub>26</sub>FN<sub>5</sub>OS [M + H]<sup>+</sup>, 500.19149. Found: 500.19186.</div></div><div id="sec4_26_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (<i>S</i>)-1-(2-(((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)thio)methyl)pyrrolidin-1-yl)prop-2-en-1-one (<b>15</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>42b</b> and acrylic acid according to general procedure I and obtained as an off-white solid after gradient silica flash chromatography (hexane → hexane/EtOAc 1:1) in 37% yield. <sup>13</sup>C NMR (50 MHz, acetone-<i>d</i><sub>6</sub>) δ 165.8, 163.1 (d, <i>J</i> = 245 Hz), 157.4, 148.6, 143.0, 142.8, 131.3 (d, <i>J</i> = 8.1 Hz), 129.5, 129.4, 128.7, 127.2, 121.6, 121.6, 119.4, 119.3, 116.2 (d, <i>J</i> = 22 Hz), 113.8, 108.1, 59.5, 48.2, 33.8, 29.6, 24.3. HRMS (ESI): exact mass calculated for C<sub>28</sub>H<sub>26</sub>FN<sub>5</sub>OS [M + H]<sup>+</sup>, 500.19149. Found: 500.19188.</div></div><div id="sec4_26_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 1-(2-((4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1<i>H</i>-imidazol-2-yl)thio)pyrrolidin-1-yl)prop-2-en-1-one (<b>16</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>46</b> and acrylic acid according to general procedure I and obtained as a pale-yellow solid after gradient silica flash chromatography (DCM → DCM/MeOH 10%) in 28% yield. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 7.91 (d, <i>J</i> = 5.5 Hz, 1H), 7.46–7.29 (m, 2H), 7.25–6.99 (m, 6H), 6.85 (t, <i>J</i> = 7.3 Hz, 1H), 6.80–6.68 (m, 2H), 6.50–6.32 (m, 1H), 6.20–6.10 (m, 1H), 5.68–5.54 (m, 1H), 4.05–3.83 (m, 2H), 3.81–3.43 (m, 3H), 2.45–2.20 (m, 1H), 2.13–1.86 (m, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.1, 162,3 (d, <i>J</i> = 245 Hz), 156.6, 153.7, 147.6, 143.1, 142.1, 139.1, 135.8, 131.1 (d, <i>J</i> = 8.0 Hz), 129.3, 128.8, 128.6, 127.0, 120.6, 118.4, 116.2 (d, <i>J</i> = 22 Hz), 112.5, 107.6, 52.1, 36.1, 28.5, 25.8. HRMS (ESI): exact mass calculated for C<sub>27</sub>H<sub>24</sub>FN<sub>5</sub>OS [M + H]<sup>+</sup>, 486.17584. Found: 486.17603.</div></div><div id="sec4_26_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> <i>N</i>-(3-((4-(4-(4-Fluorophenyl)-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)phenyl)acrylamide (<b>17a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>54a</b> according to general procedure U and obtained as an off-white solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 1:2) in 58% yield. <sup>1</sup>H NMR (200 MHz, MeOH-<i>d</i><sub>4</sub>) δ 7.98 (m, 1H), 7.82 (s, 1H), 7.54–7.35 (m, 2H), 7.29–6.96 (m, 5H), 6.92 (s, 1H), 6.84–6.69 (m, 1H), 6.66–6.21 (m, 2H), 5.94–5.61 (m, 1H), 2.77–2.36 (s, 3H). <sup>13</sup>C NMR (50 MHz, MeOH-<i>d</i><sub>4</sub>) δ 164.81, 162.7 (d, <i>J</i> = 216 Hz), 156.25, 150.84, 148.76, 146.99, 145.50, 143.19, 141.25, 138.74, 133.89, 131.05, 130.20 (d, <i>J</i> = 8 Hz), 128.66, 127.73 (d, <i>J</i> = 3 Hz), 126.23, 117.62, 115.3, 115.2 (d, <i>J</i> = 22 Hz), 114.98, 113.50, 112.60, 111.25, 109.38, 107.16, 15.31. HRMS (ESI): exact mass calculated for C<sub>24</sub>H<sub>20</sub>FN<sub>5</sub>OS [M + H]<sup>+</sup>, 445.1445. Found: 446.1471.</div></div><div id="sec4_26_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> <i>N</i>-(3-((4-(4-(4-Fluorophenyl)-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)phenyl)propionamide (<b>17b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>58a</b> according to general procedure U and obtained as a yellow solid after gradient silica flash chromatography (DCM→ DCM/iPrOH 5%) in 80% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.67 (s, 1H), 9.76 (s, 1H), 9.13–8.84 (m, 1H), 8.18–7.78 (m, 2H), 7.60–7.39 (m, 2H), 7.39–6.81 (m, 6H), 6.79–6.58 (m, 1H), 2.62 (s, 3H), 2.31 (q, <i>J</i> = 7.5 Hz, 2H), 1.07 (t, <i>J</i> = 7.5 Hz, 3H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ (major tautomer) 171.8, 161.9 (d, <i>J</i> = 246 Hz), 156.3, 147.0, 142.9, 142.09, 142.0, 141.7, 139.6, 137.9, 134.7, 130.7 (d, <i>J</i> = 8 Hz), 129.6, 128.5, 126.8 (d, <i>J</i> = 3 Hz), 115.8 (d, <i>J</i> = 22 Hz), 113.0, 112.0, 111.6, 109.1, 107.6, 29.5, 15.1, 9.8. HRMS (ESI): exact mass calculated for C<sub>24</sub>H<sub>22</sub>FN<sub>5</sub>OS [M + H]<sup>+</sup>, 448.1602. Found: 448.1597.</div></div><div id="sec4_26_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> <i>N</i>-(3-((4-(4-Phenyl-2-((2-propionamidoethyl)thio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)phenyl)acrylamide (<b>18</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>58a</b> according to general procedure U and obtained as an off-white solid after gradient silica flash chromatography (DCM→ DCM/iPrOH 10%) in 73% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.82 (s, 1H), 10.11 (s, 1H), 9.18 (s, 1H), 8.23–7.93 (m, 3H), 7.71–7.06 (m, 9H), 6.76 (d, <i>J</i> = 5.4 Hz, 1H), 6.60–6.19 (m, 2H), 5.84–5.68 (m, 1H), 4.05 (q, <i>J</i> = 7.1 Hz, 2H), 2.21–1.98 (m, 2H), 1.20 (t, <i>J</i> = 7.2 Hz, 2H), 1.04–0.95 (m, 3H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.5, 170.7, 163.4, 161.5, 156.3, 147.0, 142.1, 141.1, 139.6, 132.4, 129.1, 129.1, 128.5, 128.5, 127.0, 114.2, 112.8, 112.6, 110.0, 108.2, 28.8, 21.1, 14.5, 10.2. HRMS (ESI): exact mass calculated for C<sub>28</sub>H<sub>28</sub>N<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 513.2067. Found: 513.2099.</div></div><div id="sec4_26_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> <i>N</i>-(3-((4-(4-(4-Fluorophenyl)-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide (<b>19a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>53a</b> according to general procedure U and obtained as a white solid after gradient silica flash chromatography (DCM→ DCM/iPrOH 5%) in 80% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) mixture of tautomers: δ 12.65 (s, 1H), 10.02–9.93 (m, 1H), 8.31 (dd, <i>J</i> = 15.4, 2.5 Hz, 1H), 8.12–8.04 (m, 1H), 7.97 (d, <i>J</i> = 5.4 Hz, 1H), 7.60–7.36 (m, 3H), 7.35–7.21 (m, 2H), 7.16 (t, <i>J</i> = 8.9 Hz, 1H), 7.04 (s, 0H), 6.93 (t, <i>J</i> = 8.6 Hz, 1H), 6.72–6.61 (m, 1H), 6.53–6.39 (m, 1H), 6.28–6.14 (m, 1H), 5.76–5.64 (m, 1H), 3.79 (s, 3H), 2.62 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) major tautomer: δ 162.63, 161.8(d, <i>J</i> = 246 Hz), 156.27, 146.84, 145.59, 142.98, 142.68, 141.84, 138.93, 137.84, 134.76, 132.13, 131.87, 130.5 (d, <i>J</i> = 8 Hz), 126.75(d, <i>J</i> = 3 Hz), 115.61 (d, <i>J</i> = 22 Hz), 112.81, 112.25, 110.84, 107.85, 55.83, 15.08. HRMS (ESI): exact mass calculated for C<sub>25</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 476.1551. Found: 476.1547.</div></div><div id="sec4_26_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> <i>N</i>-(3-((4-(4-(4-Fluorophenyl)-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)-4-methoxyphenyl)propionamide (<b>19b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>57a</b> according to general procedure U and obtained as a white solid after gradient silica flash chromatography (DCM→ DCM/EtOAc 1:1) in 86% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.64 (s, 1H), 9.80–9.49 (m, 1H), 8.35–7.85 (m, 3H), 7.60–7.01 (m, 6H), 6.97–6.82 (m, 1H), 6.64 (d, <i>J</i> = 5.0 Hz, 1H), 3.77 (s, 3H), 2.62 (s, 3H), 2.29 (q, <i>J</i> = 7.5 Hz, 2H), 1.07 (t, <i>J</i> = 7.5 Hz, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub> + MeOH-<i>d</i><sub>4</sub>) mixture of tautomers give complex spectrum: δ 171.17, 162.47, 160.07, 155.39, 146.76, 146.10, 144.52, 142.36, 141.33, 138.15, 137.50, 134.06, 131.24, 129.63, 129.12, 128.79, 125.78, 125.25, 114.75, 114.53, 114.24, 114.04, 112.19, 112.02, 111.77, 110.99, 110.89, 109.62, 106.84, 54.61, 28.52, 14.04, 8.50. HRMS (ESI): exact mass calculated for C<sub>25</sub>H<sub>21</sub>FN<sub>4</sub>O [M + H]<sup>+</sup>, 478.1708. Found: 478.1710.</div></div><div id="sec4_26_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> <i>N</i>-(6-((4-(4-(4-Fluorophenyl)-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)pyridin-2-yl)acrylamide (<b>20</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>68</b> according to general procedure U and obtained as a white solid after gradient silica flash chromatography (DCM→ DCM/EtOAc 1:1) in 55% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.70 (s, 1H), 10.12 (d, <i>J</i> = 15.4 Hz, 1H), 9.58 (s, 0H), 9.35 (s, 1H), 8.24–8.04 (m, 1H), 7.83 (s, 1H), 7.77–7.39 (m, 5H), 7.34–7.08 (m, 2H), 6.96–6.51 (m, 2H), 6.45–6.26 (m, 1H), 5.87–5.69 (m, 1H), 2.65 (s, 3H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.8, 162.2 (d, <i>J</i> = 246 Hz), 155.0, 153.3, 150.2, 148.2, 143.3, 142.3, 139.6, 138.7, 135.2, 132.2, 131.1 (d, <i>J</i> = 8.4 Hz), 127.7, 127.1 (d, <i>J</i> = 2.9 Hz), 116.0 (d, <i>J</i> = 22 Hz), 114.2, 109.2, 107.9, 106.1, 15.6. HRMS (ESI): exact mass calculated for C<sub>23</sub>H<sub>19</sub>FN<sub>6</sub>OS [M + H]<sup>+</sup>, 447.13978. Found: 447.14029.</div></div><div id="sec4_26_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> <i>N</i>-(3-((4-(4-(4-Fluorophenyl)-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)benzyl)acrylamide (<b>21</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>56a</b> according to general procedure U and obtained as a white solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 1:2) in 70% yield. <sup>1</sup>H NMR (200 MHz, MeOH-<i>d</i><sub>4</sub>) δ 7.98 (d, <i>J</i> = 5.4 Hz, 1H), 7.54–7.38 (m, 2H), 7.27–7.07 (m, 5H), 6.94–6.85 (m, 2H), 6.76 (d, <i>J</i> = 5.4 Hz, 1H), 6.30–6.20 (m, 2H), 5.75–5.59 (m, 1H), 4.39 (s, 2H), 2.62 (s, 3H). <sup>13</sup>C NMR (50 MHz, MeOH-<i>d</i><sub>4</sub>) δ 166.5, 162.5 (d, <i>J</i> = 247 Hz), 156.3, 147.0, 143.2, 141.0, 139.0, 139.0, 130.5, 130.19 (d, <i>J</i> = 8 Hz), 128.6, 125.4, 120.8, 118.5, 118.1, 115.23 (d, <i>J</i> = 22 Hz), 112.6, 107.2, 42.7, 15.3. HRMS (ESI): exact mass calculated for C<sub>25</sub>H<sub>22</sub>FN<sub>5</sub>OS [M + H]<sup>+</sup>, 460.16019. Found: 460.16059.</div></div><div id="sec4_26_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> <i>N</i>-((1-(3-((4-(4-(4-Fluorophenyl)-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)benzyl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)acrylamide (<b>22</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>53c</b> according to general procedure U and obtained as a white solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 1:2) in 71% yield. <sup>1</sup>H NMR (200 MHz, MeOH-<i>d</i><sub>4</sub>) δ 7.82 (s, 1H), 7.48–7.37 (m, 3H), 7.34–7.25 (m, 1H), 7.24–7.03 (m, 4H), 6.92–6.73 (m, 3H), 6.19 (d, <i>J</i> = 6.1 Hz, 2H), 5.72–5.57 (m, 1H), 5.48 (s, 2H), 4.47 (s, 2H), 2.60 (s, 3H). <sup>13</sup>C NMR (100 MHz, MeOH-<i>d</i><sub>4</sub>) δ 166.6, 162.68 (d, <i>J</i> = 245 Hz), 156.1, 146.8, 144.9, 143.4, 141.5, 136.0, 130.3(d, <i>J</i> = 8 Hz), 129.1, 127.8, 125.6, 122.9, 121.0, 119.1, 118.8, 115.33 (d, <i>J</i> = 22 Hz), 112.9, 107.5, 53.6, 34.3, 15.3. HRMS (ESI): exact mass calculated for C<sub>23</sub>H<sub>19</sub>FN<sub>6</sub>OS [M + H]<sup>+</sup>, 447.13978. Found: 447.14029.</div></div><div id="sec4_26_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> <i>N</i>-(4-Methoxy-3-((4-(2-(methylthio)-4-(naphthalen-2-yl)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)phenyl)acrylamide (<b>23</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>53c</b> according to general procedure U and obtained as a white solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 1:2) in 66% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 12.76 (s, 1H), 9.93 (s, 1H), 8.29 (s, 1H), 8.16–7.81 (m, 7H), 7.63–7.44 (m, 3H), 7.39 (d, <i>J</i> = 8.9 Hz, 1H), 6.89 (d, <i>J</i> = 8.8 Hz, 1H), 6.78–6.62 (m, 1H), 6.56–6.10 (m, 2H), 5.79–5.60 (m, 1H), 3.76 (s, 3H), 2.64 (s, 3H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 163.0, 156.5, 146.9, 145.9, 143.7, 142.7, 133.3, 132.7, 132.5, 132.4, 132.3, 131.0, 130.3, 128.5, 128.3, 127.9, 127.3, 126.9, 126.7, 126.7, 126.4, 126.3, 125.6, 113.4, 112.4, 111.2, 108.7, 56.2, 15.5. HRMS (ESI): exact mass calculated for C<sub>28</sub>H<sub>25</sub>FN<sub>8</sub>OS [M + H]<sup>+</sup>, 508.81017. Found: 508.81095.</div></div><div id="sec4_26_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> <i>N</i>-(4-Methoxy-3-((4-(2-(methylthio)-4-(thiophen-2-yl)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)phenyl)acrylamide (<b>24</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>53d</b> according to general procedure U and obtained as a white solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 1:2) in 66% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.70 (s, 1H), 9.99 (s, 1H), 8.40–8.25 (m, 1H), 8.22–8.12 (m, 1H), 8.11–7.96 (m, 1H), 7.66–7.36 (m, 2H), 7.34–7.22 (m, 1H), 7.18–7.11 (m, 1H), 7.03–6.88 (m, 2H), 6.85–6.72 (m, 1H), 6.55–6.13 (m, 2H), 5.75–5.62 (m, 1H), 3.79 (s, 3H), 2.60 (s, 3H). HRMS (ESI): exact mass calculated for C<sub>23</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub> [M + H]<sup>+</sup>, 464.12094. Found: 464.12093.</div></div><div id="sec4_26_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> <i>N</i>-(4-Methoxy-3-((4-(2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)phenyl)acrylamide (<b>25a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>53e</b> according to general procedure U and obtained as a white solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 1:2) in 83% yield. <sup>1</sup>H NMR (200 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.24–8.13 (m, 1H), 8.08 (d, <i>J</i> = 5.5 Hz, 1H), 7.69 (s, 1H), 7.38–7.27 (m, 2H), 7.14–7.07 (m, 1H), 6.97 (d, <i>J</i> = 8.8 Hz, 1H), 6.49–6.30 (m, 2H), 5.88–5.64 (m, 1H), 3.90 (s, 3H), 2.60 (s, 3H). <sup>13</sup>C NMR (50 MHz, MeOH-<i>d</i><sub>4</sub>) δ 164.4, 156.0, 148.4, 147.5, 147.1, 146.4, 131.2, 131.1, 129.7, 125.8, 123.5, 113.8, 112.8, 111.7, 110.7, 110.3, 104.4, 55.0, 15.3. HRMS (ESI): exact mass calculated for C<sub>19</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 382.13322. Found: 382.13363.</div></div><div id="sec4_26_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> <i>N</i>-(4-Methoxy-3-((4-(2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)phenyl) propionamide (<b>25b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>57e</b> according to general procedure U and obtained as a white solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 1:2) in 83% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.51 (s, 1H), 8.29 (d, <i>J</i> = 5.6 Hz, 1H), 7.80–7.69 (m, 2H), 7.62–7.56 (m, 1H), 7.46–7.40 (m, 1H), 7.35–7.27 (m, 2H), 6.85–6.76 (m, 1H), 3.86 (s, 3H), 2.60 (s, 3H), 2.48–2.32 (m, 2H), 1.13 (t, <i>J</i> = 7.9 Hz, 3H). <sup>13</sup>C NMR (50 MHz, DMSO <i>d</i><sub>6</sub>) δ 174.0, 155.5, 154.4, 145.6, 144.8, 143.0, 134.8, 132.2, 131.0, 119.8, 119.0, 116.9, 114.1, 108.8, 107.2, 56.0, 27.4, 13.8, 9.6. HRMS (ESI): exact mass calculated for C<sub>19</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 384.14887. Found: 384.14801.</div></div><div id="sec4_26_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> <i>N</i>-(4-Methoxy-3-((4-(4-methyl-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)phenyl)acrylamide (<b>26</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>52f</b> according to general procedure U, and the crude product was directly subjected to deprotection according to general procedure R as a white solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 1:2) in 67% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.24 (s, 1H), 9.94 (s, 1H), 8.45–8.32 (m, 1H), 8.11–7.99 (m, 2H), 7.46–7.34 (m, 1H), 7.28 (s, 1H), 7.11–6.99 (m, 1H), 6.93 (d, <i>J</i> = 8.7 Hz, 1H), 6.57–6.09 (m, 2H), 5.77–5.61 (m, 1H), 3.81 (s, 3H), 2.54 (s, 3H), 2.40 (s, 3H). HRMS (ESI): exact mass calculated for C<sub>20</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 396,14887. Found: 396.14915.</div></div><div id="sec4_26_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> <i>N</i>-(3-((4-(4-Cyclopropyl-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide (<b>27</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>53g</b> according to general procedure U and obtained as a white solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 1:2) in 88% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.00 (s, 1H), 9.99 (s, 1H), 8.35 (d, <i>J</i> = 2.6 Hz, 1H), 8.10 (d, <i>J</i> = 5.4 Hz, 1H), 8.05 (s, 1H), 7.45–7.34 (m, 2H), 7.16 (s, 1H), 6.94 (d, <i>J</i> = 8.8 Hz, 1H), 6.54–6.13 (m, 2H), 5.74–5.63 (m, 1H), 3.81 (s, 3H), 2.53 (s, 3H), 2.10 (p, <i>J</i> = 7.9 Hz, 1H), 0.99–0.71 (m, 4H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.7, 162.7, 156.1, 147.0, 145.4, 143.2, 139.4, 135.1, 133.1, 132.1, 131.9, 130.2, 126.1, 112.7, 111.8, 111.6, 110.8, 106.4, 55.9, 15.3, 7.5. HRMS (ESI): exact mass calculated for C<sub>22</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 422,16452. Found: 422.16482.</div></div><div id="sec4_26_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> <i>N</i>-(3-((4-(4-Cyclobutyl-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide (<b>28</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>53h</b> according to general procedure U and obtained as a white solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 1:2) in 73% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.30 (s, 1H), 9.98 (s, 1H), 8.45–8.26 (m, 1H), 8.13–8.03 (m, 2H), 7.50–7.31 (m, 1H), 7.12 (s, 1H), 7.05–6.86 (m, 2H), 6.58–6.09 (m, 2H), 5.69 (dd, <i>J</i> = 9.9, 2.4 Hz, 1H), 3.93–3.70 (m, 4H), 2.56 (s, 3H), 2.34–2.12 (m, 4H), 2.04–1.73 (m, 2H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 163.0, 156.6, 147.4, 145.9, 143.6, 140.5, 135.0, 134.0, 132.5, 132.3, 130.6, 126.4, 113.1, 112.8, 112.1, 111.2, 107.4, 56.2, 31.1, 29.1, 17.9, 15.7. HRMS (ESI): exact mass calculated for C<sub>23</sub>H<sub>25</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 436.18017. Found: 436.18046.</div></div><div id="sec4_26_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> <i>N</i>-(3-((4-(4-Cyclopentyl-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide (<b>29</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>53i</b> according to general procedure U and obtained as a white solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 1:2) in 70% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.16 (s, 1H), 9.98 (s, 1H), 8.32 (d, <i>J</i> = 2.5 Hz, 1H), 8.08 (s, 2H), 7.42 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 7.16 (s, 1H), 7.03–6.87 (m, 2H), 6.60–6.10 (m, 2H), 5.69 (dd, <i>J</i> = 9.9, 2.4 Hz, 1H), 3.82 (s, 3H), 3.45–3.28 (m, 2H), 2.55 (s, 3H), 2.05–1.46 (m, 8H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.0, 156.6, 147.4, 145.9, 143.9, 140.4, 135.0, 134.7, 132.5, 132.3, 130.6, 126.4, 113.1, 112.6, 112.2, 111.2, 107.6, 56.2, 36.3, 33.2, 25.5, 15.7. HRMS (ESI): exact mass calculated for C<sub>24</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 450.19582. Found: 450.19584.</div></div><div id="sec4_26_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> <i>N</i>-(3-((4-(4-(<i>tert</i>-Butyl)-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide (<b>30</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>53c</b> according to general procedure U and obtained as a white solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 1:2) in 81% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i> + MeOH-<i>d</i><sub>4</sub>) δ 8.09 (d, <i>J</i> = 5.3 Hz, 1H), 7.84 (s, 1H), 7.63–7.46 (m, 1H), 7.09 (s, 1H), 6.84–6.71 (m, 2H), 6.47–6.16 (m, 2H), 5.65 (dd, <i>J</i> = 8.8, 3.0 Hz, 1H), 3.81 (s, 3H), 2.51 (s, 3H), 1.22 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i> + MeOH-<i>d</i><sub>4</sub>) δ 163.9, 154.7, 146.5, 145.7, 145.4, 140.5, 139.5, 132.3, 131.5, 131.3, 129.4, 126.7, 117.3, 113.7, 110.8, 110.6, 110.0, 55.7, 31.9, 30.6, 17.0. HRMS (ESI): exact mass calculated for C<sub>23</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 438.19582. Found: 438.19617.</div></div><div id="sec4_26_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> <i>N</i>-(3-((4-(4-(4-Fluorophenyl)-2-(3-hydroxypropyl)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide (<b>31a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>83a</b> according to general procedure U and obtained as a colorless solid after gradient silica flash chromatography (DCM:MeOH 95:5 → 10:1) in 41% yield. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 8.07 (s, 1H), 7.98 (d, <i>J</i> = 4.9 Hz, 1H), 7.48–7.37 (m, 2H), 7.35–7.27 (m, 1H), 7.13–7.00 (m, 3H), 6.92 (d, <i>J</i> = 8.5 Hz, 1H), 6.76 (s, 1H), 6.52–6.23 (m, 2H), 5.73 (d, <i>J</i> = 9.9 Hz, 1H), 3.84 (s, 3H), 3.63 (t, <i>J</i> = 5.8 Hz, 2H), 2.84 (t, <i>J</i> = 7.4 Hz, 2H), 1.97 (q, <i>J</i> = 6.8 Hz, 2H). <sup>13</sup>C NMR (100 MHz, MeOH-<i>d</i><sub>4</sub>) δ 165.9, 163.9 (d, <i>J</i> = 246.5 Hz), 157.8, 150.9 (d, <i>J</i> = 1.7 Hz), 148.6, 148.4, 132.8, 132.7, 131.7 (d, <i>J</i> = 8.2 Hz), 131.1, 127.3, 116.6 (d, <i>J</i> = 21.7 Hz), 115.8, 114.4, 114.1, 112.0, 108.2, 62.2, 56.6, 32.5, 25.7. HRMS (ESI): exact mass calculated for C<sub>27</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 488.2092. Found: 488.2090.</div></div><div id="sec4_26_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> <i>N</i>-(3-((4-(4-(4-Fluorophenyl)-2-(3-hydroxypropyl)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)-4-methoxyphenyl)propionamide (<b>31b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>83b</b> according to general procedure U and obtained as a colorless solid after gradient silica flash chromatography (DCM:MeOH 10:0.6 → DCM:MeOH 10:0.7) in 56% yield. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>) δ 7.97–7.95 (m, 2H), 7.46–7.38 (m, 2H), 7.22 (d, <i>J</i> = 8.5 Hz, 1H), 7.09–7.03 (m, 3H), 6.89 (d, <i>J</i> = 8.7 Hz, 1H), 6.74 (d, <i>J</i> = 5.3 Hz, 1H), 3.82 (s, 3H), 3.63 (t, <i>J</i> = 6.1 Hz, 2H), 2.84 (t, <i>J</i> = 7.5 Hz, 2H), 2.36 (q, <i>J</i> = 7.5 Hz, 2H), 2.03–1.93 (m, 2H), 1.20 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (100 MHz, MeOH-<i>d</i><sub>4</sub>) δ 175.10 (s), 163.91 (d, <i>J</i> = 246.4 Hz), 157.84 (s), 150.89 (s), 148.52 (s), 148.22 (s), 133.02 (s), 131.62 (d, <i>J</i> = 8.2 Hz), 130.93 (s), 116.52 (d, <i>J</i> = 21.9 Hz), 115.86 (s), 114.29 (s), 112.01 (s), 108.14 (s), 62.15 (s), 56.52 (s), 32.48 (s), 31.00 (s), 25.72 (s), 10.38 (s). HRMS (ESI): exact mass calculated for C<sub>27</sub>H<sub>28</sub>FN<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 490.2249. Found: 490.2244.</div></div><div id="sec4_26_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> <i>N</i>-(3-Fluoro-5-nitrophenyl)-4-(4-(4-fluorophenyl)-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-amine (<b>32</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>74a</b> according to general procedure U and obtained as a red solid after gradient silica flash chromatography (DCM → DCM/i-PrOH 10%) in 69% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.88–12.71 (m, 1H), 9.97–9.81 (m, 1H), 8.46–8.41 (m, 1H), 8.34–8.13 (m, 2H), 7.62–7.50 (m, 3H), 7.36 (t, <i>J</i> = 8.9 Hz, 2H), 7.22 (d, <i>J</i> = 13.7 Hz, 1H), 6.97–6.85 (m, 1H), 2.67 (s, 3H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.0 (d, <i>J</i> = 246 Hz), 161.9 (d, <i>J</i> = 244 Hz), 155.1, 148.8 (d, <i>J</i> = 12 Hz), 147.0, 144.3 (d, <i>J</i> = 12 Hz), 143.5, 142.3, 134.0, 130.7 (d, <i>J</i> = 8 Hz), 130.0, 126.7 (d, <i>J</i> = 2.5 Hz), 115.8 (d, <i>J</i> = 22 Hz), 113.4, 108.7, 108.2 (d, <i>J</i> = 28 Hz), 101.2, (d, <i>J</i> = 28 Hz), 15.0. HRMS (ESI): exact mass calculated for C<sub>21</sub>H<sub>15</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 440.09873. Found: 440.09799.</div></div><div id="sec4_26_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 4-(4-(4-Fluorophenyl)-2-(methylthio)-1<i>H</i>-imidazol-5-yl)-<i>N</i>-(3-(4-methylpiperazin-1-yl)-5-nitrophenyl)pyridin-2-amine (<b>33</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>74b</b> according to general procedure U and obtained as an orange solid after gradient silica flash chromatography (EtOAc/MeOH/NH<sub>3</sub> 90:8:2) in 75% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.85–12.57 (m, 1H), 9.39 (s, 1H), 8.27–8.20 (m, 1H), 8.08 (s, 1H), 7.62–7.56 (m, 1H), 7.56–7.47 (m, 2H), 7.35–7.10 (m, 4H), 6.84–6.73 (m, 1H), 3.21 (t, <i>J</i> = 5.0 Hz, 4H), 2.63 (s, 3H), 2.46 (t, <i>J</i> = 5.1 Hz, 4H), 2.22 (s, 3H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.2 (d, <i>J</i> = 246 Hz), 156.10, 151.94, 149.49, 147.50, 143.76, 142.62, 134.62, 131.0 (d, <i>J</i> = 8.2 Hz), 130.19, 127.08, 116.1 (d, <i>J</i> = 22 Hz), 113.16, 109.66, 108.49, 102.77, 101.64, 54.67, 47.99, 46.02, 15.34. HRMS (ESI): exact mass calculated for C<sub>26</sub>H<sub>26</sub>FN<sub>7</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 520.19255. Found: 520.19297.</div></div><div id="sec4_26_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> <i>N</i>-(3-((4-(4-(4-Fluorophenyl)-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)-5-(4-methylpiperazin-1-yl)phenyl)acrylamide (<b>34</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>74c</b> according to general procedure U and obtained as an off-white solid after gradient silica flash chromatography (DCM/MeOH/NH<sub>3</sub> 92:6:2) in 40% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 11.70 (s, 1H), 8.54 (s, 1H), 7.95 (d, <i>J</i> = 5.4 Hz, 1H), 7.58–7.12 (m, 6H), 6.99 (t, <i>J</i> = 8.5 Hz, 2H), 6.75–6.22 (m, 5H), 5.86–5.73 (m, 1H), 3.09 (t, <i>J</i> = 4.9 Hz, 4H), 2.61 (s, 3H), 2.49 (t, <i>J</i> = 4.9 Hz, 3H), 2.28 (s, 3H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 164.2, 162.3 (d, <i>J</i> = 247 Hz), 156.2, 154.6, 152.6, 148.0, 143.6, 141.2, 138.2, 133.5, 130.8, 130.2 (d, <i>J</i> = 8.1 Hz), 129.3, 128.7, 115.3 (d, <i>J</i> = 22 Hz), 113.1, 105.9, 104.5, 104.0, 102.1, 54.8, 48.5, 45.9, 30.4, 16.2. HRMS (ESI): exact mass calculated for C<sub>29</sub>H<sub>30</sub>FN<sub>7</sub>OS [M + Na]<sup>+</sup>, 566.21088 Found: 566.21113.</div></div><div id="sec4_26_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> <i>N</i>-(3-((4-(4-(4-Fluorophenyl)-2-(methylthio)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)-5-morpholinophenyl)acrylamide (<b>35</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>74d</b> according to general procedure U and obtained as an off-white solid after gradient silica flash chromatography (hexane → EtOAc) in 78% yield. <sup>1</sup>H NMR (200 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.91 (d, <i>J</i> = 5.5 Hz, 1H), 7.49–7.33 (m, 2H), 7.31–7.25 (m, 1H), 7.13–6.89 (m, 4H), 6.77–6.65 (m, 2H), 6.48–6.22 (m, 2H), 5.70 (dd, <i>J</i> = 8.8, 3.1 Hz, 1H), 3.75 (t, <i>J</i> = 5.1, 4.3 Hz, 4H), 3.05 (t, <i>J</i> = 5.1 Hz, 4H), 2.57 (s, 3H). <sup>13</sup>C NMR (50 MHz, MeOH) δ 164.6, 162.51 (d, <i>J</i> = 246 Hz), 156.3, 152.3, 146.5, 143.2, 141.6, 139.3, 131.1, 130.4, 130.2 (d, <i>J</i> = 8.4 Hz), 126.2, 115.2 (d, <i>J</i> = 22 Hz), 112.4, 107.3, 103.6, 103.6, 101.8, 66.4, 15.3. HRMS (ESI): exact mass calculated for C<sub>28</sub>H<sub>27</sub>FN<sub>6</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 531.19730 Found: 531.19765.</div></div><div id="sec4_26_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 1-(4-Fluorophenyl)-2-(2-fluoropyridin-4-yl)ethan-1-one (<b>36a</b>)</h4><div class="NLM_p last">The title compound was prepared from ethyl 4-fluorobenzoate according to general procedure A and obtained as a white solid in 69% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 4.31 (s, H), 6.85–6.86 (m, 1H), 7.07–7.26 (m, 3H), 8.00–8.07 (m, 2H), 8.19 (d, 1H, <i>J</i> = 5.14 Hz). <sup>13</sup>C NMR (chloroform-<i>d</i>) δ 43.9 (d, <i>J</i> = 3.0 Hz), 111.1 (d, <i>J</i> = 37 Hz), 116.2 (d, <i>J</i> = 22 Hz), 124.1 (d, <i>J</i> = 3.8 Hz), 131.6 (d, <i>J</i> = 9.5 Hz), 133.2 (d, <i>J</i> = 2.7 Hz), 147.3, (d, <i>J</i> = 16 Hz), 151.0 (d, <i>J</i> = 8.3 Hz), 163.5 (d, <i>J</i> = 233 Hz), 165.0 (d, <i>J</i> = 250 Hz), 194.3. LRMS (FAB-MS): 234.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 1-(4-Fluorophenyl)-2-(2-fluoropyridin-4-yl)-2-(hydroxyimino)ethan-1-one (<b>37a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>32a</b> according to general procedure B and obtained as a white solid in 84% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 200 MHz): δ 7.20–7.21 (m, 1H), 7.37–7.49 (m, 3H), 7.92–7.99 (m, 2H), 8.31 (d, 1H, <i>J</i> = 5.3 Hz), 12.70(bs, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 50 MHz): δ 105.7 (d, <i>J</i> = 40 Hz), 117.0 (d, <i>J</i> = 22 Hz), 118.6 (d, <i>J</i> = 4.1 Hz), 131.1 (d, <i>J</i> = 2.7 Hz), 132.6 (d, <i>J</i> = 10 Hz), 144.6 (d, <i>J</i> = 8.4 Hz), 149.2 (d, <i>J</i> = 16 Hz), 152.2 (d, <i>J</i> = 4.0 Hz), 163.8 (d, <i>J</i> = 234 Hz), 165.5 (d, <i>J</i> = 253 Hz), 192.4. LRMS (FAB-MS): 263.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 2-(4-Fluorophenyl)-1-(2-fluoropyridin-4-yl)-2-oxoethan-1-aminium Chloride (<b>38a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>36a</b> according to general procedure C and obtained as a white solid in 92% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ (ppm) 6.56 (bs, 1H), 7.36–7.45 (m, 2H), 7.52 (m, 2H), 8.18–8.25 (m, 2H), 8.32 (d, 1H, <i>J</i> = 5.42 Hz), 9.29 (bs, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 50 MHz) δ 56.7, 110.4 (d, <i>J</i> = 39 Hz), 116.8 (d, <i>J</i> = 22 Hz), 122.2 (d, <i>J</i> = 4.3 Hz), 129.9 (d, <i>J</i> = 2.8 Hz), 132.8 (d, <i>J</i> = 10 Hz), 147.3 (d, <i>J</i> = 8.1 Hz), 149.3 (d, <i>J</i> = 15 Hz), 163.4 (d, <i>J</i> = 235.Hz), 166.2 (d, <i>J</i> = 253 Hz), 191.2.</div></div><div id="sec4_26_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 4-(4-Fluorophenyl)-5-(2-fluoropyridin-4-yl)-1,3-dihydro-2<i>H</i>-imidazole-2-thione (<b>39a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>38a</b> according to general procedure D and obtained as a yellow solid after gradient silica flash chromatography (DCM → DMC/MeOH 20%) in 79% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 7.12–7.16 (m, 2H), 7.29–7.37 (m,2H), 7.44–7.55 (m, 2H), 8.13 (d, 1H, <i>J</i> = 5.26 Hz), 12.86 (bs, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 100 MHz) δ 106.0 (d, <i>J</i> = 40 Hz), 116.5 (d, <i>J</i> = 22 Hz,),118.8 (d, <i>J</i> = 3.8 Hz), 121.3 (d, <i>J</i> = 4.1 Hz), 124.7 (d, <i>J</i> = 3.2), 128.5, 131.5 (d, <i>J</i> = 8.5 Hz), 141.5 (d, <i>J</i> = 9.1 Hz), 148.4 (d, <i>J</i> = 16 Hz), 162.4 (d, <i>J</i> = 246 Hz), 162.9, 163.9 (d, <i>J</i> = 233 Hz). LRMS (FAB-MS): 290.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 4-(4-Fluorophenyl)-5-(2-(phenylamino)pyridin-4-yl)-1,3-dihydro-2<i>H</i>-imidazole-2-thione (<b>40a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>39a</b> according to general procedure E and obtained as a yellow solid after recrystallization from DMF/H<sub>2</sub>O in 88% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.66 (s, 2H), 8.98 (s, 1H), 8.09 (d, <i>J</i> = 5.2 Hz, 1H), 7.60–7.37 (m, 5H), 7.34–7.10 (m, 5H), 6.86 (t, <i>J</i> = 7.2 Hz, 1H), 6.76–6.63 (m, 2H). LRMS (FAB-MS): 363.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> <i>tert</i>-Butyl (<i>R</i>)-2-(Hydroxymethyl)pyrrolidine-1-carboxylate (<b>44a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>38a</b> according to general procedure J and obtained as a white solid in 62% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 4.74 (s, 1H), 3.84 (s, 1H), 3.59–3.41 (m, 2H), 3.39–3.16 (m, 2H), 1.99–1.63 (m, 3H), 1.39 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 156.8, 67.0, 59.9, 47.3, 28.3.</div></div><div id="sec4_26_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> <i>tert</i>-Butyl (<i>S</i>)-2-(Hydroxymethyl)pyrrolidine-1-carboxylate (<b>44b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>43b</b> according to general procedure J and obtained as a white solid in 65% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 4.74 (s, 1H), 3.84 (s, 1H), 3.59–3.45 (m, 2H), 3.33–3.19 (m, 2H), 1.85–1.65 (m, 2H), 1.35 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 156.9, 67.2, 60.0, 47.5, 28.4.</div></div><div id="sec4_26_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> <i>tert</i>-Butyl (<i>S</i>)-2-(Bromomethyl)pyrrolidine-1-carboxylate (<b>45b</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>43b</b> according to general procedure K and obtained as a white solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 6:1) in 65% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 4.14–3.79 (m, 1H), 3.66–3.44 (m, 1H), 3.44–3.16 (m, 3H), 2.09–1.89 (m, 2H), 1.87–1.67 (m, 2H), 1.40 (s, 9H).</div></div><div id="sec4_26_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 4-(4-(4-Fluorophenyl)-2-(pyrrolidin-3-ylthio)-1<i>H</i>-imidazol-5-yl)-<i>N</i>-phenylpyridin-2-amine (<b>51</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>50</b> according to general procedure G and obtained as a white solid after silica flash chromatography (hexane/MeOH/NH<sub>3</sub> 90:8:2) in 85% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.11 (brs, 1H), 9.44 (s, 1H), 9.25 (s, 1H), 8.05 (d, <i>J</i> = 5.5 Hz, 1H), 7.62–7.41 (m, 4H), 7.24 (q, <i>J</i> = 9.0, 8.1 Hz, 4H), 7.04–6.74 (m, 3H), 4.12 (s, 1H), 3.70 (s, 1H), 2.38 (d, <i>J</i> = 15.3 Hz, 1H), 2.12–1.87 (m, 1H), 1.33–0.95 (m, 2H), 0.83 (s, 1H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 162.3 (d, <i>J</i> = 240 Hz), 159.3, 158.7, 158.0, 155.9, 146.6, 141.3, 139.1, 130.7 (d, <i>J</i> = 8.2 Hz), 129.0, 121.5, 120.4, 119.2, 116.1 (d, <i>J</i> = 22 Hz), 114.5, 112.6, 108.5, 107.6, 50.6, 44.6, 43.3, 31.0. LRMS (FAB-MS): 232.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> 2-Bromo-1-cyclopropylethan-1-one (<b>52g</b>)</h4><div class="NLM_p last">The title compound was prepared from 1-cyclopropylethan-1-one according to general procedure L (method A) in 77% yield and was used in the next step without further purification. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 3.89–3.83 (m, 2H), 3.29–3.08 (m, 1H), 2.43–2.12 (m, 6H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 201.9, 34.8, 18.5, 12.3. LRMS (ESI): not detectable.</div></div><div id="sec4_26_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> 2-Bromo-1-(4-fluorophenyl)ethan-1-one (<b>52a</b>)</h4><div class="NLM_p last">The title compound was prepared from 4-fluoro acetophenone according to general procedure L (method B) in 95% yield and was used in the next step without further purification. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 8.09–7.91 (m, 2H), 7.22–7.07 (m, 2H), 4.41 (s, 2H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 189.8, 166.1 (d, <i>J</i> = 254), 131.7 (d, <i>J</i> = 10 Hz), 130.2, (d, <i>J</i> = 3.0 Hz), 116.06 (d, <i>J</i> = 22 Hz), 30.51. LRMS (ESI): not detected.</div></div><div id="sec4_26_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> 4-(4-Fluorophenyl)-2-(methylthio)-1<i>H</i>-imidazole (<b>53a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>52a</b> according to general procedure M and obtained as a white solid after gradient silica flash chromatography (hexane → hexane/EtOAc 1:1) in 50% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.29 (s, 1H), 7.86–7.70 (m, 2H), 7.62 (s, 1H), 7.23–7.07 (m, 2H), 2.55 (s, 3H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.2 (d, <i>J</i> = 242 Hz) 141.5, 140.5, 131.3 (d, <i>J</i> = 3 Hz), 126.3, 126.2 (d, <i>J</i> = 8 Hz), 115.5 (d, <i>J</i> = 21 Hz), 114.6, 15.8. LRMS (ESI): 209.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> 4-(4-Fluorophenyl)-2-(methylthio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazole (<b>54a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>53a</b> according to general procedure N and obtained as a colorless oil after gradient silica flash chromatography (hexane → hexane/EtOAc 3:1) in 91% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.88–7.67 (m, 3H), 7.31–7.02 (m, 2H), 5.26 (s, 2H), 3.52 (t, <i>J</i> = 7.9 Hz, 2H), 2.58 (s, 3H), 0.81–0.90 (t, <i>J</i> = 7.9 Hz, 2H), 0.01 (s, 9H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.6, 161.0 (d, <i>J</i> = 243 Hz), 143.5, 139.9, 130.4 (d, <i>J</i> = 3 Hz), 126.2 (d, <i>J</i> = 8 Hz), 118.5, 18 115.6 (d, <i>J</i> = 22 Hz), 74.9, 65.9, 17.5, 16.2, −1.0. LRMS (ESI): 339.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> 5-Bromo-4-(4-fluorophenyl)-2-(methylthio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazole (<b>55a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>54a</b> according to general prrocedure O and obtained as a yellow oil after gradient silica flash chromatography (hexane → hexane/EtOAc 5:1) in 85% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.97–7.85 (m, 2H), 7.34–7.19 (m, 2H), 5.30 (s, 2H), 3.58 (t, <i>J</i> = 7.9 Hz, 2H), 2.60 (s, 3H), 0.95–0.77 (t, <i>J</i> = 7.9 Hz, 2H), −0.05 (s, 9H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.7 (d, <i>J</i> = 244 Hz), 145.3, 137.5, 129.5 (d, <i>J</i> = 3 Hz), 128.4 (d, <i>J</i> = 8 Hz), 115.7 (d, <i>J</i> = 22 Hz), 100.8, 100.8, 74.0, 66.3, 17.5, 15.8, −1.03. LRMS (ESI): 417/418 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> <i>N</i>-(4-(4-(4-Fluorophenyl)-2-(methylthio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)acetamide (<b>56a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>55a</b> and <i>N</i>-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetamide according to general procedure P (method A) and obtained as a yellow sticky oil after gradient silica flash chromatography (hexane → hexane/EtOAc 3:1) in 80% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 9.26 (s, 1H), 8.31 (s, 1H), 8.24 (m, 1H), 7.54–7.34 (m, 2H), 7.08–6.98 (m, 1H), 6.97–6.85 (m, 2H), 5.21 (s, 2H), 3.61–3.44 (m, 2H), 2.71 (s, 3H), 2.18 (s, 3H), 0.98–0.86 (m, 2H), −0.04 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 168.7, 162.0 (d, <i>J</i> = 246 Hz), 152.2, 147.8, 145.9, 140.8, 139.5, 129.6 (d, <i>J</i> = 3 Hz), 129.1 (d, <i>J</i> = 8 Hz), 127.3, 121.1, 115.1, 115.1 (d, <i>J</i> = 21 Hz) 114.9, 74.9, 72.9, 66.3, 24.8, 17.7, 16.2, −1.6. LRMS (ESI): 473.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> 4-(4-(4-Fluorophenyl)-2-(methylthio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-5-yl)pyridin-2-amine (<b>57a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>56a</b> according to general procedure Q and obtained as a white solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 1:1) in 72% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 8.09 (d, <i>J</i> = 6.0 Hz, 1H), 7.58–7.38 (m, 2H), 7.01–6.86 (m, 2H), 6.66 (dd, <i>J</i> = 5.3, 1.4 Hz, 1H), 6.54 (s, 1H), 5.14 (s, 2H), 4.60 (s, 2H), 3.69–3.49 (m, 2H), 2.71 (s, 3H), 1.03–0.82 (m, 2H), 0.00 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 161.9 (d, <i>J</i> = 246 Hz), 158.7, 148.5, 145.4, 139.9, 138.7, 129.8 (d, <i>J</i> = 3 Hz), 128.9 (d, <i>J</i> = 8 Hz), 127.9, 127.8, 115.4, 115.1 (d, <i>J</i> = 22 Hz), 109.5, 72.8, 66.4, 17.9, 16.2, −1.5. LRMS (ESI): 431.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> 4-(2-(Methylthio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-5-yl)pyridin-2-amine (<b>57e</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>56e</b> according to general procedure R and obtained as a waxy solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 2:1) in 53% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 8.15–8.00 (m, 2H), 7.78–7.62 (m, 3H), 7.61–7.47 (m, 1H), 7.45–7.32 (m, 2H), 6.68 (d, <i>J</i> = 5.3 Hz, 1H), 6.53 (s, 1H), 5.15 (s, 2H), 4.95 (s, 2H), 3.57 (t, <i>J</i> = 8.3 Hz, 2H), 2.75 (s, 3H), 0.93 (t, <i>J</i> = 8.3 Hz, 2H), 0.00 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 158.8, 148.3, 147.3, 138.8, 133.6, 129.4, 112.6, 106.2, 73.0, 66.6, 17.8, 15.9, −1.5. LRMS (ESI): 337.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> 4-(4-Cyclopentyl-2-(methylthio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-5-yl)pyridin-2-amine (<b>57i</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>56i</b> according to general procedure S and obtained as a white solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 1:1) in 88% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 8.09 (d, <i>J</i> = 5.3 Hz, 1H), 6.70 (dd, <i>J</i> = 5.3, 1.2 Hz, 1H), 6.59–6.51 (m, 1H), 5.14 (s, 2H), 4.62 (s, 2H), 3.60–3.48 (m, 2H), 2.96 (p, <i>J</i> = 8.2 Hz, 1H), 2.60 (s, 3H), 1.84 (dd, <i>J</i> = 7.9, 3.3 Hz, 6H), 1.64–1.47 (m, 2H), 0.97–0.83 (m, 2H), −0.01 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 158.4, 147.8, 145.0, 144.2, 140.0, 127.9, 115.0, 108.9, 72.9, 66.1, 37.6, 33.3, 25.6, 17.8, 17.0, −1.5. LRMS (ESI-MS): 405.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> <i>N</i>-(3-((4-(4-(4-Fluorophenyl)-2-(methylthio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide (<b>58a</b>)</h4><div class="NLM_p last">The title compound was prepared from <b>57a</b> and <i>N</i>-(3-bromo-4-methoxyphenyl)acrylamide according to general procedure T and obtained as a waxy solid after gradient silica flash chromatography (hexane→ hexane/EtOAc 2:1) in 81% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 8.32–8.08 (m, 2H), 7.90 (d, <i>J</i> = 5.5 Hz, 1H), 7.62–7.30 (m, 2H), 7.19–7.06 (m, 3H), 6.97 (s, 1H), 6.76 (d, <i>J</i> = 8.8 Hz, 1H), 6.53 (d, <i>J</i> = 5.5 Hz, 1H), 6.39–5.94 (m, 2H), 5.56 (d, <i>J</i> = 8.1 Hz, 1H), 5.05 (s, 2H), 3.82 (s, 3H), 3.58–3.40 (m, 2H), 2.72 (s, 3H), 0.98–0.77 (m, 2H), −0.02 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 163.3, 163.1 (d, <i>J</i> = 250 Hz), 155.6, 147.0, 145.1, 144.9, 143.0, 136.1, 132.8 (d, <i>J</i> = 8 Hz), 131.6, 131.5, 131.4, 130.1, 126.3, 125.5 (d, <i>J</i> = 3 Hz), 116.0 (d, <i>J</i> = 22 Hz), 113.1, 112.6, 110.4, 110.2, 107.6, 72.6, 66.4, 55.8, 17.8, 16.3, −1.5. LRMS (ESI): 606.2 [M + H]<sup>+</sup></div></div><div id="sec4_26_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> 2-Oxo-2-phenylethan-1-aminium Chloride (<b>64</b>)</h4><div class="NLM_p last"><b>52b</b> (2.8 g, 10.05 mmol, 1 equiv)  and 1.41 g of urotropine (10.05 mmol, 1 equiv) were dissolved in 60 mL of dry chloroform. The reaction mixture was stirred at 50 °C for 2 h. A cloudy white precipitate was isolated by filtration and thoroughly washed with chloroform and ethanol to yield a white solid. This urotropinium salt was dissolved in 50 mL of absolute ethanol and 5 mL of concentrated hydrochloric acid. The mixture was heated to reflux for 2 h. The white solid was removed by filtration and washed with ethanol. The filtrate was evaporated under reduced pressure to yield the title compound as a white solid in 99% yield (1.7 g, 9.9 mmol). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.54 (s, 3H), 8.06–7.93 (m, 2H), 7.61–7.48 (m, 3H), 4.62 (s, 2H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 193.1, 134.9, 133.9, 129.4, 128.5, 45.2.</div></div><div id="sec4_26_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> 4-Phenyl-1,3-dihydro-2<i>H</i>-imidazole-2-thione (<b>65</b>)</h4><div class="NLM_p last"><b>64</b> (3.14 g, 18.3 mmol, 1 equiv) and 1.95 g (20.12 mmol, 1.1 equiv) of potassium thiocyanate were suspended in 20 mL of glacial acetic acid. The reaction mixture was refluxed for 1 h. The color of the solution solution turned from orange to yellow to colorless. Next, the mixture was cooled to 0 °C and the product precipitated by the addition of 200 mL of water as an off-white voluminous solid. The solid was isolated by filtration to yield the title compound as an off-white solid in 50% (1.6 g, 9.08 mmol) yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.55 (s, 1H), 12.17 (s, 1H), 7.66 (d, <i>J</i> = 7.6 Hz, 2H), 7.45–7.15 (m, 4H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.8, 129.1, 128.9, 128.4, 127.3, 123.9, 112.2. LRMS (FAB-MS): 177.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> 2-(2-((4-Phenyl-1<i>H</i>-imidazol-2-yl)thio)ethyl)isoindoline-1,3-dione (<b>66</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>65</b> and 2-(2-bromoethyl)isoindoline-1,3-dione according to general procedure F and obtained as an off-white solid after gradient silica flash chromatography (hexane → hexane/EtOAc 3:7) in 80% yield. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.31 (s, 1H), 7.78–7.68 (m, 4H), 7.61 (d, <i>J</i> = 7.5 Hz, 2H), 7.50 (s, 1H), 7.30 (t, <i>J</i> = 7.2 Hz, 2H), 7.23–7.10 (m, 1H), 3.93 (t, <i>J</i> = 6.4 Hz, 2H), 3.38–3.31 (m, 2H). LRMS (FAB-MS): 350.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> 2-(2-((4-Phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)thio)ethyl)isoindoline-1,3-dione (<b>67</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>66</b> according to general procedure N and obtained as a colorless oil after gradient silica flash chromatography (hexane → hexane/EtOAc 3:1) in 84% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 7.76–7.64 (m, 4H), 7.63–7.53 (m, 2H), 7.38–7.15 (m, 4H), 5.25 (s, 2H), 4.08 (t, <i>J</i> = 6.1 Hz, 2H), 3.52–3.42 (m, 2H), 1.20 (t, <i>J</i> = 7.0 Hz, 1H), 0.90 (t, <i>J</i> = 8.2 Hz, 2H), −0.02 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 166.4, 140.3, 140.1, 132.6, 132.3, 130.4, 127.1, 125.4, 123.2, 121.7, 115.9, 73.8, 64.8, 36.8, 30.2, 16.3, −2.5. LRMS (FAB-MS): 480.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> 2-((4-Phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)thio)ethan-1-amine (<b>68</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>67</b> according to general procedure G and obtained as a white solid after silica flash chromatography (hexane/MeOH/NH<sub>3</sub> 90:8:2) in 85% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 7.88–7.66 (m, 2H), 7.41–7.29 (m, 3H), 7.28–7.16 (m, 1H), 5.29 (s, 2H), 3.59–3.49 (m, 2H), 3.24–3.15 (m, 2H), 3.05–2.94 (m, 2H), 2.11 (s, 2H), 0.99–0.86 (m, 2H), −0.02 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 142.2, 142.0, 133.5, 128.4, 126.9, 124.6, 116.6, 75.1, 66.3, 41.6, 38.3, 17.6, −1.5. LRMS (FAB-MS): 350.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> <i>N</i>-(2-((4-Phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)thio)ethyl)propionamide (<b>69</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>68</b> according to general procedure I and obtained as a colorless oil after silica flash chromatography (hexane/EtOAc 2:3) in 91% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 7.75 (d, <i>J</i> = 7.4 Hz, 3H), 7.43–7.20 (m, 4H), 5.32 (s, 2H), 3.68–3.53 (m, 4H), 3.31–3.19 (m, 2H), 2.17 (q, <i>J</i> = 7.6 Hz, 2H), 1.16–1.03 (m, 3H), 0.99–0.87 (m, 2H), −0.00 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 174.3, 142.6, 141.7, 132.5, 128.6, 127.4, 124.7, 116.9, 75.4, 66.6, 40.5, 33.9, 29.6, 17.6, 9.8, −1.5. LRMS (FAB-MS): 406.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> <i>N</i>-(2-((5-Bromo-4-phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)thio)ethyl) propionamide (<b>70</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>69</b> according to general procedure O and obtained as a colorless oil in 98% yield, which was used without further purification. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 7.93 (d, <i>J</i> = 7.1 Hz, 2H), 7.61–7.50 (m, 1H), 7.46–7.28 (m, 3H), 5.38 (s, 2H), 3.68–3.55 (m, 4H), 3.32–3.16 (m, 2H), 2.14 (q, <i>J</i> = 7.6 Hz, 2H), 1.12–0.89 (m, 5H), 0.01 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 178.3, 174.4, 143.9, 139.1, 132.3, 128.2, 127.6, 126.6, 74.0, 66.7, 40.3, 33.7, 29.5, 17.7, 9.8, −1.5. LRMS (FAB-MS): 484.1/486.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> <i>N</i>-(2-((5-(2-(2,5-Dimethyl-1<i>H</i>-pyrrol-1-yl)pyridin-4-yl)-4-phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)thio)ethyl)propionamide (<b>71</b>)</h4><div class="NLM_p last">4-Bromo-2-(2,5-dimethyl-1<i>H</i>-pyrrol-1-yl)pyridine (271 mg, 1.08 mmol, 1.0 equiv) was dissolved in 10 mL of dry 1,4-dioxane. Under an atmosphere of argon, 318 mg (3.24 mmol, 3.0 equiv) of KOAc and 281 mg (1.11 mmol, 1.05 equiv) of bis(pinacolato)diboron were added. The suspension was degassed several times, followed by the addition of 12 mg (0.054 mmol, 0.05 equiv) of Pd(OAc)<sub>2</sub> and 52 mg (0.108 mmol, 0.1 equiv) of XPhos. The mixture was heated to 130 °C until complete consumption of the starting material. Upon cooling to room temperature, 236 mg (1.09 mmol, 1.05 equiv) of <b>70</b> were added to the well stirred solution, followed by a degassed aqueous solution of K<sub>3</sub>PO<sub>4</sub> (0.5 M, 10 mL, 5 equiv). The mixture was stirred at 130 °C until HPLC indicated complete consumption of the starting material. The mixture was quenched by the addition of brine, and the aqueous phase was extracted with EtOAc three times The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and the volatiles evaporated. The title compound was obtained as a yellow oil after silica flash chromatography (hexane/EtOAc 2:3) in 40% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 8.63 (d, <i>J</i> = 5.1 Hz, 1H), 7.80–7.70 (m, 1H), 7.48–7.36 (m, 3H), 7.29–7.18 (m, 4H), 5.82 (s, 2H), 5.21 (s, 2H), 3.72–3.57 (m, 4H), 3.39–3.28 (m, 2H), 2.10 (q, <i>J</i> = 7.6 Hz, 2H), 2.01 (s, 6H), 1.08–0.89 (m, 5H), −0.00 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 174.2, 152.8, 149.8, 145.3, 140.8, 140.0, 132.9, 128.5, 128.4, 127.6, 127.6, 127.3, 123.1, 123.0, 106.9, 73.2, 66.7, 40.7, 33.4, 29.5, 17.8, 13.0, 9.8, −1.5. LRMS (FAB-MS): 576.3 [M + H]<sup>+</sup></div></div><div id="sec4_26_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> <i>N</i>-(2-((5-(2-Aminopyridin-4-yl)-4-phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-2-yl)thio)ethyl)propionamide (<b>72</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>71</b> according to general procedure R and obtained as a yellow oil after silica flash chromatography (EtOAc) in 37% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 8.09 (d, <i>J</i> = 5.3 Hz, 1H), 7.94–7.84 (m, 1H), 7.56–7.43 (m, 2H), 7.33–7.18 (m, 3H), 6.67 (d, <i>J</i> = 5.2 Hz, 1H), 6.61–6.54 (m, 1H), 5.18 (s, 2H), 4.89 (s, 2H), 3.73–3.48 (m, 5H), 3.35–3.24 (m, 2H), 1.06 (t, <i>J</i> = 7.6 Hz, 3H), 0.98–0.88 (m, 2H), 0.01 (s, 10H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 174.3, 158.8, 148.2, 144.3, 139.8, 139.3, 133.1, 128.5, 128.2, 127.2, 127.1, 115.1, 109.8, 73.1, 64.0, 40.7, 33.6, 29.6, 17.9, 9.9, −1.5. LRMS (FAB-MS): 498.2 [M + H]<sup>+</sup></div></div><div id="sec4_26_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> <i>N</i>-(3-((4-(4-Phenyl-2-((2-propionamidoethyl)thio)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)phenyl)acrylamide (<b>73</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>72</b> according to general procedure T and obtained as a colorless oil after silica flash chromatography (EtOAc) in 51% yield. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 8.28 (d, <i>J</i> = 5.5 Hz, 2H), 8.28 (d, <i>J</i> = 5.3 Hz, 1H), 8.06–7.97 (m, 1H), 7.92–7.78 (m, 1H), 7.65–7.49 (m, 3H), 7.38–7.27 (m, 2H), 7.27–7.20 (m, 1H), 7.15 (t, <i>J</i> = 7.9 Hz, 1H), 7.03–6.92 (m, 2H), 6.84 (d, <i>J</i> = 5.4 Hz, 1H), 6.54–6.20 (m, 2H), 5.80–5.68 (m, 1H), 5.23 (s, 2H), 3.75–3.64 (m, 2H), 3.61–3.48 (m, 2H), 3.40–3.28 (m, 2H), 2.14 (q, <i>J</i> = 7.5 Hz, 2H), 1.06 (t, <i>J</i> = 7.6 Hz, 3H), 0.97–0.85 (m, 2H), 0.01 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 174.4, 163.6, 156.2, 148.9, 144.5, 140.5, 139.7, 139.5, 138.8, 133.3, 131.1, 129.6, 128.7, 128.3, 127.4, 127.3, 118.7, 116.1, 115.6, 114.3, 111.4, 109.8, 73.2, 66.6, 41.0, 33.6, 29.6, 17.9, 9.9, −1.5. LRMS (FAB-MS): 643.3 [M + H]<sup>+</sup></div></div><div id="sec4_26_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> 4-Fluorophenyl-oxo-acetaldehyde (<b>76</b>)</h4><div class="NLM_p last">A mixture of 14.9 g (134.0 mmol, 1.1 equiv) selenium dioxide in dioxane/water 33:1 (0.65 M) was heated to 60 °C until appearance of a clear solution. Then 16.9 g (121 mmol, 1 equiv) of 4-fluoroacetophenone was added and the solution was refluxed for 16 h. After cooling to room temperature, the solid was filtered and the solvent of the filtrate was removed in vacuo. The residue was distilled in vacuo and was used without further purification. The product was obtained as a yellow liquid (13.52 g, 88.9 mmol, 73%) at 85 °C (<i>p</i> = 1 mbar). <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 9.62 (s, 1H), 8.47–7.84 (m, 2H), 7.19 (t, <i>J</i> = 8.7 Hz, 2H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 189.6, 186.0, 167.1 (d, <i>J</i> = 258.8 Hz), 133.6 (d, <i>J</i> = 9.8 Hz), 128.3 (d, <i>J</i> = 3.0 Hz), 116.5 (d, <i>J</i> = 22.0 Hz). LRMS (FAB-MS): 153.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> 4-(Triisopropylsiloxy)butan-1-ol (<b>77</b>)</h4><div class="NLM_p last">Sodium hydride (60% in mineral oil, 1.0 equiv) was added portionwise to an ice-cold solution of the respecting diole in dry THF (0.49 M) under argon. The suspension was stirred at 0 °C for 15 min. The ice bath was removed, and the solution was stirred at room temperature for 30 min. The solution was cooled to 0 °C, and 1 equiv of TIPSCl was added dropwise. The ice bath was removed, and the solution was stirred at room temperature overnight. The suspension was cooled to 0 °C and was quenched with saturated NaHCO<sub>3</sub> solution. The organic layer and the water layer were extracted three times with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The product was obtained as an orange oil (11.6 g) and used without further purification. <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 3.74 (t, <i>J</i> = 5.7 Hz, 1H), 3.64 (t, <i>J</i> = 5.9 Hz, 1H), 1.74–1.58 (m, 2H), 1.11–1.01 (m, 13H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 63.7, 62.9, 30.4, 30.2, 18.1, 12.1.</div></div><div id="sec4_26_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> 4-(Triisopropylsiloxy)butan-1-al (<b>78</b>)</h4><div class="NLM_p last">DMSO (2.59 g, 33.21 mmol, 4.1 equiv) dissolved in dry DCM (2.1 M) was added dropwise to a–78 °C cooled solution of 1.65 g (12.96 mmol, 1.6 equiv) of oxalyl chloride in dry DCM (0.52 M) under argon and was stirred at this temperature for 25 min. Then 2.0 g (8.1 mmol, 1 equiv) of <b>77</b> dissolved in dry DCM (0.64 M) was added dropwise and the solution was stirred for 30 min. Afterward, 5.6 mL (40.5 mmol, 5.3 equiv) of triethylamine was added dropwise and the solution was warmed to room temperature. The mixture was quenched with EA and saturated NH<sub>4</sub>Cl solution. The organic layer was separated and washed with brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography (hexane:EA 9:1). The product was obtained as a colorless liquid (1.23 g, 62%). <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 9.79 (t, <i>J</i> = 1.7 Hz, 1H), 3.72 (t, <i>J</i> = 5.9 Hz, 2H), 2.53 (td, <i>J</i> = 7.1, 1.7 Hz, 2H), 2.05–1.66 (m, 2H), 1.09–0.98 (m, 21H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 202.8, 62.5, 40.9, 25.8, 18.1, 12.1.</div></div><div id="sec4_26_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> 4-(4-Fluorophenyl)-2-(3-((triisopropylsilyl)oxy)propyl)-1<i>H</i>-imidazole (<b>79</b>)</h4><div class="NLM_p last">A solution of 704 mg (4.63 mmol, 1 equiv) of <b>76</b> in methanol (0.18 M) was added dropwise to a stirring solution of 1.13 g (4.63 mmol, 1 equiv) of <b>78</b> and 1.71 g (22.2 mmol, 4.8 equiv) of NH<sub>4</sub>OAc in MeOH (0.2 M) and stirred at room temperature overnight. The solution was quenched with saturated NaHCO<sub>3</sub> solution and stirred for 30 min. MeOH was removed in vacuo, and EA was added. The organic layer was separated, and the water layer was extracted three times with EA. The combined organic layers were washed with brine and dried over NaSO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography: first column, hexane:EA 3:2; second column, DCM:MeOH 98:2. The product was obtained as a yellow oil (0.89 g, 51%). <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 7.66 (dd, <i>J</i> = 8.7, 5.4 Hz, 2H), 7.11 (s, 1H), 7.03 (t, <i>J</i> = 8.8 Hz, 2H), 3.81 (t, <i>J</i> = 5.7 Hz, 2H), 2.94 (t, <i>J</i> = 6.9 Hz, 2H), 1.97 (q, <i>J</i> = 6.0 Hz, 1H), 1.32–0.69 (m, 21H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 161.9 (d, <i>J</i> = 244.9 Hz), 149.3, 126.5 (d, <i>J</i> = 7.8 Hz), 115.5 (d, <i>J</i> = 21.5 Hz), 63.5, 30.8, 26.2, 18.1, 12.1. LRMS (FAB-MS): 377.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> 4-(4-Fluorophenyl)-2-(3-((triisopropylsilyl)oxy)propyl)-1-((2-(trimethylsilyl)ethoxy)-methyl)-1<i>H</i>-imidazole (<b>80</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>79</b> according to general procedure N. The crude product was purified by silica flash chromatography (gradient: hexane:EA 9:1 → hexane:EA 4:1). The product was obtained as a colorless oil (269 mg, 64%). <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 7.71 (dd, <i>J</i> = 8.6, 5.5 Hz, 2H), 7.13 (s, 1H), 7.03 (t, <i>J</i> = 8.7 Hz, 2H), 5.24 (s, 2H), 3.78 (t, <i>J</i> = 5.9 Hz, 2H), 3.53 (t, <i>J</i> = 8.2 Hz, 2H), 2.89 (t, <i>J</i> = 7.4 Hz, 2H), 2.02 (q, <i>J</i> = 5.8 Hz, 2H), 1.10–1.02 (m, 21H), 0.91 (t, <i>J</i> = 8.4 Hz, 1H), 0.03 to −0.06 (m, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 162.0 (d, <i>J</i> = 244.8 Hz), 149.5, 139.6, 130.6 (d, <i>J</i> = 3.1 Hz), 126.5 (d, <i>J</i> = 7.9 Hz), 115.4 (d, <i>J</i> = 21.5 Hz), 114.8 (d, <i>J</i> = 1.1 Hz), 75.00, 66.3, 62.6, 31.9, 23.4, 18.2, 17.9, 12.1, −1.30. LRMSb(ESI-MS): 507.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> 5-Bromo-4-(4-fluorophenyl)-2-(3-((triisopropylsilyl)oxy)propyl)-1-((2-(trimethylsilyl)-ethoxy)methyl)-1<i>H</i>-imidazole (<b>81</b>)</h4><div class="NLM_p last">A solution of <b>80</b> (991 mg, 1.96 mmol) in 16 mL of dry MeCN was cooled to 0 °C under argon, and NBS (383 mg, 2.15 mmol) dissolved in 6 mL of dry MeCN was added dropwise. The solution was stirred for 20 min, and the solvent was removed in vacuo. The residue was purified via flash chromatography (gradient: hexane:EA 95:5 → hexane:EA 9:1). The product was obtained as a yellow oil (990 mg, 86%). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 7.97–7.86 (m, 2H), 7.15–7.01 (m, 2H), 5.33 (s, 2H), 3.80 (t, <i>J</i> = 5.9 Hz, 2H), 3.67–3.54 (m, 2H), 3.00–2.87 (m, 2H), 2.15–1.92 (m, 2H), 1.09–1.01 (m, 21H), 0.99–0.89 (m, 2H), 0.03 to −0.02 (m, 9H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 162.18 (d, <i>J</i> = 246.2 Hz), 150.50 (s), 136.68 (s), 129.63 (d, <i>J</i> = 3.2 Hz), 128.72 (d, <i>J</i> = 8.0 Hz), 115.22 (d, <i>J</i> = 21.4 Hz), 98.82 (d, <i>J</i> = 1.1 Hz), 73.16 (s), 66.37 (s), 62.51 (s), 31.31 (s), 24.30 (s), 18.17 (s), 18.00 (s), 12.12 (s), −1.29 (s). LRMS (ESI-MS): 585.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> <i>N</i>-(4-(4-(4-Fluorophenyl)-2-(3-((triisopropylsilyl)oxy)propyl)-1-((2-(trimethylsilyl)ethoxy)-methyl)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)acetamide (<b>82</b>)</h4><div class="NLM_p last">A mixture of <b>81</b> (300 mg, 0.51 mmol), <i>N</i>-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetamide (296 mg, 1.13 mmol), K<sub>3</sub>PO<sub>4</sub> (325 mg, 1.53 mmol), X-Phos (49 mg, 0.10 mmol), and Pd(OAc)<sub>2</sub> (11 mg, 0.05 mmol) in a mixture of 2.4 mL of degassed dioxane and 0.6 mL of degassed water under argon was stirred a 60 °C for 2 d. The mixture was cooled to room temperature, quenched with DCM and saturated NH<sub>4</sub>Cl solution, and stirred for 10 min. The organic layer was separated, and the water layer was extracted twice with DCM. The combined organic layers were washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The residue was purified via flash chromatography (hexane:EA 7:3). The product was obtained as a yellow oil (246 mg, 75%). <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 8.56 (bs, 1H), 8.30–8.19 (m, 2H), 7.47–7.35 (m, 2H), 7.01–6.84 (m, 3H), 5.17 (s, 2H), 3.84 (t, <i>J</i> = 5.7 Hz, 2H), 3.48–3.33 (m, 2H), 3.08–2.93 (m, 2H), 2.19 (s, 3H), 2.16–2.03 (m, 2H), 1.14–0.98 (m, 21H), 0.93–0.81 (m, 2H), −0.05 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 168.39 (s), 161.91 (d, <i>J</i> = 246.1 Hz), 152.01 (s), 150.40 (s), 147.95 (s), 141.23 (s), 137.48 (s), 129.85 (d, <i>J</i> = 3.1 Hz), 129.20 (d, <i>J</i> = 8.0 Hz), 125.38 (d, <i>J</i> = 0.6 Hz), 121.54 (s), 115.02 (d, <i>J</i> = 21.4 Hz), 115.00 (s), 72.30 (s), 65.86 (s), 62.42 (s), 31.39 (s), 24.52 (s), 23.57 (s), 17.93 (s), 17.66 (s), 11.89 (s), −1.63 (s). LRMS (ESI-MS): 641.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> 4-(4-(4-Fluorophenyl)-2-(3-((triisopropylsilyl)oxy)propyl)-1-((2-(trimethylsilyl)ethoxy)-methyl)-1<i>H</i>-imidazol-5-yl)pyridin-2-amine (<b>83</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>82</b> according to general procedure Q. The residue was purified via flash chromatography (hexane:EA 1:1). The product was obtained as a yellow oil (143 mg, 63%). <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 8.08 (d, <i>J</i> = 5.7 Hz, 1H), 7.50–7.37 (m, 2H), 6.99–6.85 (m, 2H), 6.63 (dd, <i>J</i> = 5.1, 1.2 Hz, 1H), 6.48 (s, 1H), 5.08 (s, 2H), 4.63 (s, 2H), 3.82 (t, <i>J</i> = 5.9 Hz, 2H), 3.50–3.35 (m, 2H), 3.02–2.85 (m, 2H), 2.18–1.99 (m, 2H), 1.13–0.98 (m, 21H), 0.93–0.73 (m, 2H), −0.03 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 161.75 (d, <i>J</i> = 245.8 Hz), 158.67 (s), 150.01 (s), 148.25 (s), 140.72 (s), 136.89 (s), 130.18 (d, <i>J</i> = 3.2 Hz), 128.86 (d, <i>J</i> = 7.9 Hz), 125.80 (d, <i>J</i> = 0.7 Hz), 115.61 (s), 114.97 (d, <i>J</i> = 21.4 Hz), 109.85 (s), 72.18 (s), 65.84 (s), 62.39 (s), 31.35 (s), 23.56 (s), 17.93 (s), 17.79 (s), 11.87 (s), −1.57 (s). LRMS (ESI-MS): 599.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> <i>N</i>-(3-((4-(4-(4-Fluorophenyl)-2-(3-((triisopropylsilyl)oxy)propyl)-1-((2-(trimethylsilyl)-ethoxy)methyl)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)-4-methoxyphenyl)acrylamide (<b>84a</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>83</b> and <i>N</i>-(3-bromo-4-methoxyphenyl)acrylamide according to general procedure T. The residue was purified via flash chromatography (gradient: hexane:EA 6:4 → hexane:EA 1:1). The product was obtained as an off-white solid (51 mg, 62%). <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 3.51 (d, <i>J</i> = 5.4 Hz, 1H), 3.40–3.33 (m, 1H), 2.81–2.60 (m, 4H), 2.35 (s, 1H), 2.27–1.90 (m, 5H), 1.70–1.36 (m, 2H), 0.95 (dd, <i>J</i> = 10.3, 1.0 Hz, 1H), 0.37 (s, 2H), −0.85 to −1.02 (m, 5H), −1.25 to −1.52 (m, 2H), −1.63 to −1.96 (m, 2H), −2.39 to −2.86 (m, 2H), −3.61 to −3.77 (m, 21H), −3.85 to −3.97 (m, 2H), −4.81 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 163.50 (s), 161.97 (d, <i>J</i> = 246.0 Hz), 155.90 (s), 150.38 (s), 148.58 (s), 145.46 (s), 140.58 (s), 137.06 (s), 131.44 (s), 131.29 (s), 130.35 (d, <i>J</i> = 3.1 Hz), 129.98 (s), 129.21 (d, <i>J</i> = 7.9 Hz), 127.32 (s), 126.06 (s), 116.85 (s), 115.29 (d, <i>J</i> = 21.4 Hz), 114.27 (s), 113.87 (s), 111.54 (s), 110.52 (s), 72.54 (s), 66.13 (s), 62.66 (s), 56.05 (s), 31.63 (s), 23.83 (s), 18.19 (s), 18.00 (s), 12.12 (s), −1.35 (s). LRMS (ESI-MS): found 775.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_26_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130"> <i>N</i>-(3-((4-(4-(4-Fluorophenyl)-2-(3-((triisopropylsilyl)oxy)propyl)-1-((2-(trimethylsilyl)-ethoxy)methyl)-1<i>H</i>-imidazol-5-yl)pyridin-2-yl)amino)-4-methoxyphenyl)propionamide (<b>84b</b>)</h4><div class="NLM_p last">The title compound was synthesized from <b>83</b> and <i>N</i>-(3-bromo-4-methoxyphenyl)propionamide according to general procedure T. The residue was purified via flash chromatography (gradient: DCM 100% → DCM:MeOH 98:2). The product was obtained as a yellow solid (142 mg, 74%). <sup>1</sup>H NMR (200 MHz, chloroform-<i>d</i>) δ 8.26 (d, <i>J</i> = 5.3 Hz, 2H), 8.06 (d, <i>J</i> = 2.5 Hz, 2H), 7.54–7.29 (m, 4H), 7.09 (s, 1H), 7.01–6.68 (m, 5H), 5.12 (s, 2H), 3.88–3.74 (m, 5H), 3.46–3.36 (m, 2H), 3.03–2.89 (m, 2H), 2.31 (q, <i>J</i> = 7.7 Hz, 2H), 2.18–2.00 (m, 2H), 1.19 (t, <i>J</i> = 7.6 Hz, 3H), 1.11–1.02 (m, 21H), 0.91–0.78 (m, 2H), −0.05 (s, 9H). <sup>13</sup>C NMR (50 MHz, chloroform-<i>d</i>) δ 171.99 (s), 161.90 (d, <i>J</i> = 245.9 Hz), 155.91 (s), 150.32 (s), 148.62 (s), 145.12 (s), 140.50 (s), 136.98 (s), 131.54 (s), 130.39 (d, <i>J</i> = 3.1 Hz), 129.87 (s), 129.13 (d, <i>J</i> = 7.9 Hz), 126.06 (s), 116.76 (s), 115.22 (d, <i>J</i> = 21.4 Hz), 113.64 (s), 111.45 (s), 110.45 (s), 110.39 (s), 72.48 (s), 66.06 (s), 62.62 (s), 55.99 (s), 31.59 (s), 30.61 (s), 23.80 (s), 18.14 (s), 17.94 (s), 12.07 (s), 9.82 (s), −1.39 (s). LRMS (ESI-MS): 776.9 [M + H]<sup>+</sup>.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i131"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00316">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14715" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14715" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00316" class="ext-link">10.1021/acs.jmedchem.7b00316</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Additional chemistry (schemes and description); all general methods; experimental section of materials, intermediates and precursors; metabolic stability determination in vitro (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_005.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">3D coordinates of proteins for docking studies: <b>31a</b> covalently docked with <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_001.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">3D coordinates of proteins for docking studies: <b>6a</b> covalently docked with <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">3D coordinates of proteins for docking studies: <b>6a</b> Glide docked with <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_004.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_001.pdb">jm7b00316_si_001.pdb (400.95 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_002.csv">jm7b00316_si_002.csv (3.56 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_003.pdb">jm7b00316_si_003.pdb (393.06 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_004.pdb">jm7b00316_si_004.pdb (393.4 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_005.pdf">jm7b00316_si_005.pdf (703.46 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00316" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08303" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08303" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Laufer</span> - <span class="hlFld-Affiliation affiliation">Institute
of Pharmaceutical Sciences, Pharmaceutical and Medicinal Chemistry, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6952-1486" title="Orcid link">http://orcid.org/0000-0001-6952-1486</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f182859497909fdf9d9084979483b1849f98dc85849493989f96949fdf9594"><span class="__cf_email__" data-cfemail="2a595e4f4c4b4404464b5f4c4f586a5f4443075e5f4f4843444d4f44044e4f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marcel Günther</span> - <span class="hlFld-Affiliation affiliation">Institute
of Pharmaceutical Sciences, Pharmaceutical and Medicinal Chemistry, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonas Lategahn</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Chemistry and Chemical Biology, TU Dortmund
University, Otto-Hahn-Straße
4a, 44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Juchum</span> - <span class="hlFld-Affiliation affiliation">Institute
of Pharmaceutical Sciences, Pharmaceutical and Medicinal Chemistry, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eva Döring</span> - <span class="hlFld-Affiliation affiliation">Institute
of Pharmaceutical Sciences, Pharmaceutical and Medicinal Chemistry, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marina Keul</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Chemistry and Chemical Biology, TU Dortmund
University, Otto-Hahn-Straße
4a, 44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julian Engel</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Chemistry and Chemical Biology, TU Dortmund
University, Otto-Hahn-Straße
4a, 44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hannah L. Tumbrink</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Chemistry and Chemical Biology, TU Dortmund
University, Otto-Hahn-Straße
4a, 44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Rauh</span> - <span class="hlFld-Affiliation affiliation">Faculty
of Chemistry and Chemical Biology, TU Dortmund
University, Otto-Hahn-Straße
4a, 44227 Dortmund, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1970-7642" title="Orcid link">http://orcid.org/0000-0002-1970-7642</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M.G. and J.L. contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d126e7607-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i134">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52185" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52185" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Michael Forster for the synthesis of Buchwald precatalysts used for cross coupling reactions and Bent Praefke for fruitful discussions and his help in the synthesis of (<i>t</i>Bu)<sub>3</sub>P*HBF<sub>4</sub>.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i135" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i135"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i136" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i136"> Abbreviations Used</h2><tr><td class="NLM_term">bs</td><td class="NLM_def"><p class="first last">broad signal</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">HR</td><td class="NLM_def"><p class="first last">hydrophobic region</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small cell lung cancer</p></td></tr><tr><td class="NLM_term">PAIN</td><td class="NLM_def"><p class="first last">pan-assay interference compound</p></td></tr><tr><td class="NLM_term">PB</td><td class="NLM_def"><p class="first last">phosphate binding site</p></td></tr><tr><td class="NLM_term">PG</td><td class="NLM_def"><p class="first last">protecting group</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">2-(trimethylsilyl)ethoxymethyl</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last"><i>O</i>-(benzoriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium tetrafluoroborate</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">X-Phos</td><td class="NLM_def"><p class="first last">2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl</p></td></tr><tr><td class="NLM_term">BrettPhos</td><td class="NLM_def"><p class="first last">2-(dicyclohexylphosphino)3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl</p></td></tr><tr><td class="NLM_term">dba</td><td class="NLM_def"><p class="first last">dibenzylidene–acetone</p></td></tr><tr><td class="NLM_term">HOAc</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term"><i>t</i>-BuOH</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl alcohol</p></td></tr><tr><td class="NLM_term">iPrOH</td><td class="NLM_def"><p class="first last">isopropyl alcohol</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i137">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33043" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33043" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 35 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekar, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, A.</span><span> </span><span class="NLM_article-title">Epidermal growth-factor receptor-mediated cell motility - phospholipase-C activity is required, but mitogen-activated protein-kinase activity is not sufficient for induced cell-movement</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">847</span><span class="NLM_x">–</span> <span class="NLM_lpage">857</span><span class="refDoi"> DOI: 10.1083/jcb.127.3.847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1083%2Fjcb.127.3.847" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=1994&pages=847-857&author=P.+Chenauthor=H.+Xieauthor=M.+C.+Sekarauthor=K.+Guptaauthor=A.+Wells&title=Epidermal+growth-factor+receptor-mediated+cell+motility+-+phospholipase-C+activity+is+required%2C+but+mitogen-activated+protein-kinase+activity+is+not+sufficient+for+induced+cell-movement&doi=10.1083%2Fjcb.127.3.847"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1083%2Fjcb.127.3.847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.127.3.847%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DSekar%26aufirst%3DM.%2BC.%26aulast%3DGupta%26aufirst%3DK.%26aulast%3DWells%26aufirst%3DA.%26atitle%3DEpidermal%2520growth-factor%2520receptor-mediated%2520cell%2520motility%2520-%2520phospholipase-C%2520activity%2520is%2520required%252C%2520but%2520mitogen-activated%2520protein-kinase%2520activity%2520is%2520not%2520sufficient%2520for%2520induced%2520cell-movement%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1994%26volume%3D127%26spage%3D847%26epage%3D857%26doi%3D10.1083%2Fjcb.127.3.847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurubhagavatula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haserlat, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiani, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2129</span><span class="NLM_x">–</span> <span class="NLM_lpage">2139</span><span class="refDoi"> DOI: 10.1056/NEJMoa040938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa040938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0ljqapgKE1A7ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139%26doi%3D10.1056%2FNEJMoa040938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Gazdar, A. F.</span><span> </span><span class="NLM_article-title">Personalized medicine and inhibition of EGFR signaling in lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">1018</span><span class="NLM_x">–</span> <span class="NLM_lpage">1020</span><span class="refDoi"> DOI: 10.1056/NEJMe0905763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1056%2FNEJMe0905763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=19692681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVygtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=1018-1020&author=A.+F.+Gazdar&title=Personalized+medicine+and+inhibition+of+EGFR+signaling+in+lung+cancer&doi=10.1056%2FNEJMe0905763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Personalized medicine and inhibition of EGFR signaling in lung cancer</span></div><div class="casAuthors">Gazdar, Adi F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1018-1020</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruWSWxEJWr-7Vg90H21EOLACvtfcHk0ljqapgKE1A7ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVygtr7I&md5=5cea925dd321f98fea2a4c3af197eaec</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMe0905763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe0905763%26sid%3Dliteratum%253Aachs%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26atitle%3DPersonalized%2520medicine%2520and%2520inhibition%2520of%2520EGFR%2520signaling%2520in%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D1018%26epage%3D1020%26doi%3D10.1056%2FNEJMe0905763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Kawahara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakashima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kage, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, M.</span><span> </span><span class="NLM_article-title">Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3163</span><span class="NLM_x">–</span> <span class="NLM_lpage">3170</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-3239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1158%2F1078-0432.CCR-09-3239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=20423982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlKru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=3163-3170&author=A.+Kawaharaauthor=C.+Yamamotoauthor=K.+Nakashimaauthor=K.+Azumaauthor=S.+Hattoriauthor=M.+Kashiharaauthor=H.+Aizawaauthor=Y.+Basakiauthor=M.+Kuwanoauthor=M.+Kageauthor=T.+Mitsudomiauthor=M.+Ono&title=Molecular+diagnosis+of+activating+EGFR+mutations+in+non-small+cell+lung+cancer+using+mutation-specific+antibodies+for+immunohistochemical+analysis&doi=10.1158%2F1078-0432.CCR-09-3239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Diagnosis of Activating EGFR Mutations in Non-Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis</span></div><div class="casAuthors">Kawahara, Akihiko; Yamamoto, Chizuko; Nakashima, Kazutaka; Azuma, Koichi; Hattori, Satoshi; Kashihara, Masaki; Aizawa, Hisamichi; Basaki, Yuji; Kuwano, Michihiko; Kage, Masayoshi; Mitsudomi, Tetsuya; Ono, Mayumi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3163-3170</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Therapeutic responses of non-small cell lung carcinoma (NSCLC) to epidermal growth factor receptor (EGFR)-targeted drugs, such as gefitinib and erlotinib, are closely assocd. with activating EGFR mutations.  The most common mutations are delE746-A750 in exon 19 and L858R in exon 21, accounting for ∼90% of all EGFR mutations.  Recently, EGFR mutation-specific antibodies were developed and did well in immunohistochem. anal., giving a sensitivity of ∼90%.  We have investigated whether this method detects activating EGFR mutations with sensitivity comparable with direct DNA sequencing, which is used to detect these mutations in NSCLC.  Exptl. Design: We used antibodies specific for the E746-A750 deletion mutation in exon 19 and the L858R point mutation in exon 21 in Western blot anal. and immunohistochem. to det. the presence of these mutations in NSCLC cell lines.  We also examd. these EGFR mutations in NSCLC tumor samples from 60 patients by immunohistochem. and direct DNA sequencing.  RESULTS: We were able to identify EGFR mutations in NSCLC tumor samples immunohistochem. with a sensitivity of 79% using the anti-delE746-A750 antibody and 83% using the anti-L858R antibody.  Addnl. DNA sequencing markedly improved the sensitivity obtained by immunohistochem.  CONCLUSIONS: This simple and rapid assay for detecting EGFR mutations, even in the small bronchial biopsies obtained in stage IV NSCLC patients, will be useful for diagnosing responsiveness to EGFR-targeted drugs in patients with NSCLC.  Combining this with DNA sequencing is recommended for the development of improved personalized EGFR-targeted therapeutics.  Clin Cancer Res; 16(12); 3163-70.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgLapDx4QziLVg90H21EOLACvtfcHk0ljqapgKE1A7ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlKru7s%253D&md5=fae66f88f790009cbebf274d57247054</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-3239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-3239%26sid%3Dliteratum%253Aachs%26aulast%3DKawahara%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DC.%26aulast%3DNakashima%26aufirst%3DK.%26aulast%3DAzuma%26aufirst%3DK.%26aulast%3DHattori%26aufirst%3DS.%26aulast%3DKashihara%26aufirst%3DM.%26aulast%3DAizawa%26aufirst%3DH.%26aulast%3DBasaki%26aufirst%3DY.%26aulast%3DKuwano%26aufirst%3DM.%26aulast%3DKage%26aufirst%3DM.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DOno%26aufirst%3DM.%26atitle%3DMolecular%2520diagnosis%2520of%2520activating%2520EGFR%2520mutations%2520in%2520non-small%2520cell%2520lung%2520cancer%2520using%2520mutation-specific%2520antibodies%2520for%2520immunohistochemical%2520analysis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D3163%26epage%3D3170%26doi%3D10.1158%2F1078-0432.CCR-09-3239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkaria, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupfer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">EGF receptor gene mutations are common in lung cancers from ″never smokers″ and are associated with sensitivity of tumors to gefitinib and erlotinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">13306</span><span class="NLM_x">–</span> <span class="NLM_lpage">13311</span><span class="refDoi"> DOI: 10.1073/pnas.0405220101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1073%2Fpnas.0405220101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=15329413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFems70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+Millerauthor=M.+Zakowskiauthor=J.+Dohertyauthor=K.+Politiauthor=I.+Sarkariaauthor=B.+Singhauthor=R.+Heelanauthor=V.+Ruschauthor=L.+Fultonauthor=E.+Mardisauthor=D.+Kupferauthor=R.+Wilsonauthor=M.+Krisauthor=H.+Varmus&title=EGF+receptor+gene+mutations+are+common+in+lung+cancers+from+%E2%80%B3never+smokers%E2%80%B3+and+are+associated+with+sensitivity+of+tumors+to+gefitinib+and+erlotinib&doi=10.1073%2Fpnas.0405220101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib</span></div><div class="casAuthors">Pao, William; Miller, Vincent; Zakowski, Maureen; Doherty, Jennifer; Politi, Katerina; Sarkaria, Inderpal; Singh, Bhuvanesh; Heelan, Robert; Rusch, Valerie; Fulton, Lucinda; Mardis, Elaine; Kupfer, Doris; Wilson, Richard; Kris, Mark; Varmus, Harold</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">13306-13311</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly assocd. with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor.  In-frame deletions occur in exon 19, whereas point mutations occur frequently in codon 858 (exon 21).  We found from sequencing the EGFR TK domain that 7 of 10 gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib-refractory tumors (P = 0.004).  Five of seven tumors sensitive to erlotinib (Tarceva), a related kinase inhibitor for which the clin. relevant target is undocumented, had analogous somatic mutations, as opposed to none of 10 erlotinib-refractory tumors (P = 0.003).  Because most mutation-pos. tumors were adenocarcinomas from patients who smoked <100 cigarettes in a lifetime ("never smokers"), we screened EGFR exons 2-28 in 15 adenocarcinomas resected from untreated never smokers.  Seven tumors had TK domain mutations, in contrast to 4 of 81 non-small cell lung cancers resected from untreated former or current smokers (P = 0.0001).  Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concns. of drug.  Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently contg. mutations within the TK domain of EGFR that are assocd. with gefitinib and erlotinib sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovevWonTGqELVg90H21EOLACvtfcHk0lhAINxDM5TNXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFems70%253D&md5=38f491968552501b7463a688fa0e62ff</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0405220101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0405220101%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DZakowski%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DKupfer%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DEGF%2520receptor%2520gene%2520mutations%2520are%2520common%2520in%2520lung%2520cancers%2520from%2520%25E2%2580%25B3never%2520smokers%25E2%2580%25B3%2520and%2520are%2520associated%2520with%2520sensitivity%2520of%2520tumors%2520to%2520gefitinib%2520and%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311%26doi%3D10.1073%2Fpnas.0405220101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Takeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span> </span><span class="NLM_article-title">Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">200</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span><span class="refDoi"> DOI: 10.1097/JTO.0000000000000053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1097%2FJTO.0000000000000053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=24419417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvVemtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=200-204&author=M.+Takedaauthor=I.+Okamotoauthor=K.+Nakagawa&title=Survival+outcome+assessed+according+to+tumor+response+and+shrinkage+pattern+in+patients+with+EGFR+mutation-positive+non-small-cell+lung+cancer+treated+with+gefitinib+or+erlotinib&doi=10.1097%2FJTO.0000000000000053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib</span></div><div class="casAuthors">Takeda, Masayuki; Okamoto, Isamu; Nakagawa, Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">200-204</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: Somatic mutations in the epidermal growth factor receptor gene (EGFR) are assocd. with a marked therapeutic response to EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC).  Clin. indicators of the likely survival benefit of EGFR-TKI treatment in NSCLC patients with EGFR mutations have not been identified, however.  We therefore evaluated progression-free survival (PFS) and overall survival (OS) according to tumor response and tumor shrinkage pattern in such patients.  Methods: Among 145 EGFR mutation-pos. NSCLC patients treated with EGFR-TKIs, 68 individuals were selected for anal.  Results: Of the 68 selected patients, 6 achieved a complete response (CR), 42 a partial response (PR), and 14 stable disease (SD).  Both PFS and OS were significantly longer in patients who achieved a CR or PR than in those who experienced SD.  Multivariate anal. showed that a response (CR or PR) to EGFR-TKIs was significantly assocd. with both PFS and OS.  Among the CR/PR group, the median maximal tumor shrinkage relative to baseline was 56%, and the median time to response (TTR) was 4.2 wk.  The subsets of these patients who experienced rapid tumor regression (TTR of ≤4.2 wk) or a high degree of tumor shrinkage (≥56%) did not show a more favorable PFS or OS compared with those who experienced slow tumor regression or a low degree of tumor shrinkage.  Conclusion: Response (CR or PR) may represent the optimal surrogate for efficacy among EGFR mutation-pos. NSCLC patients treated with EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhh9XFjf5TQrVg90H21EOLACvtfcHk0lhAINxDM5TNXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvVemtQ%253D%253D&md5=e10a852974cb7c80d6fdc1636a0e7df7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000053%26sid%3Dliteratum%253Aachs%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3DSurvival%2520outcome%2520assessed%2520according%2520to%2520tumor%2520response%2520and%2520shrinkage%2520pattern%2520in%2520patients%2520with%2520EGFR%2520mutation-positive%2520non-small-cell%2520lung%2520cancer%2520treated%2520with%2520gefitinib%2520or%2520erlotinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2014%26volume%3D9%26spage%3D200%26epage%3D204%26doi%3D10.1097%2FJTO.0000000000000053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0ljBPv4khp_hgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2eYZeLOA6DG3eLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekhtman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sima, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2240</span><span class="NLM_x">–</span> <span class="NLM_lpage">2247</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+tumor+specimens+at+the+time+of+acquired+resistance+to+EGFR-TKI+therapy+in+155+patients+with+EGFR-mutant+lung+cancers&doi=10.1158%2F1078-0432.CCR-12-2246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0ljBPv4khp_hgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520tumor%2520specimens%2520at%2520the%2520time%2520of%2520acquired%2520resistance%2520to%2520EGFR-TKI%2520therapy%2520in%2520155%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2240%26epage%3D2247%26doi%3D10.1158%2F1078-0432.CCR-12-2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span><span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lihKtUikNhpzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">–</span> <span class="NLM_lpage">7670</span><span class="refDoi"> DOI: 10.1073/pnas.0502860102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1073%2Fpnas.0502860102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=15897464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslOmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib&doi=10.1073%2Fpnas.0502860102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span></div><div class="casAuthors">Kwak, Eunice L.; Sordella, Raffaella; Bell, Daphne W.; Godin-Heymann, Nadia; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Driscoll, David R.; Fidias, Panos; Lynch, Thomas J.; Rabindran, Sridhar K.; McGinnis, John P.; Wissner, Allan; Sharma, Sreenath V.; Isselbacher, Kurt J.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7665-7670</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonsmall cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR) demonstrate dramatic, but transient, responses to the reversible tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva).  Some recurrent tumors have a common secondary mutation in the EGFR kinase domain, T790M, conferring drug resistance, but in other cases the mechanism underlying acquired resistance is unknown.  In studying multiple sites of recurrent NSCLCs, the authors detected T790M in only a small percentage of tumor cells.  To identify addnl. mechanisms of acquired resistance to gefitinib, the authors used NSCLC cells harboring an activating EGFR mutation to generate multiple resistant clones in vitro.  These drug-resistant cells demonstrate continued dependence on EGFR and ERBB2 signaling for their viability and have not acquired secondary EGFR mutations.  However, they display increased internalization of ligand-activated EGFR, consistent with altered receptor trafficking.  Although gefitinib-resistant clones are cross-resistant to related anilinoquinazolines, they demonstrate sensitivity to a class of irreversible inhibitors of EGFR.  These inhibitors also show effective inhibition of signaling by T790M-mutant EGFR and killing of NSCLC cells with the T790M mutation.  Both mechanisms of gefitinib resistance are therefore circumvented by irreversible tyrosine kinase inhibitors.  Our findings suggest that one of these, HKI-272, may prove highly effective in the treatment of EGFR-mutant NSCLCs, including tumors that have become resistant to gefitinib or erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW5BSM8yaZe7Vg90H21EOLACvtfcHk0lihKtUikNhpzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslOmsr0%253D&md5=f3fb866c3673fd4dff8a3f0a8c9be65b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0502860102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0502860102%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670%26doi%3D10.1073%2Fpnas.0502860102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Kluter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grutter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raaijmakers, H. C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Otterlo, W. A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2557</span><span class="NLM_x">–</span> <span class="NLM_lpage">2566</span><span class="refDoi"> DOI: 10.1002/cbic.201000352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1002%2Fcbic.201000352" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=2557-2566&author=S.+Kluterauthor=J.+R.+Simardauthor=H.+B.+Rodeauthor=C.+Grutterauthor=V.+Pawarauthor=H.+C.+A.+Raaijmakersauthor=T.+A.+Barfauthor=M.+Rabillerauthor=W.+A.+L.+van+Otterloauthor=D.+Rauh&title=Characterization+of+irreversible+kinase+inhibitors+by+directly+detecting+covalent+bond+formation%3A+a+tool+for+dissecting+kinase+drug+resistance&doi=10.1002%2Fcbic.201000352"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201000352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201000352%26sid%3Dliteratum%253Aachs%26aulast%3DKluter%26aufirst%3DS.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DPawar%26aufirst%3DV.%26aulast%3DRaaijmakers%26aufirst%3DH.%2BC.%2BA.%26aulast%3DBarf%26aufirst%3DT.%2BA.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3Dvan%2BOtterlo%26aufirst%3DW.%2BA.%2BL.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DCharacterization%2520of%2520irreversible%2520kinase%2520inhibitors%2520by%2520directly%2520detecting%2520covalent%2520bond%2520formation%253A%2520a%2520tool%2520for%2520dissecting%2520kinase%2520drug%2520resistance%26jtitle%3DChemBioChem%26date%3D2010%26volume%3D11%26spage%3D2557%26epage%3D2566%26doi%3D10.1002%2Fcbic.201000352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Katakami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atagi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koboyashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebisawa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span> </span><span class="NLM_article-title">LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">3335</span><span class="NLM_x">–</span> <span class="NLM_lpage">3341</span><span class="refDoi"> DOI: 10.1200/JCO.2012.45.0981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1200%2FJCO.2012.45.0981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=23816963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KrsrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3335-3341&author=N.+Katakamiauthor=S.+Atagiauthor=K.+Gotoauthor=T.+Hidaauthor=T.+Horaiauthor=A.+Inoueauthor=Y.+Ichinoseauthor=K.+Koboyashiauthor=K.+Takedaauthor=K.+Kiuraauthor=K.+Nishioauthor=Y.+Sekiauthor=R.+Ebisawaauthor=M.+Shahidiauthor=N.+Yamamoto&title=LUX-Lung+4%3A+a+phase+II+trial+of+afatinib+in+patients+with+advanced+non-small-cell+lung+cancer+who+progressed+during+prior+treatment+with+erlotinib%2C+gefitinib%2C+or+both&doi=10.1200%2FJCO.2012.45.0981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">LUX-lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both</span></div><div class="casAuthors">Katakami, Noboyuki; Atagi, Shinji; Goto, Koichi; Hida, Toyoaki; Horai, Takeshi; Inoue, Akira; Ichinose, Yukito; Koboyashi, Kunihiko; Takeda, Koji; Kiura, Katsuyuki; Nishio, Kazuto; Seki, Yoko; Ebisawa, Ryuichi; Shahidi, Mehdi; Yamamoto, Nobuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3335-3341</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose New mol. targeted agents are needed for patients with non-small-cell lung cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both.  Afatinib, an oral irreversible ErbB family blocker, has preclin. activity in epidermal growth factor receptor (EGFR [ErbB1]) mutant models with EGFR-activating mutations, including T790M.  Patients and Methods This was a Japanese single-arm phase II trial conducted in patients with stage IIIB to IV pulmonary adenocarcinoma who progressed after ≥ 12 wk of prior erlotinib and/or gefitinib.  Patients received afatinib 50 mg per day.  The primary end point was objective response rate (complete response or partial response) by independent review.  Secondary end points included progression-free survival (PFS), overall survival (OS), and safety.  Results Of 62 treated patients, 45 (72.6%) were EGFR mutation pos. in their primary tumor according to local and/or central lab. analyses.  Fifty-one patients (82.3%) fulfilled the criteria of acquired resistance to erlotinib and/or gefitinib.  Of 61 evaluable patients, five (8.2%; 95% CI, 2.7% to 18.1 %) had a confirmed objective response rate (partial response).  Median PFS was 4.4 mo (95% CI, 2.8 to 4.6 mo), and median OS was 19.0 mo (95% CI, 14.9 mo to not achieved).  Two patients had acquired T790M mutations: L858R + T790M, and deletion in exon 19 + T790M; they had stable disease for 9 mo and 1 mo, resp.  The most common afatinib-related adverse events (AEs) were diarrhea (100%) and rash/acne (91.9%).  Treatment-related AEs leading to afatinib discontinuation were experienced by 18 patients (29%), of whom four also had progressive disease.  Conclusion Afatinib demonstrated modest but noteworthy efficacy in patients with NSCLC who had received third- or fourth-line treatment and who progressed while receiving erlotinib and/or gefitinib, including those with acquired resistance to erlotinib, gefitinib, or both.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM0F6fZnWKTbVg90H21EOLACvtfcHk0lhxffob57POLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KrsrzK&md5=1666aeb642dbc953dd9bcc818bab9098</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.45.0981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.45.0981%26sid%3Dliteratum%253Aachs%26aulast%3DKatakami%26aufirst%3DN.%26aulast%3DAtagi%26aufirst%3DS.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DHida%26aufirst%3DT.%26aulast%3DHorai%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DIchinose%26aufirst%3DY.%26aulast%3DKoboyashi%26aufirst%3DK.%26aulast%3DTakeda%26aufirst%3DK.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DNishio%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DY.%26aulast%3DEbisawa%26aufirst%3DR.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DN.%26atitle%3DLUX-Lung%25204%253A%2520a%2520phase%2520II%2520trial%2520of%2520afatinib%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%2520who%2520progressed%2520during%2520prior%2520treatment%2520with%2520erlotinib%252C%2520gefitinib%252C%2520or%2520both%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D3335%26epage%3D3341%26doi%3D10.1200%2FJCO.2012.45.0981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadranel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cong, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorence, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C. H.</span><span> </span><span class="NLM_article-title">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">528</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span><span class="refDoi"> DOI: 10.1016/S1470-2045(12)70087-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1016%2FS1470-2045%2812%2970087-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=22452896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=528-538&author=V.+A.+Millerauthor=V.+Hirshauthor=J.+Cadranelauthor=Y.+M.+Chenauthor=K.+Parkauthor=S.+W.+Kimauthor=C.+C.+Zhouauthor=W.+C.+Suauthor=M.+Z.+Wangauthor=Y.+Sunauthor=D.+S.+Heoauthor=L.+Crinoauthor=E.+H.+Tanauthor=T.+Y.+Chaoauthor=M.+Shahidiauthor=X.+J.+Congauthor=R.+M.+Lorenceauthor=J.+C.+H.+Yang&title=Afatinib+versus+placebo+for+patients+with+advanced%2C+metastatic+non-small-cell+lung+cancer+after+failure+of+erlotinib%2C+gefitinib%2C+or+both%2C+and+one+or+two+lines+of+chemotherapy+%28LUX-Lung+1%29%3A+a+phase+2b%2F3+randomised+trial&doi=10.1016%2FS1470-2045%2812%2970087-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span></div><div class="casAuthors">Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-538</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Afatinib, an irreversible ErbB-family blocker, has shown preclin. activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors.  We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.  Methods: In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncol. Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 wk of treatment with erlotinib or gefitinib.  We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care.  Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2).  Investigators, patients, and the trial sponsor were masked to treatment assignment.  The primary endpoint was overall survival (from date of randomisation to death), analyzed on an intention-to-treat basis.  This study is registered with ClinicalTrials.gov, no. NCT00656136.  Findings: Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo).  Median overall survival was 10·8 mo (95% CI 10·0-12·0) in the afatinib group and 12·0 mo (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74).  Median progression-free survival was longer in the afatinib group (3·3 mo, 95% CI 2·79-4·40) than it was in the placebo group (1·1 mo, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001).  No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group.  Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group.  The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3).  These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2.  Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group.  We recorded two possibly treatment-related deaths in the afatinib group.  Interpretation: Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 wk of previous EGFR tyrosine-kinase inhibitor treatment.  Funding: Boehringer Ingelheim Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrR4FNSnKJbVg90H21EOLACvtfcHk0lhxffob57POLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D&md5=6ddd7f552e8ab1ebb43fb699e27894f5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970087-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970087-6%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%2BM.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DZhou%26aufirst%3DC.%2BC.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DM.%2BZ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DChao%26aufirst%3DT.%2BY.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DCong%26aufirst%3DX.%2BJ.%26aulast%3DLorence%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26atitle%3DAfatinib%2520versus%2520placebo%2520for%2520patients%2520with%2520advanced%252C%2520metastatic%2520non-small-cell%2520lung%2520cancer%2520after%2520failure%2520of%2520erlotinib%252C%2520gefitinib%252C%2520or%2520both%252C%2520and%2520one%2520or%2520two%2520lines%2520of%2520chemotherapy%2520%2528LUX-Lung%25201%2529%253A%2520a%2520phase%25202b%252F3%2520randomised%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D528%26epage%3D538%26doi%3D10.1016%2FS1470-2045%2812%2970087-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+E.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+L.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.+W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lhxffob57POLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%2BL.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Zhou, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+J.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+N.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lgP3GrtK0tUDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%2BJ.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%2BN.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Hope and disappointment: covalent inhibitors to overcome drug resistance in non-small cell lung cancer</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00475</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00475" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2-5&author=J.+Engelauthor=J.+Lategahnauthor=D.+Rauh&title=Hope+and+disappointment%3A+covalent+inhibitors+to+overcome+drug+resistance+in+non-small+cell+lung+cancer&doi=10.1021%2Facsmedchemlett.5b00475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Engel, Julian; Lategahn, Jonas; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-5</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the development of a third-generation of covalent EGFR inhibitors with excellent clin. outcomes.  However, the emergence of a newly discovered acquired drug resistance challenges the concept of small mol. targeted cancer therapy in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcxNkfyBm4vrVg90H21EOLACvtfcHk0lgP3GrtK0tUDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D&md5=738e3286dd1b1d4110249e33cceec9ac</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00475%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHope%2520and%2520disappointment%253A%2520covalent%2520inhibitors%2520to%2520overcome%2520drug%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D2%26epage%3D5%26doi%3D10.1021%2Facsmedchemlett.5b00475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Thress, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paweletz, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stetson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougherty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markovets, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivancos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxnard, G. R.</span><span> </span><span class="NLM_article-title">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">560</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+Janneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+mutation+mediates+resistance+to+AZD9291+in+non-small+cell+lung+cancer+harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0liAih0hJIbZow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520AZD9291%2520in%2520non-small%2520cell%2520lung%2520cancer%2520harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Gunther, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juchum, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiebig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">Lung cancer: EGFR inhibitors with low nanomolar activity against a therapy-resistant L858R/T790M/C797S mutant</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10890</span><span class="NLM_x">–</span> <span class="NLM_lpage">10894</span><span class="refDoi"> DOI: 10.1002/anie.201603736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1002%2Fanie.201603736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A280%3ADC%252BC2s3ltFeqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10890-10894&author=M.+Guntherauthor=M.+Juchumauthor=G.+Kelterauthor=H.+Fiebigauthor=S.+Laufer&title=Lung+cancer%3A+EGFR+inhibitors+with+low+nanomolar+activity+against+a+therapy-resistant+L858R%2FT790M%2FC797S+mutant&doi=10.1002%2Fanie.201603736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant</span></div><div class="casAuthors">Gunther Marcel; Juchum Michael; Laufer Stefan; Kelter Gerhard; Fiebig Heiner</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10890-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The treatment of non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) inhibitors is made challenging by acquired resistance caused by somatic mutations.  Third-generation EGFR inhibitors have been designed to overcome resistance through covalent binding to the Cys 797 residue of the enzyme, and these inhibitors are effective against most clinically relevant EGFR mutants.  However, the high dependence of these recent EGFR inhibitors on this particular interaction means that additional mutation of Cys 797 results in poor inhibitory activity, which leads to tumor relapse in initially responding patients.  A new generation of irreversible and reversible mutant EGFR inhibitors was developed with strong noncovalent binding properties, and these compounds show high inhibitory activities against the cysteine-mutated L858R/T790M/C797S EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlYaGbpc39GpZoeNcnHOQ9fW6udTcc2eYC4kruAKZ2h7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3ltFeqsA%253D%253D&md5=fb87e3c6d0c334f1811894d0341d0679</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603736%26sid%3Dliteratum%253Aachs%26aulast%3DGunther%26aufirst%3DM.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DKelter%26aufirst%3DG.%26aulast%3DFiebig%26aufirst%3DH.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DLung%2520cancer%253A%2520EGFR%2520inhibitors%2520with%2520low%2520nanomolar%2520activity%2520against%2520a%2520therapy-resistant%2520L858R%252FT790M%252FC797S%2520mutant%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10890%26epage%3D10894%26doi%3D10.1002%2Fanie.201603736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kollipara, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahedi, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Insight into the inhibition of drug-resistant mutants of the receptor tyrosine kinase EGFR</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10909</span><span class="NLM_x">–</span> <span class="NLM_lpage">10912</span><span class="refDoi"> DOI: 10.1002/anie.201605011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1002%2Fanie.201605011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=27496389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10909-10912&author=J.+Engelauthor=C.+Beckerauthor=J.+Lategahnauthor=M.+Keulauthor=J.+Ketzerauthor=T.+Muhlenbergauthor=L.+Kolliparaauthor=C.+Schultz-Fademrechtauthor=R.+P.+Zahediauthor=S.+Bauerauthor=D.+Rauh&title=Insight+into+the+inhibition+of+drug-resistant+mutants+of+the+receptor+tyrosine+kinase+EGFR&doi=10.1002%2Fanie.201605011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR</span></div><div class="casAuthors">Engel, Julian; Becker, Christian; Lategahn, Jonas; Keul, Marina; Ketzer, Julia; Muehlenberg, Thomas; Kollipara, Laxmikanth; Schultz-Fademrecht, Carsten; Zahedi, Rene P.; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10909-10912</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Targeting acquired drug resistance represents the major challenge in the treatment of EGFR-driven nonsmall-cell lung cancer (NSCLC).  Herein, the authors describe the structure-based design, synthesis, and biol. evaluation of a novel class of covalent EGFR inhibitors that exhibit excellent inhibition of EGFR-mutant drug-resistant cells.  Protein x-ray crystallog. combined with detailed kinetic studies led to a deeper understanding of the mode of inhibition of EGFR-T790M and provided insight into the key principles for effective inhibition of the recently discovered tertiary mutation at EGFR-C797S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBqcuaKxIuCbVg90H21EOLACvtfcHk0liAih0hJIbZow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ&md5=d16c5339a6f2b9ca018c56f6b3f0b8e8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fanie.201605011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201605011%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DMuhlenberg%26aufirst%3DT.%26aulast%3DKollipara%26aufirst%3DL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DInsight%2520into%2520the%2520inhibition%2520of%2520drug-resistant%2520mutants%2520of%2520the%2520receptor%2520tyrosine%2520kinase%2520EGFR%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10909%26epage%3D10912%26doi%3D10.1002%2Fanie.201605011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Laufer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotschenreuther, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, W.</span><span> </span><span class="NLM_article-title">Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3230</span><span class="NLM_x">–</span> <span class="NLM_lpage">3244</span><span class="refDoi"> DOI: 10.1021/jm030766k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030766k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3230-3244&author=S.+A.+Lauferauthor=G.+K.+Wagnerauthor=D.+A.+Kotschenreutherauthor=W.+Albrecht&title=Novel+substituted+pyridinyl+imidazoles+as+potent+anticytokine+agents+with+low+activity+against+hepatic+cytochrome+P450+enzymes&doi=10.1021%2Fjm030766k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm030766k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030766k%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DWagner%26aufirst%3DG.%2BK.%26aulast%3DKotschenreuther%26aufirst%3DD.%2BA.%26aulast%3DAlbrecht%26aufirst%3DW.%26atitle%3DNovel%2520substituted%2520pyridinyl%2520imidazoles%2520as%2520potent%2520anticytokine%2520agents%2520with%2520low%2520activity%2520against%2520hepatic%2520cytochrome%2520P450%2520enzymes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3230%26epage%3D3244%26doi%3D10.1021%2Fjm030766k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Koch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauerlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jank, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: synthesis and biological testing of 2-alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5630</span><span class="NLM_x">–</span> <span class="NLM_lpage">5640</span><span class="refDoi"> DOI: 10.1021/jm800373t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800373t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVymtbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5630-5640&author=P.+Kochauthor=C.+Bauerleinauthor=H.+Jankauthor=S.+Laufer&title=Targeting+the+ribose+and+phosphate+binding+site+of+p38+mitogen-activated+protein+%28MAP%29+kinase%3A+synthesis+and+biological+testing+of+2-alkylsulfanyl-%2C+4%285%29-aryl-%2C+5%284%29-heteroaryl-substituted+imidazoles&doi=10.1021%2Fjm800373t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Ribose and Phosphate Binding Site of p38 Mitogen-Activated Protein (MAP) Kinase: Synthesis and Biological Testing of 2-Alkylsulfanyl-, 4(5)-Aryl-, 5(4)-Heteroaryl-Substituted Imidazoles</span></div><div class="casAuthors">Koch, Pierre; Baeuerlein, Christiane; Jank, Hartmut; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5630-5640</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three series of substituted 2-alkylsulfanyl-4-(4-fluorophenyl)imidazoles, 5-pyridinyl-, 1-methyl-5-pyridinyl-, and 5-(2-aminopyridin-4-yl)-imidazoles, were prepd. and tested for their ability to inhibit p38 MAP kinase and TNF-α release.  These compds. were tested by applying a nonradioactive p38 MAP kinase assay and by measurement of TNF-α release in human whole blood.  Potent inhibitors (IC50values in the low nanomolar range, as low as 2 nM in the enzyme assay and 37 nM in the human whole blood test) were identified by variation of substituents at the imidazole-C2-thio position as well as at the 2-aminopyridinyl functionality.  In contrast to other known kinase inhibitors, these novel imidazole derivs. with the substituents at the imidazole-C2-thio position may interact with the ribose as well as with the phosphate binding site of the p38 MAP kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodYYCjSY3UNbVg90H21EOLACvtfcHk0ljgE70YewLBcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVymtbrK&md5=508c3e699dd65ee83a6592f2e719d17a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm800373t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800373t%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DBauerlein%26aufirst%3DC.%26aulast%3DJank%26aufirst%3DH.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTargeting%2520the%2520ribose%2520and%2520phosphate%2520binding%2520site%2520of%2520p38%2520mitogen-activated%2520protein%2520%2528MAP%2529%2520kinase%253A%2520synthesis%2520and%2520biological%2520testing%2520of%25202-alkylsulfanyl-%252C%25204%25285%2529-aryl-%252C%25205%25284%2529-heteroaryl-substituted%2520imidazoles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5630%26epage%3D5640%26doi%3D10.1021%2Fjm800373t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomassi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Termathe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer-Wrangowski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruetter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhlenbrock, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaumann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eppmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kibies, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffgaard, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heil, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menninger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz-Cuaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tinnefeld, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahedi, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kast, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Targeting drug resistance in EGFR with covalent inhibitors: a structure-based design approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6844</span><span class="NLM_x">–</span> <span class="NLM_lpage">6863</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01082</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01082" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6844-6863&author=J.+Engelauthor=A.+Richtersauthor=M.+Getlikauthor=S.+Tomassiauthor=M.+Keulauthor=M.+Termatheauthor=J.+Lategahnauthor=C.+Beckerauthor=S.+Mayer-Wrangowskiauthor=C.+Gruetterauthor=N.+Uhlenbrockauthor=J.+Kruellauthor=N.+Schaumannauthor=S.+Eppmannauthor=P.+Kibiesauthor=F.+Hoffgaardauthor=J.+Heilauthor=S.+Menningerauthor=S.+Ortiz-Cuaranauthor=J.+M.+Heuckmannauthor=V.+Tinnefeldauthor=R.+P.+Zahediauthor=M.+L.+Sosauthor=C.+Schultz-Fademrechtauthor=R.+K.+Thomasauthor=S.+M.+Kastauthor=D.+Rauh&title=Targeting+drug+resistance+in+EGFR+with+covalent+inhibitors%3A+a+structure-based+design+approach&doi=10.1021%2Facs.jmedchem.5b01082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach</span></div><div class="casAuthors">Engel, Julian; Richters, Andre; Getlik, Matthaeus; Tomassi, Stefano; Keul, Marina; Termathe, Martin; Lategahn, Jonas; Becker, Christian; Mayer-Wrangowski, Svenja; Gruetter, Christian; Uhlenbrock, Niklas; Kruell, Jasmin; Schaumann, Niklas; Eppmann, Simone; Kibies, Patrick; Hoffgaard, Franziska; Heil, Jochen; Menninger, Sascha; Ortiz-Cuaran, Sandra; Heuckmann, Johannes M.; Tinnefeld, Verena; Zahedi, Rene P.; Sos, Martin L.; Schultz-Fademrecht, Carsten; Thomas, Roman K.; Kast, Stefan M.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6844-6863</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases represent one of the prime targets in cancer therapy, as the dysregulation of these elementary transducers of extracellular signals, like the epidermal growth factor receptor (EGFR), contributes to the onset of cancer, such as non-small cell lung cancer (NSCLC).  Strong efforts were directed to the development of irreversible inhibitors and led to compd. CO-1686, which takes advantage of increased residence time at EGFR by alkylating Cys797 and thereby preventing toxic effects.  Here, the authors present a structure-based approach, rationalized by subsequent computational anal. of conformational ligand ensembles in soln., to design novel and irreversible EGFR inhibitors based on a screening hit that was identified in a phenotype screen of 80 NSCLC cell lines against approx. 1500 compds.  Using protein x-ray crystallog., the authors deciphered the binding mode in engineered cSrc (T338M/S345C), a validated model system for EGFR-T790M, which constituted the basis for further rational design approaches.  Chem. synthesis led to further compd. collections that revealed increased biochem. potency and, in part, selectivity toward mutated (L858R and L858R/T790M) vs. nonmutated EGFR.  Further cell-based and kinetic studies were performed to substantiate the authors initial findings.  Utilizing proteolytic digestion and nano-LC-MS/MS anal., the authors confirmed the alkylation of Cys797.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNGJPIuqoVObVg90H21EOLACvtfcHk0ljgE70YewLBcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsrvM&md5=d5264a2a99d7752af0e587f23aeb7723</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01082%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DTomassi%26aufirst%3DS.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DTermathe%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DGruetter%26aufirst%3DC.%26aulast%3DUhlenbrock%26aufirst%3DN.%26aulast%3DKruell%26aufirst%3DJ.%26aulast%3DSchaumann%26aufirst%3DN.%26aulast%3DEppmann%26aufirst%3DS.%26aulast%3DKibies%26aufirst%3DP.%26aulast%3DHoffgaard%26aufirst%3DF.%26aulast%3DHeil%26aufirst%3DJ.%26aulast%3DMenninger%26aufirst%3DS.%26aulast%3DOrtiz-Cuaran%26aufirst%3DS.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DTinnefeld%26aufirst%3DV.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DKast%26aufirst%3DS.%2BM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DTargeting%2520drug%2520resistance%2520in%2520EGFR%2520with%2520covalent%2520inhibitors%253A%2520a%2520structure-based%2520design%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6844%26epage%3D6863%26doi%3D10.1021%2Facs.jmedchem.5b01082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Tomassi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumbrink, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Indazole-based covalent inhibitors to target drug-resistant epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2361</span><span class="NLM_x">–</span> <span class="NLM_lpage">2372</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01626</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01626" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjt1WltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2361-2372&author=S.+Tomassiauthor=J.+Lategahnauthor=J.+Engelauthor=M.+Keulauthor=H.+L.+Tumbrinkauthor=J.+Ketzerauthor=T.+Muhlenbergauthor=M.+Baumannauthor=C.+Schultz-Fademrechtauthor=S.+Bauerauthor=D.+Rauh&title=Indazole-based+covalent+inhibitors+to+target+drug-resistant+epidermal+growth+factor+receptor&doi=10.1021%2Facs.jmedchem.6b01626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor</span></div><div class="casAuthors">Tomassi, Stefano; Lategahn, Jonas; Engel, Julian; Keul, Marina; Tumbrink, Hannah L.; Ketzer, Julia; Muehlenberg, Thomas; Baumann, Matthias; Schultz-Fademrecht, Carsten; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2361-2372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The specific targeting of oncogenic mutant epidermal growth factor receptor (EGFR) is a breakthrough in targeted cancer therapy and marks a drastic change in the treatment of non-small cell lung cancer (NSCLC).  The recurrent emergence of resistance to these targeted drugs requires the development of novel chem. entities that efficiently inhibit drug-resistant EGFR.  Herein, the authors report the optimization process for a hit compd. that has emerged from a phenotypic screen resulting in indazole-based compds.  These inhibitors are conformationally less flexible, target gatekeeper mutated drug resistant EGFR-L858R/T790M and covalently alkylate Cys 797.  Western blot anal., as well as characterization of the binding kinetics and kinase selectivity profiling, substantiates the authors' approach of targeting drug-resistant EGFR-L858R/T790M with inhibitors incorporating the indazole as hinge binder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwwmG17YkaV7Vg90H21EOLACvtfcHk0ljFqhcXv13Zfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjt1WltL0%253D&md5=25e24252dc5a03ec5349359289ebd808</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01626%26sid%3Dliteratum%253Aachs%26aulast%3DTomassi%26aufirst%3DS.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DMuhlenberg%26aufirst%3DT.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DIndazole-based%2520covalent%2520inhibitors%2520to%2520target%2520drug-resistant%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2361%26epage%3D2372%26doi%3D10.1021%2Facs.jmedchem.6b01626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Laufer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Striegel, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, G. K.</span><span> </span><span class="NLM_article-title">Imidazole inhibitors of cytokine release: probing substituents in the 2 position</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4695</span><span class="NLM_x">–</span> <span class="NLM_lpage">4705</span><span class="refDoi"> DOI: 10.1021/jm020873z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020873z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=4695-4705&author=S.+A.+Lauferauthor=H.+G.+Striegelauthor=G.+K.+Wagner&title=Imidazole+inhibitors+of+cytokine+release%3A+probing+substituents+in+the+2+position&doi=10.1021%2Fjm020873z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm020873z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020873z%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DStriegel%26aufirst%3DH.%2BG.%26aulast%3DWagner%26aufirst%3DG.%2BK.%26atitle%3DImidazole%2520inhibitors%2520of%2520cytokine%2520release%253A%2520probing%2520substituents%2520in%2520the%25202%2520position%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D4695%26epage%3D4705%26doi%3D10.1021%2Fjm020873z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Koch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">4-Aryl-5-heteroaryl-2-thio-imidazoles: warhead for a macrocycle-based drug targeting</span> <span class="citation_source-journal">Inflammation Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">446</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2007&pages=446&author=P.+Kochauthor=S.+Laufer&title=4-Aryl-5-heteroaryl-2-thio-imidazoles%3A+warhead+for+a+macrocycle-based+drug+targeting"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3D4-Aryl-5-heteroaryl-2-thio-imidazoles%253A%2520warhead%2520for%2520a%2520macrocycle-based%2520drug%2520targeting%26jtitle%3DInflammation%2520Res.%26date%3D2007%26volume%3D56%26spage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Guzzo, P.; Surman, M. D.; Henderson, A. J.; Hadden, M.; Jiang, M. X.</span><span> </span><span class="NLM_article-title">Preparation of 5-pyridinone substituted indazoles as modulators of melanin-concentrating hormone (MCH1) receptor</span>. PCT Int. Appl. 2008086404 A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=P.+Guzzo&author=M.+D.+Surman&author=A.+J.+Henderson&author=M.+Hadden&author=M.+X.+Jiang&title=Preparation+of+5-pyridinone+substituted+indazoles+as+modulators+of+melanin-concentrating+hormone+%28MCH1%29+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGuzzo%26aufirst%3DP.%26atitle%3DPreparation%2520of%25205-pyridinone%2520substituted%2520indazoles%2520as%2520modulators%2520of%2520melanin-concentrating%2520hormone%2520%2528MCH1%2529%2520receptor%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Busch-Petersen, J.</span><span> </span><span class="NLM_article-title">Preparation of <i>N</i>-sulfonylphenyl-<i>N</i>′-(hetero)arylureas as antagonists of chemokines, in particular interleukin 8 (IL-8)</span>. U.S. Pat. Appl. 20070249672 A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+Busch-Petersen&title=Preparation+of+N-sulfonylphenyl-N%E2%80%B2-%28hetero%29arylureas+as+antagonists+of+chemokines%2C+in+particular+interleukin+8+%28IL-8%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26atitle%3DPreparation%2520of%2520N-sulfonylphenyl-N%25E2%2580%25B2-%2528hetero%2529arylureas%2520as%2520antagonists%2520of%2520chemokines%252C%2520in%2520particular%2520interleukin%25208%2520%2528IL-8%2529%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Joo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toure, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sames, D.</span><span> </span><span class="NLM_article-title">C-H bonds as ubiquitous functionality: a general approach to complex arylated imidazoles via regioselective sequential arylation of all three C-H bonds and regioselective N-alkylation enabled by SEM-group transposition</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">4911</span><span class="NLM_x">–</span> <span class="NLM_lpage">4920</span><span class="refDoi"> DOI: 10.1021/jo100727j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo100727j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosFaksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=4911-4920&author=J.+M.+Jooauthor=B.+B.+Toureauthor=D.+Sames&title=C-H+bonds+as+ubiquitous+functionality%3A+a+general+approach+to+complex+arylated+imidazoles+via+regioselective+sequential+arylation+of+all+three+C-H+bonds+and+regioselective+N-alkylation+enabled+by+SEM-group+transposition&doi=10.1021%2Fjo100727j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">C-H Bonds as Ubiquitous Functionality: A General Approach to Complex Arylated Imidazoles via Regioselective Sequential Arylation of All Three C-H Bonds and Regioselective N-Alkylation Enabled by SEM-Group Transposition</span></div><div class="casAuthors">Joo, Jung Min; Toure, B. Barry; Sames, Dalibor</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4911-4920</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Imidazoles are an important group of the azole family of heterocycles frequently found in pharmaceuticals, drug candidates, ligands for transition metal catalysts, and other mol. functional materials.  Owing to their wide application in academia and industry, new methods and strategies for the generation of functionalized imidazole derivs. are in demand.  We here describe a general and comprehensive approach for the synthesis of complex aryl imidazoles, e.g. I, where all three C-H bonds of the imidazole core can be arylated in a regioselective and sequential manner.  We report new catalytic methods for selective C5- and C2-arylation of SEM-imidazoles and provide a mechanistic hypothesis for the obsd. positional selectivity based on electronic properties of C-H bonds and the heterocyclic ring.  Importantly, aryl bromides and low-cost aryl chlorides can be used as arene donors under practical lab. conditions.  To circumvent the low reactivity of the C-4 position, we developed the SEM-switch that transfers the SEM-group from N-1 to N-3 nitrogen and thus enables prepn. of 4-arylimidazoles and sequential C4-C5-arylation of the imidazole core.  Furthermore, selective N3-alkylation followed by the SEM-group deprotection (trans-N-alkylation) allows for regioselective N-alkylation of complex imidazoles.  The sequential C-arylation enabled by the SEM-switch allowed us to produce a variety of mono-, di-, and triarylimidazoles using diverse bromo- and chloroarenes.  Using our approach, the synthesis of individual compds. or libraries of analogs can begin from either the parent imidazole or a substituted imidazole, providing rapid access to complex imidazole structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrxOPv_g_e07Vg90H21EOLACvtfcHk0ljFqhcXv13Zfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosFaksrs%253D&md5=25b4fe2a06bc6982640665f00c86ca2c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjo100727j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo100727j%26sid%3Dliteratum%253Aachs%26aulast%3DJoo%26aufirst%3DJ.%2BM.%26aulast%3DToure%26aufirst%3DB.%2BB.%26aulast%3DSames%26aufirst%3DD.%26atitle%3DC-H%2520bonds%2520as%2520ubiquitous%2520functionality%253A%2520a%2520general%2520approach%2520to%2520complex%2520arylated%2520imidazoles%2520via%2520regioselective%2520sequential%2520arylation%2520of%2520all%2520three%2520C-H%2520bonds%2520and%2520regioselective%2520N-alkylation%2520enabled%2520by%2520SEM-group%2520transposition%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2010%26volume%3D75%26spage%3D4911%26epage%3D4920%26doi%3D10.1021%2Fjo100727j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Molander, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trice, S. L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, S. M.</span><span> </span><span class="NLM_article-title">Scope of the two-step, one-pot palladium-catalyzed borylation/Suzuki cross-coupling reaction utilizing bis-boronic acid</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">8678</span><span class="NLM_x">–</span> <span class="NLM_lpage">8688</span><span class="refDoi"> DOI: 10.1021/jo301642v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo301642v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlygtLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2012&pages=8678-8688&author=G.+A.+Molanderauthor=S.+L.+J.+Triceauthor=S.+M.+Kennedy&title=Scope+of+the+two-step%2C+one-pot+palladium-catalyzed+borylation%2FSuzuki+cross-coupling+reaction+utilizing+bis-boronic+acid&doi=10.1021%2Fjo301642v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Scope of the Two-Step, One-Pot Palladium-Catalyzed Borylation/Suzuki Cross-Coupling Reaction Utilizing Bis-Boronic Acid</span></div><div class="casAuthors">Molander, Gary A.; Trice, Sarah L. J.; Kennedy, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8678-8688</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The use of bis-boronic acid for the direct synthesis of boronic acids has greatly facilitated the two-step, one-pot borylation/Suzuki cross-coupling reaction between aryl and heteroaryl halides.  With use of Buchwald's second-generation XPhos preformed catalyst, high yields of cross-coupled products were obtained for most substrates.  The method also allows an efficient two-step, one-pot synthesis, providing access to three distinct cross-coupled products after column chromatog.  The method also provides a rapid and convenient route to teraryl compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDMxPPa0A15rVg90H21EOLACvtfcHk0ljFqhcXv13Zfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlygtLjO&md5=80b369825dd060e4e3d243d3c85a9354</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjo301642v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo301642v%26sid%3Dliteratum%253Aachs%26aulast%3DMolander%26aufirst%3DG.%2BA.%26aulast%3DTrice%26aufirst%3DS.%2BL.%2BJ.%26aulast%3DKennedy%26aufirst%3DS.%2BM.%26atitle%3DScope%2520of%2520the%2520two-step%252C%2520one-pot%2520palladium-catalyzed%2520borylation%252FSuzuki%2520cross-coupling%2520reaction%2520utilizing%2520bis-boronic%2520acid%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2012%26volume%3D77%26spage%3D8678%26epage%3D8688%26doi%3D10.1021%2Fjo301642v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manuia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juarez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palakurthi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelais, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiDonato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epple, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">534</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nature17960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1038%2Fnature17960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=27251290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=129-132&author=Y.+Jiaauthor=C.+H.+Yunauthor=E.+Parkauthor=D.+E.+Ercanauthor=M.+Manuiaauthor=J.+Juarezauthor=C.+X.+Xuauthor=K.+Rheeauthor=T.+Chenauthor=H.+K.+Zhangauthor=S.+Palakurthiauthor=J.+B.+Jangauthor=G.+Lelaisauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=P.+Y.+Michellysauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=M.+McNeillauthor=W.+S.+Luauthor=J.+Harrisauthor=S.+Benderauthor=K.+K.+Wongauthor=P.+A.+Janneauthor=M.+J.+Eck&title=Overcoming+EGFR%28T790M%29+and+EGFR%28C797S%29+resistance+with+mutant-selective+allosteric+inhibitors&doi=10.1038%2Fnature17960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span></div><div class="casAuthors">Jia, Yong; Yun, Cai-Hong; Park, Eunyoung; Ercan, Dalia; Manuia, Mari; Juarez, Jose; Xu, Chunxiao; Rhee, Kevin; Chen, Ting; Zhang, Haikuo; Palakurthi, Sangeetha; Jang, Jaebong; Lelais, Gerald; DiDonato, Michael; Bursulaya, Badry; Michellys, Pierre-Yves; Epple, Robert; Marsilje, Thomas H.; McNeill, Matthew; Lu, Wenshuo; Harris, Jennifer; Bender, Steven; Wong, Kwok-Kin; Janne, Pasi A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7605</span>),
    <span class="NLM_cas:pages">129-132</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutations in the EGFR kinase, but resistance arises rapidly, most frequently owing to the secondary T790M mutation within the ATP site of the receptor.  Recently developed mutant-selective irreversible inhibitors are highly active against the T790M mutant, but their efficacy can be compromised by acquired mutation of C797, the cysteine residue with which they form a key covalent bond.  All current EGFR TKIs target the ATP-site of the kinase, highlighting the need for therapeutic agents with alternative mechanisms of action.  Here we describe the rational discovery of EAI045, an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.  The crystal structure shows that the compd. binds an allosteric site created by the displacement of the regulatory C-helix in an inactive conformation of the kinase.  The compd. inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochem. assays.  However, as a single agent it is not effective in blocking EGFR-driven proliferation in cells owing to differential potency on the two subunits of the dimeric receptor, which interact in an asym. manner in the active state.  We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to the allosteric agent.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S), a mutant that is resistant to all currently available EGFR TKIs.  More generally, our findings illustrate the utility of purposefully targeting allosteric sites to obtain mutant-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQkr363w1dMLVg90H21EOLACvtfcHk0lhPvtH2r1t04g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D&md5=f4c2d2362eb900c64bad8550b9da0872</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnature17960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17960%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DErcan%26aufirst%3DD.%2BE.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%2BX.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%2BK.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DJ.%2BB.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DW.%2BS.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DOvercoming%2520EGFR%2528T790M%2529%2520and%2520EGFR%2528C797S%2529%2520resistance%2520with%2520mutant-selective%2520allosteric%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D534%26spage%3D129%26epage%3D132%26doi%3D10.1038%2Fnature17960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Greenberg, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchou-Wong, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rom, W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. C.</span><span> </span><span class="NLM_article-title">Selective p38 activation in human non-small cell lung cancer</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">558</span><span class="NLM_x">–</span> <span class="NLM_lpage">564</span><span class="refDoi"> DOI: 10.1165/ajrcmb.26.5.4689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1165%2Fajrcmb.26.5.4689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=11970907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFWkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2002&pages=558-564&author=A.+K.+Greenbergauthor=S.+Basuauthor=J.+Huauthor=T.+A.+Yieauthor=K.+M.+Tchou-Wongauthor=W.+N.+Romauthor=T.+C.+Lee&title=Selective+p38+activation+in+human+non-small+cell+lung+cancer&doi=10.1165%2Fajrcmb.26.5.4689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Selective p38 activation in human non-small cell lung cancer</span></div><div class="casAuthors">Greenberg, Alissa K.; Basu, Sharmila; Hu, Jing; Yie, Ting-An; Tchou-Wong, Kam Meng; Rom, William N.; Lee, Theodore C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">558-564</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">The mitogen-activated protein kinase (MAPK) pathways transmit signals from the cell membrane to the nucleus.  Activation of MAPK cascades may play a role in malignant transformation.  We hypothesized that enhanced expression of one or more of these pathways would occur in human lung cancers.  Using Western blot anal. of tissue homogenates from resected non-small cell lung cancers and matched non-neoplastic lung tissue, we detd. that only activated p38 was consistently increased in tumor compared with normal tissue.  In vitro kinase assays confirmed that the levels of activated MAPK correlated with the activity of the enzymes, and immunohistochem. anal. confirmed the cellular localization of the activated MAPKs.  We incubated a lung cancer cell line in a hypoxic chamber to simulate the hypoxic environment in solid lung tumors, but found no increase in p38 activation.  Contrary to our expectations, ERK and JNK, the MAPK pathways traditionally assocd. with cell growth and perhaps malignant transformation, were not consistently activated in the human lung tumor samples.  However, p38, a MAPK usually assocd. with stress responses, growth arrest, and apoptosis, was activated in all of the human lung cancer samples, suggesting an addnl. role for this pathway in malignant cell growth or transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIAmfxqEZ1wLVg90H21EOLACvtfcHk0lhPvtH2r1t04g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFWkt7g%253D&md5=f0d7d71351549557a4650e9774dd39e7</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1165%2Fajrcmb.26.5.4689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Fajrcmb.26.5.4689%26sid%3Dliteratum%253Aachs%26aulast%3DGreenberg%26aufirst%3DA.%2BK.%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DYie%26aufirst%3DT.%2BA.%26aulast%3DTchou-Wong%26aufirst%3DK.%2BM.%26aulast%3DRom%26aufirst%3DW.%2BN.%26aulast%3DLee%26aufirst%3DT.%2BC.%26atitle%3DSelective%2520p38%2520activation%2520in%2520human%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2002%26volume%3D26%26spage%3D558%26epage%3D564%26doi%3D10.1165%2Fajrcmb.26.5.4689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Duong-Ly, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, J. R.</span><span> </span><span class="NLM_article-title">A high-throughput radiometric kinase assay</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">1360</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span><span class="refDoi"> DOI: 10.1007/978-1-4939-3073-9_7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1007%2F978-1-4939-3073-9_7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=26501904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVems78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1360&publication_year=2016&pages=87-95&author=K.+C.+Duong-Lyauthor=J.+R.+Peterson&title=A+high-throughput+radiometric+kinase+assay&doi=10.1007%2F978-1-4939-3073-9_7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A High-Throughput Radiometric Kinase Assay</span></div><div class="casAuthors">Duong-Ly, Krisna C.; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1360</span>
        (<span class="NLM_cas:issue">Kinase Screening and Profiling</span>),
    <span class="NLM_cas:pages">87-95</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Aberrant kinase signaling has been implicated in a no. of diseases.  While kinases have become attractive drug targets, only a small fraction of human protein kinases have validated inhibitors.  Screening of libraries of compds. against a kinase or kinases of interest is routinely performed during kinase inhibitor development to identify promising scaffolds for a particular target and to identify kinase targets for compds. of interest.  Screening of more focused compd. libraries may also be conducted in the later stages of inhibitor development to improve potency and optimize selectivity.  The dot blot kinase assay is a robust, high-throughput kinase assay that can be used to screen a no. of small-mol. compds. against one kinase of interest or several kinases.  Here, a protocol for a dot blot kinase assay used for measuring insulin receptor kinase activity is presented.  This protocol can be readily adapted for use with other protein kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1VWJf_NuisLVg90H21EOLACvtfcHk0lhPvtH2r1t04g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVems78%253D&md5=27351bf4930bd2a5168b109436b17945</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-3073-9_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-3073-9_7%26sid%3Dliteratum%253Aachs%26aulast%3DDuong-Ly%26aufirst%3DK.%2BC.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DA%2520high-throughput%2520radiometric%2520kinase%2520assay%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2016%26volume%3D1360%26spage%3D87%26epage%3D95%26doi%3D10.1007%2F978-1-4939-3073-9_7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Anastassiadis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deacon, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devarajan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, J. R.</span><span> </span><span class="NLM_article-title">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1045</span><span class="refDoi"> DOI: 10.1038/nbt.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1038%2Fnbt.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=22037377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1039-1045&author=T.+Anastassiadisauthor=S.+W.+Deaconauthor=K.+Devarajanauthor=H.+Maauthor=J.+R.+Peterson&title=Comprehensive+assay+of+kinase+catalytic+activity+reveals+features+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span></div><div class="casAuthors">Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1039-1045</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. protein kinase inhibitors are widely used to elucidate cellular signaling pathways and are promising therapeutic agents.  Owing to evolutionary conservation of the ATP-binding site, most kinase inhibitors that target this site promiscuously inhibit multiple kinases.  Interpretation of expts. that use these compds. is confounded by a lack of data on the comprehensive kinase selectivity of most inhibitors.  Here we used functional assays to profile the activity of 178 com. available kinase inhibitors against a panel of 300 recombinant protein kinases.  Quant. anal. revealed complex and often unexpected interactions between protein kinases and kinase inhibitors, with a wide spectrum of promiscuity.  Many off-target interactions occur with seemingly unrelated kinases, revealing how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases.  The results have implications for drug development and provide a resource for selecting compds. to elucidate kinase function and for interpreting the results of expts. involving kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUljWIhZGPkrVg90H21EOLACvtfcHk0lhtPSakTdI3fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E&md5=b2f705509b0e09afa46b01d4669f0515</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2017%26sid%3Dliteratum%253Aachs%26aulast%3DAnastassiadis%26aufirst%3DT.%26aulast%3DDeacon%26aufirst%3DS.%2BW.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DComprehensive%2520assay%2520of%2520kinase%2520catalytic%2520activity%2520reveals%2520features%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1039%26epage%3D1045%26doi%3D10.1038%2Fnbt.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Krippendorff, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuhaus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lienau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huisinga, W.</span><span> </span><span class="NLM_article-title">Mechanism-Based Inhibition: Deriving <i>K</i><sub>I</sub> and <i>k</i><sub>inact</sub> Directly from Time-Dependent IC<sub>50</sub> Values</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">–</span> <span class="NLM_lpage">923</span><span class="refDoi"> DOI: 10.1177/1087057109336751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1177%2F1087057109336751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=19675314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSjtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=913-923&author=B.+F.+Krippendorffauthor=R.+Neuhausauthor=P.+Lienauauthor=A.+Reichelauthor=W.+Huisinga&title=Mechanism-Based+Inhibition%3A+Deriving+KI+and+kinact+Directly+from+Time-Dependent+IC50+Values&doi=10.1177%2F1087057109336751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inhibition: deriving KI and kinact directly from time-dependent IC50 values</span></div><div class="casAuthors">Krippendorff, Ben-Fillippo; Neuhaus, Roland; Lienau, Philip; Reichel, Andreas; Huisinga, Wilhelm</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">913-923</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The potential of enzyme inhibition of a drug is frequently quantified in terms of IC50 values.  Although this is a suitable quantity for reversible inhibitors, concerns arise when dealing with irreversible or mechanism-based inhibitors (MBIs).  IC50 values of MBIs are time dependent, causing serious problems when aiming at ranking different compds. with respect to their inhibitory potential.  As a consequence, most studies and ranking schemes related to MBIs rely on the inhibition const. (KI) and the rate of enzyme inactivation (kinact) rather than on IC50 values.  In this article, the authors derive a novel relation between potentially time-dependent IC50 values and KI, kinact parameters for different types of inhibition.  This allows for direct estn. of KI and kinact values from time-dependent IC50 values, even without the need of addnl. preincubation expts.  The application of this approach is illustrated using a fluorimetric assay to access the drug-drug interaction potential assocd. with new chem. entities.  The approach can easily be implemented using std. software tools (e.g., XLfit) and may also be suitable for applications where mechanism-based inhibition is a desired mode of action (e.g., at particular pharmacol. drug targets).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSOIpe0vN8JLVg90H21EOLACvtfcHk0lhtPSakTdI3fQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSjtLjF&md5=93cb5f8644c7e1bdf872cf46756039cf</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1177%2F1087057109336751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057109336751%26sid%3Dliteratum%253Aachs%26aulast%3DKrippendorff%26aufirst%3DB.%2BF.%26aulast%3DNeuhaus%26aufirst%3DR.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DReichel%26aufirst%3DA.%26aulast%3DHuisinga%26aufirst%3DW.%26atitle%3DMechanism-Based%2520Inhibition%253A%2520Deriving%2520KI%2520and%2520kinact%2520Directly%2520from%2520Time-Dependent%2520IC50%2520Values%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2009%26volume%3D14%26spage%3D913%26epage%3D923%26doi%3D10.1177%2F1087057109336751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 49 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yonggang Meng, Bin Yu, He Huang, Youmei Peng, Ertong Li, Yongfang Yao, Chuanjun Song, Wenquan Yu, Kaikai Zhu, Kai Wang, Dongxu Yi, Jinfa Du, <span class="NLM_string-name hlFld-ContribAuthor">Junbiao Chang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 925-937. <a href="https://doi.org/10.1021/acs.jmedchem.0c02005" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02005%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BDosimertinib%25252C%252Ba%252BHighly%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BEfficacious%252BDeuterated%252BEGFR%252BTargeting%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DMeng%26aufirst%3DYonggang%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D19112020%26date%3D18012021%26volume%3D64%26issue%3D2%26spage%3D925%26epage%3D937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">David E. Heppner, Marcel Günther, Florian Wittlinger, Stefan A. Laufer, <span class="NLM_string-name hlFld-ContribAuthor">Michael J. Eck</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (8)
                                     , 4293-4305. <a href="https://doi.org/10.1021/acs.jmedchem.0c00200" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00200</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00200%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BBasis%252Bfor%252BEGFR%252BMutant%252BInhibition%252Bby%252BTrisubstituted%252BImidazole%252BInhibitors%26aulast%3DHeppner%26aufirst%3DDavid%2BE.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04022020%26date%3D14042020%26date%3D03042020%26volume%3D63%26issue%3D8%26spage%3D4293%26epage%3D4305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">René Lebl, Trevor Murray, Andrea Adamo, David Cantillo, <span class="NLM_string-name hlFld-ContribAuthor">C. Oliver Kappe</span>. </span><span class="cited-content_cbyCitation_article-title">Continuous Flow Synthesis of Methyl Oximino Acetoacetate: Accessing Greener Purification Methods with Inline Liquid–Liquid Extraction and Membrane Separation Technology. </span><span class="cited-content_cbyCitation_journal-name">ACS Sustainable Chemistry & Engineering</span><span> <strong>2019,</strong> <em>7 </em>
                                    (24)
                                     , 20088-20096. <a href="https://doi.org/10.1021/acssuschemeng.9b05954" title="DOI URL">https://doi.org/10.1021/acssuschemeng.9b05954</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acssuschemeng.9b05954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facssuschemeng.9b05954%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Sustainable%2520Chemistry%2520%2526%2520Engineering%26atitle%3DContinuous%252BFlow%252BSynthesis%252Bof%252BMethyl%252BOximino%252BAcetoacetate%25253A%252BAccessing%252BGreener%252BPurification%252BMethods%252Bwith%252BInline%252BLiquid%2525E2%252580%252593Liquid%252BExtraction%252Band%252BMembrane%252BSeparation%252BTechnology%26aulast%3DLebl%26aufirst%3DRen%25C3%25A9%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D06102019%26date%3D13112019%26date%3D02122019%26date%3D15112019%26volume%3D7%26issue%3D24%26spage%3D20088%26epage%3D20096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Harald Engelhardt, Dietrich Böse, Mark Petronczki, Dirk Scharn, Gerd Bader, Anke Baum, Andreas Bergner, Eugene Chong, Sandra Döbel, Georg Egger, Christian Engelhardt, Peter Ettmayer, Julian E. Fuchs, Thomas Gerstberger, Nina Gonnella, Andreas Grimm, Elisabeth Grondal, Nizar Haddad, Barbara Hopfgartner, Roland Kousek, Mariusz Krawiec, Monika Kriz, Lyne Lamarre, Joyce Leung, Moriz Mayer, Nitinchandra D. Patel, Biljana Peric Simov, Jonathan T. Reeves, Renate Schnitzer, Andreas Schrenk, Bernadette Sharps, Flavio Solca, Heinz Stadtmüller, Zhulin Tan, Tobias Wunberg, Andreas Zoephel, <span class="NLM_string-name hlFld-ContribAuthor">Darryl B. McConnell</span>. </span><span class="cited-content_cbyCitation_article-title">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (22)
                                     , 10272-10293. <a href="https://doi.org/10.1021/acs.jmedchem.9b01169" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStart%252BSelective%252Band%252BRigidify%25253A%252BThe%252BDiscovery%252BPath%252Btoward%252Ba%252BNext%252BGeneration%252Bof%252BEGFR%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DEngelhardt%26aufirst%3DHarald%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14082019%26date%3D13112019%26date%3D05112019%26volume%3D62%26issue%3D22%26spage%3D10272%26epage%3D10293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ian de Toledo, Thiago A. Grigolo, James M. Bennett, Jonathan M. Elkins, <span class="NLM_string-name hlFld-ContribAuthor">Ronaldo A. Pilli</span>. </span><span class="cited-content_cbyCitation_article-title">Modular Synthesis of Di- and Trisubstituted Imidazoles from Ketones and Aldehydes: A Route to Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (21)
                                     , 14187-14201. <a href="https://doi.org/10.1021/acs.joc.9b01844" title="DOI URL">https://doi.org/10.1021/acs.joc.9b01844</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b01844&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b01844%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DModular%252BSynthesis%252Bof%252BDi-%252Band%252BTrisubstituted%252BImidazoles%252Bfrom%252BKetones%252Band%252BAldehydes%25253A%252BA%252BRoute%252Bto%252BKinase%252BInhibitors%26aulast%3Dde%2BToledo%26aufirst%3DIan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D08072019%26date%3D30092019%26date%3D28082019%26volume%3D84%26issue%3D21%26spage%3D14187%26epage%3D14201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Farideh Badichi Akher, Abdolkarim Farrokhzadeh, Neil Ravenscroft, <span class="NLM_string-name hlFld-ContribAuthor">Michelle M. Kuttel</span>. </span><span class="cited-content_cbyCitation_article-title">A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2019,</strong> <em>58 </em>
                                    (41)
                                     , 4246-4259. <a href="https://doi.org/10.1021/acs.biochem.9b00710" title="DOI URL">https://doi.org/10.1021/acs.biochem.9b00710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.9b00710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.9b00710%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DA%252BMechanistic%252BStudy%252Bof%252Ba%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitor%252Bagainst%252Bthe%252BL858R%25252FT790M%252BResistance%252BMutation%26aulast%3DAkher%26aufirst%3DFarideh%2BBadichi%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D13082019%26date%3D23092019%26date%3D07102019%26volume%3D58%26issue%3D41%26spage%3D4246%26epage%3D4259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sean T. Toenjes, Valeria Garcia, Sean M. Maddox, Gregory A. Dawson, Maria A. Ortiz, F. Javier Piedrafita, <span class="NLM_string-name hlFld-ContribAuthor">Jeffrey L. Gustafson</span>. </span><span class="cited-content_cbyCitation_article-title">Leveraging Atropisomerism to Obtain a Selective Inhibitor of RET Kinase with Secondary Activities toward EGFR Mutants. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2019,</strong> <em>14 </em>
                                    (9)
                                     , 1930-1939. <a href="https://doi.org/10.1021/acschembio.9b00407" title="DOI URL">https://doi.org/10.1021/acschembio.9b00407</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.9b00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.9b00407%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DLeveraging%252BAtropisomerism%252Bto%252BObtain%252Ba%252BSelective%252BInhibitor%252Bof%252BRET%252BKinase%252Bwith%252BSecondary%252BActivities%252Btoward%252BEGFR%252BMutants%26aulast%3DToenjes%26aufirst%3DSean%2BT.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22052019%26date%3D19082019%26date%3D29082019%26date%3D19082019%26volume%3D14%26issue%3D9%26spage%3D1930%26epage%3D1939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zheng Zhao, Lei Xie, <span class="NLM_string-name hlFld-ContribAuthor">Philip E. Bourne</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Insights into Characterizing Binding Sites in Epidermal Growth Factor Receptor Kinase Mutants. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (1)
                                     , 453-462. <a href="https://doi.org/10.1021/acs.jcim.8b00458" title="DOI URL">https://doi.org/10.1021/acs.jcim.8b00458</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.8b00458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.8b00458%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DStructural%252BInsights%252Binto%252BCharacterizing%252BBinding%252BSites%252Bin%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BKinase%252BMutants%26aulast%3DZhao%26aufirst%3DZheng%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D10072018%26date%3D11012019%26date%3D24122018%26volume%3D59%26issue%3D1%26spage%3D453%26epage%3D462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Tao Zhang, Su-Jie Zhu, Qiuju Xun, Lingjiang Tong, Xianglong Hu, Yan Li, Shingpan Chan, Yi Su, Yiming Sun, Yi Chen, Jian Ding, Cai-Hong Yun, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (11)
                                     , 1123-1127. <a href="https://doi.org/10.1021/acsmedchemlett.8b00373" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00373%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BJND3229%252Bas%252Ba%252BNew%252BEGFRC797S%252BMutant%252BInhibitor%252Bwith%252BIn%252BVivo%252BMonodrug%252BEfficacy%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D15082018%26date%3D08102018%26date%3D10102018%26date%3D08102018%26volume%3D9%26issue%3D11%26spage%3D1123%26epage%3D1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tobias Grabe, Jonas Lategahn, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (8)
                                     , 779-782. <a href="https://doi.org/10.1021/acsmedchemlett.8b00314" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00314</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00314%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DC797S%252BResistance%25253A%252BThe%252BUndruggable%252BEGFR%252BMutation%252Bin%252BNon-Small%252BCell%252BLung%252BCancer%25253F%26aulast%3DGrabe%26aufirst%3DTobias%26date%3D2018%26date%3D2018%26date%3D23072018%26volume%3D9%26issue%3D8%26spage%3D779%26epage%3D782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lingfeng Chen, Weitao Fu, Lulu Zheng, Zhiguo Liu, <span class="NLM_string-name hlFld-ContribAuthor">Guang Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (10)
                                     , 4290-4300. <a href="https://doi.org/10.1021/acs.jmedchem.7b01310" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01310</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01310%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BProgress%252Bof%252BSmall-Molecule%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%252Bagainst%252BC797S%252BResistance%252Bin%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DChen%26aufirst%3DLingfeng%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D02092017%26date%3D27112017%26date%3D14112017%26volume%3D61%26issue%3D10%26spage%3D4290%26epage%3D4300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Scalvini</span>, <span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>, <span class="hlFld-ContribAuthor ">Silvia  La Monica</span>, <span class="hlFld-ContribAuthor ">Marcello  Tiseo</span>, <span class="hlFld-ContribAuthor ">Roberta  Alfieri</span>. </span><span class="cited-content_cbyCitation_article-title">Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2021,</strong> <em>190 </em>, 114643. <a href="https://doi.org/10.1016/j.bcp.2021.114643" title="DOI URL">https://doi.org/10.1016/j.bcp.2021.114643</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2021.114643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2021.114643%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DFighting%252Btertiary%252Bmutations%252Bin%252BEGFR-driven%252Blung-cancers%25253A%252BCurrent%252Badvances%252Band%252Bfuture%252Bperspectives%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DScalvini%26aufirst%3DLaura%26date%3D2021%26volume%3D190%26spage%3D114643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David E.  Heppner</span>, <span class="hlFld-ContribAuthor ">Michael J.  Eck</span>. </span><span class="cited-content_cbyCitation_article-title">A structural perspective on targeting the
              RTK
              /Ras/
              MAP
              kinase pathway in cancer. </span><span class="cited-content_cbyCitation_journal-name">Protein Science</span><span> <strong>2021,</strong> <em>30 </em>
                                    (8)
                                     , 1535-1553. <a href="https://doi.org/10.1002/pro.4125" title="DOI URL">https://doi.org/10.1002/pro.4125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pro.4125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpro.4125%26sid%3Dliteratum%253Aachs%26jtitle%3DProtein%2520Science%26atitle%3DA%252Bstructural%252Bperspective%252Bon%252Btargeting%252Bthe%252BRTK%252B%25252FRas%25252F%252BMAP%252Bkinase%252Bpathway%252Bin%252Bcancer%26aulast%3DHeppner%26aufirst%3DDavid%2BE.%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D8%26spage%3D1535%26epage%3D1553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tingting  Jia</span>, <span class="hlFld-ContribAuthor ">Gongruixue  Zeng</span>, <span class="hlFld-ContribAuthor ">Chong  Zhang</span>, <span class="hlFld-ContribAuthor ">Linghui  Zeng</span>, <span class="hlFld-ContribAuthor ">Wenya  Zheng</span>, <span class="hlFld-ContribAuthor ">Siyao  Li</span>, <span class="hlFld-ContribAuthor ">Keyi  Wu</span>, <span class="hlFld-ContribAuthor ">Jiaan  Shao</span>, <span class="hlFld-ContribAuthor ">Jiankang  Zhang</span>, <span class="hlFld-ContribAuthor ">Huajian  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">The reaction of prop-2-ynylsulfonium salts and sulfonyl-protected β-amino ketones to epoxide-fused 2-methylenepyrrolidines and S-containing pyrroles. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2021,</strong> <em>57 </em>
                                    (21)
                                     , 2657-2660. <a href="https://doi.org/10.1039/D0CC07745C" title="DOI URL">https://doi.org/10.1039/D0CC07745C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CC07745C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CC07745C%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DThe%252Breaction%252Bof%252Bprop-2-ynylsulfonium%252Bsalts%252Band%252Bsulfonyl-protected%252B%2525CE%2525B2-amino%252Bketones%252Bto%252Bepoxide-fused%252B2-methylenepyrrolidines%252Band%252BS-containing%252Bpyrroles%26aulast%3DJia%26aufirst%3DTingting%26date%3D2021%26date%3D2021%26volume%3D57%26issue%3D21%26spage%3D2657%26epage%3D2660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrey N.  Komogortsev</span>, <span class="hlFld-ContribAuthor ">Valeriya G.  Melekhina</span>, <span class="hlFld-ContribAuthor ">Boris V.  Lichitsky</span>. </span><span class="cited-content_cbyCitation_article-title">The synthesis of novel type of α-aminoketones containing allomaltol fragment. </span><span class="cited-content_cbyCitation_journal-name">Synthetic Communications</span><span> <strong>2021,</strong> <em>51 </em>
                                    (5)
                                     , 701-708. <a href="https://doi.org/10.1080/00397911.2020.1849725" title="DOI URL">https://doi.org/10.1080/00397911.2020.1849725</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00397911.2020.1849725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00397911.2020.1849725%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthetic%2520Communications%26atitle%3DThe%252Bsynthesis%252Bof%252Bnovel%252Btype%252Bof%252B%2525CE%2525B1-aminoketones%252Bcontaining%252Ballomaltol%252Bfragment%26aulast%3DKomogortsev%26aufirst%3DAndrey%2BN.%26date%3D2021%26date%3D2020%26volume%3D51%26issue%3D5%26spage%3D701%26epage%3D708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Igor V.  Levkov</span>, <span class="hlFld-ContribAuthor ">Andrii I.  Kysil</span>, <span class="hlFld-ContribAuthor ">Angelina V.  Biitseva</span>, <span class="hlFld-ContribAuthor ">Sergey V.  Shilin</span>, <span class="hlFld-ContribAuthor ">Nathalie  Saffon-Merceron</span>, <span class="hlFld-ContribAuthor ">Tatyana V.  Yegorova</span>, <span class="hlFld-ContribAuthor ">Zoia V.  Voitenko</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 2-(methoxymethyl)isoindolin-1-imine derivatives via an unusual Delépine reaction. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2021,</strong> <em>67 </em>, 152866. <a href="https://doi.org/10.1016/j.tetlet.2021.152866" title="DOI URL">https://doi.org/10.1016/j.tetlet.2021.152866</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2021.152866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2021.152866%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DSynthesis%252Bof%252B2-%252528methoxymethyl%252529isoindolin-1-imine%252Bderivatives%252Bvia%252Ban%252Bunusual%252BDel%2525C3%2525A9pine%252Breaction%26aulast%3DLevkov%26aufirst%3DIgor%2BV.%26date%3D2021%26volume%3D67%26spage%3D152866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  He</span>, <span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Xin  Sun</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>210 </em>, 112995. <a href="https://doi.org/10.1016/j.ejmech.2020.112995" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112995</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112995%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bnew%252Bopportunities%252Bin%252Bmedicinal%252Bchemistry%252Bof%252Bfourth-generation%252BEGFR%252Binhibitors%252Bto%252Bovercome%252BC797S%252Bmutation%26aulast%3DHe%26aufirst%3DJie%26date%3D2021%26volume%3D210%26spage%3D112995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Iqrar  Ahmad</span>, <span class="hlFld-ContribAuthor ">Matin  Shaikh</span>, <span class="hlFld-ContribAuthor ">Sanjay  Surana</span>, <span class="hlFld-ContribAuthor ">Arabinda  Ghosh</span>, <span class="hlFld-ContribAuthor ">Harun  Patel</span>. </span><span class="cited-content_cbyCitation_article-title">p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em>3 </em>, 1-14. <a href="https://doi.org/10.1080/07391102.2020.1844801" title="DOI URL">https://doi.org/10.1080/07391102.2020.1844801</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1844801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1844801%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3Dp38%2525CE%2525B1%252BMAP%252Bkinase%252Binhibitors%252Bto%252Bovercome%252BEGFR%252Btertiary%252BC797S%252Bpoint%252Bmutation%252Bassociated%252Bwith%252Bosimertinib%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%252B%252528NSCLC%252529%25253A%252Bemergence%252Bof%252Bfourth-generation%252BEGFR%252Binhibitor%26aulast%3DAhmad%26aufirst%3DIqrar%26date%3D2020%26date%3D2020%26volume%3D3%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingguang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yunyun  Wang</span>, <span class="hlFld-ContribAuthor ">Jia  Wang</span>, <span class="hlFld-ContribAuthor ">Zhaogang  Liu</span>, <span class="hlFld-ContribAuthor ">Jingmiao  Shi</span>, <span class="hlFld-ContribAuthor ">Mingxin  Li</span>, <span class="hlFld-ContribAuthor ">Yongqiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Shifa  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical and Pharmaceutical Bulletin</span><span> <strong>2020,</strong> <em>68 </em>
                                    (10)
                                     , 971-980. <a href="https://doi.org/10.1248/cpb.c20-00411" title="DOI URL">https://doi.org/10.1248/cpb.c20-00411</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c20-00411&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c20-00411%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520and%2520Pharmaceutical%2520Bulletin%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252Bthe%252BQuinazoline%252BDerivatives%252Bas%252BL858R%25252FT790M%25252FC797S%252BTriple%252BMutant%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DZhang%26aufirst%3DMingguang%26date%3D2020%26volume%3D68%26issue%3D10%26spage%3D971%26epage%3D980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ravi  Saini</span>, <span class="hlFld-ContribAuthor ">Shehnaz  Fatima</span>, <span class="hlFld-ContribAuthor ">Subhash Mohan  Agarwal</span>. </span><span class="cited-content_cbyCitation_article-title">TMLRpred: A machine learning classification model to distinguish reversible EGFR double mutant inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2020,</strong> <em>96 </em>
                                    (3)
                                     , 921-930. <a href="https://doi.org/10.1111/cbdd.13697" title="DOI URL">https://doi.org/10.1111/cbdd.13697</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13697%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DTMLRpred%25253A%252BA%252Bmachine%252Blearning%252Bclassification%252Bmodel%252Bto%252Bdistinguish%252Breversible%252BEGFR%252Bdouble%252Bmutant%252Binhibitors%26aulast%3DSaini%26aufirst%3DRavi%26date%3D2020%26date%3D2020%26volume%3D96%26issue%3D3%26spage%3D921%26epage%3D930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhicheng  Su</span>, <span class="hlFld-ContribAuthor ">Tingyuan  Yang</span>, <span class="hlFld-ContribAuthor ">Jie  Wang</span>, <span class="hlFld-ContribAuthor ">Mengzhen  Lai</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Gulinuer  Wumaier</span>, <span class="hlFld-ContribAuthor ">Zhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Shengqing  Li</span>, <span class="hlFld-ContribAuthor ">Honglin  Li</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Zhenjiang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (16)
                                     , 127327. <a href="https://doi.org/10.1016/j.bmcl.2020.127327" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127327</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127327%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bpotent%252BEGFR%252Bkinase%252Binhibitors%252Bagainst%252B19D%25252FT790M%25252FC797S%252Bmutation%26aulast%3DSu%26aufirst%3DZhicheng%26date%3D2020%26volume%3D30%26issue%3D16%26spage%3D127327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Somayeh  Salarinejad</span>, <span class="hlFld-ContribAuthor ">Maliheh  Safavi</span>, <span class="hlFld-ContribAuthor ">Behjat  Pouramiri</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103811. <a href="https://doi.org/10.1016/j.bioorg.2020.103811" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103811</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103811%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Bprogression%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Binhibitors%252Bas%252Ban%252Befficient%252Bapproach%252Bin%252Bcancer%252Btargeted%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2020%26volume%3D99%26spage%3D103811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayah  Abdeldayem</span>, <span class="hlFld-ContribAuthor ">Yasir S.  Raouf</span>, <span class="hlFld-ContribAuthor ">Stefan N.  Constantinescu</span>, <span class="hlFld-ContribAuthor ">Richard  Moriggl</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in covalent kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2020,</strong> <em>49 </em>
                                    (9)
                                     , 2617-2687. <a href="https://doi.org/10.1039/C9CS00720B" title="DOI URL">https://doi.org/10.1039/C9CS00720B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CS00720B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CS00720B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DAdvances%252Bin%252Bcovalent%252Bkinase%252Binhibitors%26aulast%3DAbdeldayem%26aufirst%3DAyah%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D9%26spage%3D2617%26epage%3D2687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Priyanka  Halder</span>, <span class="hlFld-ContribAuthor ">Mahesh D.  Pol</span>, <span class="hlFld-ContribAuthor ">Milind M.  Ahire</span>, <span class="hlFld-ContribAuthor ">Santosh B.  Mhaske</span>. </span><span class="cited-content_cbyCitation_article-title">Construction of unique SCF
              3
              -containing building blocks
              via
              allylic alkylation of Morita–Baylis–Hillman adducts. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (11)
                                     , 2085-2093. <a href="https://doi.org/10.1039/D0OB00104J" title="DOI URL">https://doi.org/10.1039/D0OB00104J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB00104J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB00104J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DConstruction%252Bof%252Bunique%252BSCF%252B3%252B-containing%252Bbuilding%252Bblocks%252Bvia%252Ballylic%252Balkylation%252Bof%252BMorita%2525E2%252580%252593Baylis%2525E2%252580%252593Hillman%252Badducts%26aulast%3DHalder%26aufirst%3DPriyanka%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D11%26spage%3D2085%26epage%3D2093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haikui  Yang</span>, <span class="hlFld-ContribAuthor ">Ruohong  Yan</span>, <span class="hlFld-ContribAuthor ">Ying  Jiang</span>, <span class="hlFld-ContribAuthor ">Zichao  Yang</span>, <span class="hlFld-ContribAuthor ">Xingmei  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Wu</span>, <span class="hlFld-ContribAuthor ">Tingting  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiajie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 2-amino-4-(1,2,4-triazol)pyridine derivatives as potent EGFR inhibitors to overcome TKI-resistance. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>187 </em>, 111966. <a href="https://doi.org/10.1016/j.ejmech.2019.111966" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111966</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111966%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B2-amino-4-%2525281%25252C2%25252C4-triazol%252529pyridine%252Bderivatives%252Bas%252Bpotent%252BEGFR%252Binhibitors%252Bto%252Bovercome%252BTKI-resistance%26aulast%3DYang%26aufirst%3DHaikui%26date%3D2020%26volume%3D187%26spage%3D111966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Kinase Inhibitors: An Overview. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 43-94. <a href="https://doi.org/10.1007/7355_2020_103" title="DOI URL">https://doi.org/10.1007/7355_2020_103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_103%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252BKinase%252BInhibitors%25253A%252BAn%252BOverview%26aulast%3DGehringer%26aufirst%3DMatthias%26date%3D2020%26date%3D2020%26spage%3D43%26epage%3D94%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierre  Koch</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of c-Jun N-Terminal Kinase 3. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 203-224. <a href="https://doi.org/10.1007/7355_2020_98" title="DOI URL">https://doi.org/10.1007/7355_2020_98</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_98&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_98%26sid%3Dliteratum%253Aachs%26atitle%3DInhibitors%252Bof%252Bc-Jun%252BN-Terminal%252BKinase%252B3%26aulast%3DKoch%26aufirst%3DPierre%26date%3D2020%26date%3D2020%26spage%3D203%26epage%3D224%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Lei</span>, <span class="hlFld-ContribAuthor ">Shu  Fan</span>, <span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Yan-Jie  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">Jun-Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">A-Qun  Zheng</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>186 </em>, 111888. <a href="https://doi.org/10.1016/j.ejmech.2019.111888" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111888</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111888%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B9-heterocyclyl%252Bsubstituted%252B9H-purines%252Bas%252BL858R%25252FT790M%25252FC797S%252Bmutant%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DLei%26aufirst%3DHao%26date%3D2020%26volume%3D186%26spage%3D111888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xing-Xing  Yang</span>, <span class="hlFld-ContribAuthor ">Guang-Yao  Ran</span>, <span class="hlFld-ContribAuthor ">Chen  Chen</span>, <span class="hlFld-ContribAuthor ">Jing-Fei  Yue</span>, <span class="hlFld-ContribAuthor ">Wei  Du</span>, <span class="hlFld-ContribAuthor ">Ying-Chun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">C 1-Symmetric Ligand-Enabled Stereoselective Formal [5+4] Cycloadditions of Palladium-Containing 1,5-Carbodipoles. </span><span class="cited-content_cbyCitation_journal-name">SSRN Electronic Journal</span><span> <strong>2020,</strong> <em>3 </em><a href="https://doi.org/10.2139/ssrn.3582692" title="DOI URL">https://doi.org/10.2139/ssrn.3582692</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2139/ssrn.3582692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2139%2Fssrn.3582692%26sid%3Dliteratum%253Aachs%26jtitle%3DSSRN%2520Electronic%2520Journal%26atitle%3DC%252B1-Symmetric%252BLigand-Enabled%252BStereoselective%252BFormal%252B%25255B5%25252B4%25255D%252BCycloadditions%252Bof%252BPalladium-Containing%252B1%25252C5-Carbodipoles%26aulast%3DYang%26aufirst%3DXing-Xing%26date%3D2020%26volume%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonas  Lategahn</span>, <span class="hlFld-ContribAuthor ">Marina  Keul</span>, <span class="hlFld-ContribAuthor ">Philip  Klövekorn</span>, <span class="hlFld-ContribAuthor ">Hannah L.  Tumbrink</span>, <span class="hlFld-ContribAuthor ">Janina  Niggenaber</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Müller</span>, <span class="hlFld-ContribAuthor ">Luke  Hodson</span>, <span class="hlFld-ContribAuthor ">Maren  Flaßhoff</span>, <span class="hlFld-ContribAuthor ">Julia  Hardick</span>, <span class="hlFld-ContribAuthor ">Tobias  Grabe</span>, <span class="hlFld-ContribAuthor ">Julian  Engel</span>, <span class="hlFld-ContribAuthor ">Carsten  Schultz-Fademrecht</span>, <span class="hlFld-ContribAuthor ">Matthias  Baumann</span>, <span class="hlFld-ContribAuthor ">Julia  Ketzer</span>, <span class="hlFld-ContribAuthor ">Thomas  Mühlenberg</span>, <span class="hlFld-ContribAuthor ">Wolf  Hiller</span>, <span class="hlFld-ContribAuthor ">Georgia  Günther</span>, <span class="hlFld-ContribAuthor ">Anke  Unger</span>, <span class="hlFld-ContribAuthor ">Heiko  Müller</span>, <span class="hlFld-ContribAuthor ">Alena  Heimsoeth</span>, <span class="hlFld-ContribAuthor ">Christopher  Golz</span>, <span class="hlFld-ContribAuthor ">Bernhard  Blank-Landeshammer</span>, <span class="hlFld-ContribAuthor ">Laxmikanth  Kollipara</span>, <span class="hlFld-ContribAuthor ">René P.  Zahedi</span>, <span class="hlFld-ContribAuthor ">Carsten  Strohmann</span>, <span class="hlFld-ContribAuthor ">Jan G.  Hengstler</span>, <span class="hlFld-ContribAuthor ">Willem A. L.  van Otterlo</span>, <span class="hlFld-ContribAuthor ">Sebastian  Bauer</span>, <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2019,</strong> <em>10 </em>
                                    (46)
                                     , 10789-10801. <a href="https://doi.org/10.1039/C9SC03445E" title="DOI URL">https://doi.org/10.1039/C9SC03445E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9SC03445E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9SC03445E%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DInhibition%252Bof%252Bosimertinib-resistant%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252BEGFR-T790M%25252FC797S%26aulast%3DLategahn%26aufirst%3DJonas%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D46%26spage%3D10789%26epage%3D10801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Efthymios-Spyridon  Gavriil</span>, <span class="hlFld-ContribAuthor ">Aris  Doukatas</span>, <span class="hlFld-ContribAuthor ">Theodoros  Karampelas</span>, <span class="hlFld-ContribAuthor ">Vassilios  Myrianthopoulos</span>, <span class="hlFld-ContribAuthor ">Spyridon  Dimitrakis</span>, <span class="hlFld-ContribAuthor ">Emmanuel  Mikros</span>, <span class="hlFld-ContribAuthor ">Panagiotis  Marakos</span>, <span class="hlFld-ContribAuthor ">Constantin  Tamvakopoulos</span>, <span class="hlFld-ContribAuthor ">Nicole  Pouli</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>176 </em>, 393-409. <a href="https://doi.org/10.1016/j.ejmech.2019.05.029" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.05.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.05.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.05.029%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bsubstituted%252Bpurine%252Bisosters%252Bas%252BEGFR%252Bkinase%252Binhibitors%25252C%252Bwith%252Bpromising%252Bpharmacokinetic%252Bprofile%252Band%252Bin%2525C2%2525A0vivo%252Befficacy%26aulast%3DGavriil%26aufirst%3DEfthymios-Spyridon%26date%3D2019%26volume%3D176%26spage%3D393%26epage%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shehnaz  Fatima</span>, <span class="hlFld-ContribAuthor ">Divyani  Pal</span>, <span class="hlFld-ContribAuthor ">Subhash Mohan  Agarwal</span>. </span><span class="cited-content_cbyCitation_article-title">QSAR of clinically important EGFR mutant L858R/T790M pyridinylimidazole inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2019,</strong> <em>94 </em>
                                    (1)
                                     , 1306-1315. <a href="https://doi.org/10.1111/cbdd.13505" title="DOI URL">https://doi.org/10.1111/cbdd.13505</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13505%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DQSAR%252Bof%252Bclinically%252Bimportant%252BEGFR%252Bmutant%252BL858R%25252FT790M%252Bpyridinylimidazole%252Binhibitors%26aulast%3DFatima%26aufirst%3DShehnaz%26date%3D2019%26date%3D2019%26volume%3D94%26issue%3D1%26spage%3D1306%26epage%3D1315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tarek S.  Mansour</span>, <span class="hlFld-ContribAuthor ">Vijay  Potluri</span>, <span class="hlFld-ContribAuthor ">Ranga R.  Pallepati</span>, <span class="hlFld-ContribAuthor ">Vishnu  Basetti</span>, <span class="hlFld-ContribAuthor ">Mallaiah  Keesara</span>, <span class="hlFld-ContribAuthor ">Ashok G.  Moghudula</span>, <span class="hlFld-ContribAuthor ">Pranab  Maiti</span>. </span><span class="cited-content_cbyCitation_article-title">Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 1435-1439. <a href="https://doi.org/10.1016/j.bmcl.2019.04.029" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.04.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.04.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.04.029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DLead%252Bgeneration%252Bof%252B1%25252C2-dithiolanes%252Bas%252Bexon%252B19%252Band%252Bexon%252B21%252Bmutant%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DMansour%26aufirst%3DTarek%2BS.%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D1435%26epage%3D1439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Avick Kumar  Ghosh</span>, <span class="hlFld-ContribAuthor ">Indranil  Samanta</span>, <span class="hlFld-ContribAuthor ">Anushree  Mondal</span>, <span class="hlFld-ContribAuthor ">Wenshe Ray  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Inhibition in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2019,</strong> <em>14 </em>
                                    (9)
                                     , 889-906. <a href="https://doi.org/10.1002/cmdc.201900107" title="DOI URL">https://doi.org/10.1002/cmdc.201900107</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900107%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DCovalent%252BInhibition%252Bin%252BDrug%252BDiscovery%26aulast%3DGhosh%26aufirst%3DAvick%2BKumar%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D9%26spage%3D889%26epage%3D906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Donghwa  Kim</span>, <span class="hlFld-ContribAuthor ">Duc-Hiep  Bach</span>, <span class="hlFld-ContribAuthor ">Yan-Hua  Fan</span>, <span class="hlFld-ContribAuthor ">Thi-Thu-Trang  Luu</span>, <span class="hlFld-ContribAuthor ">Ji-Young  Hong</span>, <span class="hlFld-ContribAuthor ">Hyen Joo  Park</span>, <span class="hlFld-ContribAuthor ">Sang Kook  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Cell Death & Disease</span><span> <strong>2019,</strong> <em>10 </em>
                                    (5)
                                     <a href="https://doi.org/10.1038/s41419-019-1601-6" title="DOI URL">https://doi.org/10.1038/s41419-019-1601-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41419-019-1601-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41419-019-1601-6%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Death%2520%2526%2520Disease%26atitle%3DAXL%252Bdegradation%252Bin%252Bcombination%252Bwith%252BEGFR-TKI%252Bcan%252Bdelay%252Band%252Bovercome%252Bacquired%252Bresistance%252Bin%252Bhuman%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bcells%26aulast%3DKim%26aufirst%3DDonghwa%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Farideh Badichi  Akher</span>, <span class="hlFld-ContribAuthor ">Abdolkarim  Farrokhzadeh</span>, <span class="hlFld-ContribAuthor ">Mahmoud E. S.  Soliman</span>. </span><span class="cited-content_cbyCitation_article-title">Noteworthy effect of slight variation in aliphatic chain length of trisubstituted imidazole inhibitors against epidermal growth factor receptor L858R/T790M/C797S mutant in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2019,</strong> <em>93 </em>
                                    (5)
                                     , 798-810. <a href="https://doi.org/10.1111/cbdd.13467" title="DOI URL">https://doi.org/10.1111/cbdd.13467</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13467%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DNoteworthy%252Beffect%252Bof%252Bslight%252Bvariation%252Bin%252Baliphatic%252Bchain%252Blength%252Bof%252Btrisubstituted%252Bimidazole%252Binhibitors%252Bagainst%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252BL858R%25252FT790M%25252FC797S%252Bmutant%252Bin%252Bcancer%252Btherapy%26aulast%3DAkher%26aufirst%3DFarideh%2BBadichi%26date%3D2019%26date%3D2019%26volume%3D93%26issue%3D5%26spage%3D798%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Farideh Badichi  Akher</span>, <span class="hlFld-ContribAuthor ">Abdolkarim  Farrokhzadeh</span>, <span class="hlFld-ContribAuthor ">Mahmoud E. S.  Soliman</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent vs. Non‐Covalent Inhibition: Tackling Drug Resistance in EGFR – A Thorough Dynamic Perspective. </span><span class="cited-content_cbyCitation_journal-name">Chemistry & Biodiversity</span><span> <strong>2019,</strong> <em>16 </em>
                                    (3)
                                     , e1800518. <a href="https://doi.org/10.1002/cbdv.201800518" title="DOI URL">https://doi.org/10.1002/cbdv.201800518</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbdv.201800518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbdv.201800518%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%2526%2520Biodiversity%26atitle%3DCovalent%252Bvs.%252BNon%2525E2%252580%252590Covalent%252BInhibition%25253A%252BTackling%252BDrug%252BResistance%252Bin%252BEGFR%252B%2525E2%252580%252593%252BA%252BThorough%252BDynamic%252BPerspective%26aulast%3DAkher%26aufirst%3DFarideh%2BBadichi%26date%3D2019%26date%3D2019%26volume%3D16%26issue%3D3%26spage%3De1800518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed  El-Gokha</span>, <span class="hlFld-ContribAuthor ">Francesco  Ansideri</span>, <span class="hlFld-ContribAuthor ">Stanislav  Andreev</span>, <span class="hlFld-ContribAuthor ">Dieter  Schollmeyer</span>, <span class="hlFld-ContribAuthor ">Stefan  Laufer</span>, <span class="hlFld-ContribAuthor ">Pierre  Koch</span>. </span><span class="cited-content_cbyCitation_article-title">N1-{4-[2-(Methylthio)-1H-imidazol-5-yl]pyridin-2-yl}benzene-1,4-diamine. </span><span class="cited-content_cbyCitation_journal-name">Molbank</span><span> <strong>2019,</strong> <em>2019 </em>
                                    (1)
                                     , M1048. <a href="https://doi.org/10.3390/M1048" title="DOI URL">https://doi.org/10.3390/M1048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/M1048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2FM1048%26sid%3Dliteratum%253Aachs%26jtitle%3DMolbank%26atitle%3DN1-%25257B4-%25255B2-%252528Methylthio%252529-1H-imidazol-5-yl%25255Dpyridin-2-yl%25257Dbenzene-1%25252C4-diamine%26aulast%3DEl-Gokha%26aufirst%3DAhmed%26date%3D2019%26date%3D2019%26volume%3D2019%26issue%3D1%26spage%3DM1048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcel  Günther</span>, <span class="hlFld-ContribAuthor ">Julian  Laux</span>, <span class="hlFld-ContribAuthor ">Stefan  Laufer</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and structure‑activity‑relationship of 3,4‑Diaryl‑1H‑pyrrolo[2,3‑b]pyridines as irreversible Inhibitors of mutant EGFR‑L858R/T790M. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutical Sciences</span><span> <strong>2019,</strong> <em>128 </em>, 91-96. <a href="https://doi.org/10.1016/j.ejps.2018.11.021" title="DOI URL">https://doi.org/10.1016/j.ejps.2018.11.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejps.2018.11.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejps.2018.11.021%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DSynthesis%252Band%252Bstructure%2525E2%252580%252591activity%2525E2%252580%252591relationship%252Bof%252B3%25252C4%2525E2%252580%252591Diaryl%2525E2%252580%2525911H%2525E2%252580%252591pyrrolo%25255B2%25252C3%2525E2%252580%252591b%25255Dpyridines%252Bas%252Birreversible%252BInhibitors%252Bof%252Bmutant%252BEGFR%2525E2%252580%252591L858R%25252FT790M%26aulast%3DG%25C3%25BCnther%26aufirst%3DMarcel%26date%3D2019%26volume%3D128%26spage%3D91%26epage%3D96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vineeth  Sukrithan</span>, <span class="hlFld-ContribAuthor ">Lei  Deng</span>, <span class="hlFld-ContribAuthor ">Alexander  Barbaro</span>, <span class="hlFld-ContribAuthor ">Haiying  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging drugs for EGFR-mutated non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Emerging Drugs</span><span> <strong>2019,</strong> <em>24 </em>
                                    (1)
                                     , 5-16. <a href="https://doi.org/10.1080/14728214.2018.1558203" title="DOI URL">https://doi.org/10.1080/14728214.2018.1558203</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14728214.2018.1558203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14728214.2018.1558203%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Emerging%2520Drugs%26atitle%3DEmerging%252Bdrugs%252Bfor%252BEGFR-mutated%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DSukrithan%26aufirst%3DVineeth%26date%3D2019%26date%3D2018%26volume%3D24%26issue%3D1%26spage%3D5%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chee-Seng  Tan</span>, <span class="hlFld-ContribAuthor ">Nesaretnam Barr  Kumarakulasinghe</span>, <span class="hlFld-ContribAuthor ">Yi-Qing  Huang</span>, <span class="hlFld-ContribAuthor ">Yvonne Li En  Ang</span>, <span class="hlFld-ContribAuthor ">Joan Rou-En  Choo</span>, <span class="hlFld-ContribAuthor ">Boon-Cher  Goh</span>, <span class="hlFld-ContribAuthor ">Ross A.  Soo</span>. </span><span class="cited-content_cbyCitation_article-title">Third generation EGFR TKIs: current data and future directions. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2018,</strong> <em>17 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-018-0778-0" title="DOI URL">https://doi.org/10.1186/s12943-018-0778-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-018-0778-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-018-0778-0%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DThird%252Bgeneration%252BEGFR%252BTKIs%25253A%252Bcurrent%252Bdata%252Band%252Bfuture%252Bdirections%26aulast%3DTan%26aufirst%3DChee-Seng%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting EGFR
              L858R/T790M
              and EGFR
              L858R/T790M/C797S
              resistance mutations in NSCLC: Current developments in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (5)
                                     , 1550-1581. <a href="https://doi.org/10.1002/med.21488" title="DOI URL">https://doi.org/10.1002/med.21488</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21488%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTargeting%252BEGFR%252BL858R%25252FT790M%252Band%252BEGFR%252BL858R%25252FT790M%25252FC797S%252Bresistance%252Bmutations%252Bin%252BNSCLC%25253A%252BCurrent%252Bdevelopments%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D5%26spage%3D1550%26epage%3D1581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin  Wang</span>, <span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Xue-Yan  Yang</span>, <span class="hlFld-ContribAuthor ">Hao  Lei</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (12)
                                     , 3619-3633. <a href="https://doi.org/10.1016/j.bmc.2018.05.039" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.05.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.05.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.05.039%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Birreversible%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%252Bcontaining%252Bpyrido%25255B3%25252C4-d%25255Dpyrimidine%252Bscaffold%26aulast%3DZhang%26aufirst%3DHao%26date%3D2018%26volume%3D26%26issue%3D12%26spage%3D3619%26epage%3D3633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Apirat  Chaikuad</span>, <span class="hlFld-ContribAuthor ">Pierre  Koch</span>, <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>. </span><span class="cited-content_cbyCitation_article-title">Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2018,</strong> <em>130 </em>
                                    (16)
                                     , 4456-4470. <a href="https://doi.org/10.1002/ange.201707875" title="DOI URL">https://doi.org/10.1002/ange.201707875</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201707875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201707875%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DDas%252BCysteinom%252Bder%252BProteinkinasen%252Bals%252BZielstruktur%252Bin%252Bder%252BArzneistoffentwicklung%26aulast%3DChaikuad%26aufirst%3DApirat%26date%3D2018%26date%3D2018%26volume%3D130%26issue%3D16%26spage%3D4456%26epage%3D4470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Apirat  Chaikuad</span>, <span class="hlFld-ContribAuthor ">Pierre  Koch</span>, <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>, <span class="hlFld-ContribAuthor ">Stefan  Knapp</span>. </span><span class="cited-content_cbyCitation_article-title">The Cysteinome of Protein Kinases as a Target in Drug Development. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2018,</strong> <em>57 </em>
                                    (16)
                                     , 4372-4385. <a href="https://doi.org/10.1002/anie.201707875" title="DOI URL">https://doi.org/10.1002/anie.201707875</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201707875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201707875%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DThe%252BCysteinome%252Bof%252BProtein%252BKinases%252Bas%252Ba%252BTarget%252Bin%252BDrug%252BDevelopment%26aulast%3DChaikuad%26aufirst%3DApirat%26date%3D2018%26date%3D2018%26volume%3D57%26issue%3D16%26spage%3D4372%26epage%3D4385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joan Rou-En  Choo</span>, <span class="hlFld-ContribAuthor ">Chee-Seng  Tan</span>, <span class="hlFld-ContribAuthor ">Ross A.  Soo</span>. </span><span class="cited-content_cbyCitation_article-title">Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Targeted Oncology</span><span> <strong>2018,</strong> <em>13 </em>
                                    (2)
                                     , 141-156. <a href="https://doi.org/10.1007/s11523-018-0554-5" title="DOI URL">https://doi.org/10.1007/s11523-018-0554-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11523-018-0554-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11523-018-0554-5%26sid%3Dliteratum%253Aachs%26jtitle%3DTargeted%2520Oncology%26atitle%3DTreatment%252Bof%252BEGFR%252BT790M-Positive%252BNon-Small%252BCell%252BLung%252BCancer%26aulast%3DChoo%26aufirst%3DJoan%2BRou-En%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D2%26spage%3D141%26epage%3D156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Shen</span>, <span class="hlFld-ContribAuthor ">Hui-Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Wei-Ming  Duan</span>, <span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>148 </em>, 221-237. <a href="https://doi.org/10.1016/j.ejmech.2018.02.051" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.051%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2%25252C4%25252C6-trisubstitued%252Bpyrido%25255B3%25252C4-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bnew%252BEGFR-TKIs%26aulast%3DZhang%26aufirst%3DHao%26date%3D2018%26volume%3D148%26spage%3D221%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pierre  Koch</span>, <span class="hlFld-ContribAuthor ">Francesco  Ansideri</span>. </span><span class="cited-content_cbyCitation_article-title">2-Alkylsulfanyl-4(5)-aryl-5(4)-heteroarylimidazoles: An Overview on Synthetic Strategies and Biological Activity. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2017,</strong> <em>350 </em>
                                    (12)
                                     , 1700258. <a href="https://doi.org/10.1002/ardp.201700258" title="DOI URL">https://doi.org/10.1002/ardp.201700258</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201700258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201700258%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3D2-Alkylsulfanyl-4%2525285%252529-aryl-5%2525284%252529-heteroarylimidazoles%25253A%252BAn%252BOverview%252Bon%252BSynthetic%252BStrategies%252Band%252BBiological%252BActivity%26aulast%3DKoch%26aufirst%3DPierre%26date%3D2017%26date%3D2017%26volume%3D350%26issue%3D12%26spage%3D1700258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiuqin  Hu</span>, <span class="hlFld-ContribAuthor ">Disha  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Tong</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Xia  Wang</span>, <span class="hlFld-ContribAuthor ">Lili  Zhu</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Shiliang  Li</span>, <span class="hlFld-ContribAuthor ">You  Yang</span>, <span class="hlFld-ContribAuthor ">Yufang  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2017,</strong> <em>5 </em><a href="https://doi.org/10.3389/fchem.2017.00101" title="DOI URL">https://doi.org/10.3389/fchem.2017.00101</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2017.00101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2017.00101%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BEvaluation%252Bof%252BRibose-Modified%252BAnilinopyrimidine%252BDerivatives%252Bas%252BEGFR%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DHu%26aufirst%3DXiuqin%26date%3D2017%26date%3D2017%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0001.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. First-, second-, and third-generation EGFR inhibitors and their binding modes: (A) Two-dimensional binding mode of osimertinib found in the X-ray structure compared to pyridinylimidazoles based on our molecular model. HR, hydrophobic region; PB, phosphate binding site; PFG, pocket-filling group. (B) Difference between the dihedral angle of gefitinib and a vicinally substituted imidazole. (C) Generations of EGFR inhibitors occupying the ATP binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0002.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Proposed three-dimensional (left) and two-dimensional (right) binding modes of lead compound <b>1</b> in PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>. Hydrogen bond acceptors are depicted as red arrows and hydrogen bond donors as green arrows. Hydrophobic interactions are depicted as yellow spheres (3D model) or yellow brackets (2D model).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Trisubstituted Imidazoles (<b>1</b>–<b>13</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaHMDS, THF, 0 °C to rt, 65–79%. (ii) NaNO<sub>2</sub>, HOAc, 10 °C, 84–97%. (iii) Zn dust, HOAc, 10 °C, 78–85%. (iv) KSCN, DMF, reflux, 73–84%. (v) aniline, NMP, conc HCl<sub>aq</sub>, reflux, 63–88%. (vi) alkyl halide, K<sub>2</sub>CO<sub>3</sub>, THF, reflux, 48–79%. (vii) (<i>n</i> = 2), <i>N</i>-(2-bromoethyl)phthalimide, K<sub>2</sub>CO<sub>3</sub>, THF, reflux; (<i>n</i> = 3), <i>N</i>-(3-Iodopropyl)phthalimide, K<sub>2</sub>CO<sub>3</sub>, THF, reflux, 57–81%. (viii) Hydrazine hydrate, EtOH, 70 °C, 55–65%. (ix) Carboxylic acid, TBTU, DIPEA, THF, 27–63%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Trisubstituted Imidazoles with Cyclic Alkyl Linkers (<b>14</b>–<b>16</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) BH<sub>3</sub>*THF, THF, 0 °C 62–65%; (ii) PPh<sub>3</sub>, CBr<sub>4</sub>, rt, 65–71%; (iii) <b>36a</b>, K<sub>2</sub>CO<sub>3</sub>, THF, reflux, 76–80%; (iv) TFA, DCM, rt, 81–88%; (v) acrylic acid, TBTU, DIPEA, THF, 28–37%; (vi) Boc<sub>2</sub>O, neat, rt; DMAP, 90%; (vii) PPh<sub>3</sub>, CBr<sub>4</sub>,THF, 0 °C to rt, 62%; (viii) <b>36a</b>, K<sub>2</sub>CO<sub>3</sub>, THF, reflux, 84%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>17a</b>,<b>b</b> and <b>19a</b>–<b>30</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Br<sub>2</sub>, DCM or MeOH, rt, 64–95%; (ii) <i>S</i>-methylisothiourea hemisulfate salt, NaHCO<sub>3</sub>,THF/H<sub>2</sub>O, reflux, 15–65%; (iii) NaH, SEM-Cl, THF, −15 °C, quant; (iv) SEM-Cl (5 mol %), MeCN, 80 °C, 50–91%; (v) NBS, MeCN, −30 °C, 21–90%; (vi) corresponding boronic acid or acid ester, Pd(OAc)<sub>2</sub>/XPhos or Pd<sub>2</sub>(dba)<sub>3</sub>/(<i>t</i>-Bu)<sub>3</sub>P*HBF<sub>4</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane/H<sub>2</sub>O, reflux, 54–91%; (vii) 5 M NaOH<sub>aq</sub>, MeOH, 60 °C, 63–92% or NH<sub>2</sub>OH, DIPEA, ethanol, rt 53–63% or TFA, DCM, rt 88–99%; (viii) (hetero)aryl bromide, Brettphos Pd G1, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/<i>t</i>-BuOH, 130 °C, 61–91%; (ix) TFA, DCM, rt, 55–86%.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0008.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Br<sub>2</sub>, DCM, rt, 90%; (ii) urotropine, CHCl<sub>3</sub>, 50 °C, then conc HCl<sub>aq</sub>, EtOH, rt, 99% (over two steps); (iii) KSCN, AcOH, reflux, 50%; (iv) <i>N</i>-(2-bromoethyl)phthalimide, K<sub>2</sub>CO<sub>3</sub>, THF, reflux, 80%; (v) NaH, SEM-Cl, DMF, rt, 84%; (vi) N<sub>2</sub>H<sub>4</sub>*H<sub>2</sub>O, EtOH, 50 °C, 85%; (vii) propionic acid, TBTU, DIPEA, THF, rt, 91%; (viii) NBS, DMF, rt, 98%; (ix) 4-bromo-2-(2,5-dimethyl-1<i>H</i>-pyrrol-1-yl)pyridine, bis(pinacolato)diboron, KOAc, Pd(OAc)<sub>2</sub>, XPhos, K<sub>3</sub>PO<sub>4</sub>, 40%; (x) NH<sub>2</sub>OH*HCl, trimethylamine, EtOH/H<sub>2</sub>O, 45 °C, 37%; (xi) <i>N</i>-(3-bromophenyl)acrylamide, Cs<sub>2</sub>CO<sub>3</sub>, Brettphos Pd G1, 1,4-dioxane/<i>t</i>-BuOH, 51%; (xii) TFA, DCM, rt, 73%.</p></p></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0009.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>32</b>–<b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Cs<sub>2</sub>CO<sub>3</sub>, Brettphos Pd G1, 1,4-dioxane/<i>t</i>-BuOH, 78–92%; (ii) TFA, DCM, 50–93%.</p></p></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0010.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>31a</b> and <b>31b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) SeO<sub>2</sub>, 1,4-dioxane/H2O, reflux, 73%; (ii) NaH, TIPSCl, THF, 0 °C to rt, quant; (iii) C<sub>2</sub>O<sub>2</sub>Cl<sub>2</sub>, DMSO, DCM, −78 °C to rt, 62%; (iv) NH<sub>4</sub>OAc, MeOH, rt, 51%; (v) NaH, SEMCl, DMF, 0 °C to rt, 64%; (vi) NBS, MeCN, 0 °C to rt, 86%; (vii) <i>N</i>-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetamide, X-Phos/Pd(OAc)<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane/H<sub>2</sub>O, 60 °C, 75%; (viii) 5 N NaOH(aq), 1,4-dioxane/MeOH, 60 °C, 63%; (ix) substituted 3-bromoaniline, BrettPhos Pd G I, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/<i>t</i>-BuOH, 120 °C, 62% (acrylamide)/74% (propionyl chloride); (x) TFA,DCM, rt, 41% (acryloylamide)/ 56% (propionylamide).</p></p></figure><figure data-id="fig3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0003.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Different outcomes of modeling studies of <b>6a</b> using covalent docking (A) and induced-fit docking (B) (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>). Covalent docking indicates a bond formation with Cys797 and bidentate hinge binding, while induced-fit docking indicates an additional hydrogen bond to Asp855, preventing the Michael acceptor from covalent binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/medium/jm-2017-00316d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0004.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Left: Three-dimensional binding mode of <b>31a</b> in a docking study with EGFR T790M (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a>). Right: Pharmacophore model produced with the computer software ligandscout 4.11. Hydrogen bond acceptors are depicted as green arrows; hydrogen bond donors are depicted as red arrows. Hydrophobic interactions are depicted as yellow spheres.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-13/acs.jmedchem.7b00316/20170707/images/large/jm-2017-00316d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00316&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i137">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36853" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36853" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 35 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekar, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, A.</span><span> </span><span class="NLM_article-title">Epidermal growth-factor receptor-mediated cell motility - phospholipase-C activity is required, but mitogen-activated protein-kinase activity is not sufficient for induced cell-movement</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">847</span><span class="NLM_x">–</span> <span class="NLM_lpage">857</span><span class="refDoi"> DOI: 10.1083/jcb.127.3.847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1083%2Fjcb.127.3.847" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=1994&pages=847-857&author=P.+Chenauthor=H.+Xieauthor=M.+C.+Sekarauthor=K.+Guptaauthor=A.+Wells&title=Epidermal+growth-factor+receptor-mediated+cell+motility+-+phospholipase-C+activity+is+required%2C+but+mitogen-activated+protein-kinase+activity+is+not+sufficient+for+induced+cell-movement&doi=10.1083%2Fjcb.127.3.847"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1083%2Fjcb.127.3.847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.127.3.847%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DSekar%26aufirst%3DM.%2BC.%26aulast%3DGupta%26aufirst%3DK.%26aulast%3DWells%26aufirst%3DA.%26atitle%3DEpidermal%2520growth-factor%2520receptor-mediated%2520cell%2520motility%2520-%2520phospholipase-C%2520activity%2520is%2520required%252C%2520but%2520mitogen-activated%2520protein-kinase%2520activity%2520is%2520not%2520sufficient%2520for%2520induced%2520cell-movement%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1994%26volume%3D127%26spage%3D847%26epage%3D857%26doi%3D10.1083%2Fjcb.127.3.847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurubhagavatula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haserlat, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Supko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haluska, F. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Louis, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christiani, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2129</span><span class="NLM_x">–</span> <span class="NLM_lpage">2139</span><span class="refDoi"> DOI: 10.1056/NEJMoa040938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa040938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0lgK2nQLXI4lkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139%26doi%3D10.1056%2FNEJMoa040938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Gazdar, A. F.</span><span> </span><span class="NLM_article-title">Personalized medicine and inhibition of EGFR signaling in lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">1018</span><span class="NLM_x">–</span> <span class="NLM_lpage">1020</span><span class="refDoi"> DOI: 10.1056/NEJMe0905763</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1056%2FNEJMe0905763" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=19692681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVygtr7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2009&pages=1018-1020&author=A.+F.+Gazdar&title=Personalized+medicine+and+inhibition+of+EGFR+signaling+in+lung+cancer&doi=10.1056%2FNEJMe0905763"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Personalized medicine and inhibition of EGFR signaling in lung cancer</span></div><div class="casAuthors">Gazdar, Adi F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1018-1020</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruWSWxEJWr-7Vg90H21EOLACvtfcHk0lh_lkfk3RPP-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVygtr7I&md5=5cea925dd321f98fea2a4c3af197eaec</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMe0905763&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe0905763%26sid%3Dliteratum%253Aachs%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26atitle%3DPersonalized%2520medicine%2520and%2520inhibition%2520of%2520EGFR%2520signaling%2520in%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2009%26volume%3D361%26spage%3D1018%26epage%3D1020%26doi%3D10.1056%2FNEJMe0905763" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Kawahara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakashima, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashihara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kage, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitsudomi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, M.</span><span> </span><span class="NLM_article-title">Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3163</span><span class="NLM_x">–</span> <span class="NLM_lpage">3170</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-3239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1158%2F1078-0432.CCR-09-3239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=20423982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlKru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=3163-3170&author=A.+Kawaharaauthor=C.+Yamamotoauthor=K.+Nakashimaauthor=K.+Azumaauthor=S.+Hattoriauthor=M.+Kashiharaauthor=H.+Aizawaauthor=Y.+Basakiauthor=M.+Kuwanoauthor=M.+Kageauthor=T.+Mitsudomiauthor=M.+Ono&title=Molecular+diagnosis+of+activating+EGFR+mutations+in+non-small+cell+lung+cancer+using+mutation-specific+antibodies+for+immunohistochemical+analysis&doi=10.1158%2F1078-0432.CCR-09-3239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Diagnosis of Activating EGFR Mutations in Non-Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis</span></div><div class="casAuthors">Kawahara, Akihiko; Yamamoto, Chizuko; Nakashima, Kazutaka; Azuma, Koichi; Hattori, Satoshi; Kashihara, Masaki; Aizawa, Hisamichi; Basaki, Yuji; Kuwano, Michihiko; Kage, Masayoshi; Mitsudomi, Tetsuya; Ono, Mayumi</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3163-3170</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Therapeutic responses of non-small cell lung carcinoma (NSCLC) to epidermal growth factor receptor (EGFR)-targeted drugs, such as gefitinib and erlotinib, are closely assocd. with activating EGFR mutations.  The most common mutations are delE746-A750 in exon 19 and L858R in exon 21, accounting for ∼90% of all EGFR mutations.  Recently, EGFR mutation-specific antibodies were developed and did well in immunohistochem. anal., giving a sensitivity of ∼90%.  We have investigated whether this method detects activating EGFR mutations with sensitivity comparable with direct DNA sequencing, which is used to detect these mutations in NSCLC.  Exptl. Design: We used antibodies specific for the E746-A750 deletion mutation in exon 19 and the L858R point mutation in exon 21 in Western blot anal. and immunohistochem. to det. the presence of these mutations in NSCLC cell lines.  We also examd. these EGFR mutations in NSCLC tumor samples from 60 patients by immunohistochem. and direct DNA sequencing.  RESULTS: We were able to identify EGFR mutations in NSCLC tumor samples immunohistochem. with a sensitivity of 79% using the anti-delE746-A750 antibody and 83% using the anti-L858R antibody.  Addnl. DNA sequencing markedly improved the sensitivity obtained by immunohistochem.  CONCLUSIONS: This simple and rapid assay for detecting EGFR mutations, even in the small bronchial biopsies obtained in stage IV NSCLC patients, will be useful for diagnosing responsiveness to EGFR-targeted drugs in patients with NSCLC.  Combining this with DNA sequencing is recommended for the development of improved personalized EGFR-targeted therapeutics.  Clin Cancer Res; 16(12); 3163-70.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgLapDx4QziLVg90H21EOLACvtfcHk0lh_lkfk3RPP-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlKru7s%253D&md5=fae66f88f790009cbebf274d57247054</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-3239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-3239%26sid%3Dliteratum%253Aachs%26aulast%3DKawahara%26aufirst%3DA.%26aulast%3DYamamoto%26aufirst%3DC.%26aulast%3DNakashima%26aufirst%3DK.%26aulast%3DAzuma%26aufirst%3DK.%26aulast%3DHattori%26aufirst%3DS.%26aulast%3DKashihara%26aufirst%3DM.%26aulast%3DAizawa%26aufirst%3DH.%26aulast%3DBasaki%26aufirst%3DY.%26aulast%3DKuwano%26aufirst%3DM.%26aulast%3DKage%26aufirst%3DM.%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DOno%26aufirst%3DM.%26atitle%3DMolecular%2520diagnosis%2520of%2520activating%2520EGFR%2520mutations%2520in%2520non-small%2520cell%2520lung%2520cancer%2520using%2520mutation-specific%2520antibodies%2520for%2520immunohistochemical%2520analysis%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D3163%26epage%3D3170%26doi%3D10.1158%2F1078-0432.CCR-09-3239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarkaria, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusch, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fulton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mardis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupfer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">EGF receptor gene mutations are common in lung cancers from ″never smokers″ and are associated with sensitivity of tumors to gefitinib and erlotinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">101</span><span class="NLM_x">, </span> <span class="NLM_fpage">13306</span><span class="NLM_x">–</span> <span class="NLM_lpage">13311</span><span class="refDoi"> DOI: 10.1073/pnas.0405220101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1073%2Fpnas.0405220101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=15329413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFems70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+Millerauthor=M.+Zakowskiauthor=J.+Dohertyauthor=K.+Politiauthor=I.+Sarkariaauthor=B.+Singhauthor=R.+Heelanauthor=V.+Ruschauthor=L.+Fultonauthor=E.+Mardisauthor=D.+Kupferauthor=R.+Wilsonauthor=M.+Krisauthor=H.+Varmus&title=EGF+receptor+gene+mutations+are+common+in+lung+cancers+from+%E2%80%B3never+smokers%E2%80%B3+and+are+associated+with+sensitivity+of+tumors+to+gefitinib+and+erlotinib&doi=10.1073%2Fpnas.0405220101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib</span></div><div class="casAuthors">Pao, William; Miller, Vincent; Zakowski, Maureen; Doherty, Jennifer; Politi, Katerina; Sarkaria, Inderpal; Singh, Bhuvanesh; Heelan, Robert; Rusch, Valerie; Fulton, Lucinda; Mardis, Elaine; Kupfer, Doris; Wilson, Richard; Kris, Mark; Varmus, Harold</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">13306-13311</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly assocd. with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor.  In-frame deletions occur in exon 19, whereas point mutations occur frequently in codon 858 (exon 21).  We found from sequencing the EGFR TK domain that 7 of 10 gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib-refractory tumors (P = 0.004).  Five of seven tumors sensitive to erlotinib (Tarceva), a related kinase inhibitor for which the clin. relevant target is undocumented, had analogous somatic mutations, as opposed to none of 10 erlotinib-refractory tumors (P = 0.003).  Because most mutation-pos. tumors were adenocarcinomas from patients who smoked <100 cigarettes in a lifetime ("never smokers"), we screened EGFR exons 2-28 in 15 adenocarcinomas resected from untreated never smokers.  Seven tumors had TK domain mutations, in contrast to 4 of 81 non-small cell lung cancers resected from untreated former or current smokers (P = 0.0001).  Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concns. of drug.  Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently contg. mutations within the TK domain of EGFR that are assocd. with gefitinib and erlotinib sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovevWonTGqELVg90H21EOLACvtfcHk0lh_lkfk3RPP-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFems70%253D&md5=38f491968552501b7463a688fa0e62ff</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0405220101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0405220101%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DZakowski%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DKupfer%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DEGF%2520receptor%2520gene%2520mutations%2520are%2520common%2520in%2520lung%2520cancers%2520from%2520%25E2%2580%25B3never%2520smokers%25E2%2580%25B3%2520and%2520are%2520associated%2520with%2520sensitivity%2520of%2520tumors%2520to%2520gefitinib%2520and%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311%26doi%3D10.1073%2Fpnas.0405220101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Takeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span> </span><span class="NLM_article-title">Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib</span> <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">200</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span><span class="refDoi"> DOI: 10.1097/JTO.0000000000000053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1097%2FJTO.0000000000000053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=24419417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvVemtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=200-204&author=M.+Takedaauthor=I.+Okamotoauthor=K.+Nakagawa&title=Survival+outcome+assessed+according+to+tumor+response+and+shrinkage+pattern+in+patients+with+EGFR+mutation-positive+non-small-cell+lung+cancer+treated+with+gefitinib+or+erlotinib&doi=10.1097%2FJTO.0000000000000053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib</span></div><div class="casAuthors">Takeda, Masayuki; Okamoto, Isamu; Nakagawa, Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">200-204</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: Somatic mutations in the epidermal growth factor receptor gene (EGFR) are assocd. with a marked therapeutic response to EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC).  Clin. indicators of the likely survival benefit of EGFR-TKI treatment in NSCLC patients with EGFR mutations have not been identified, however.  We therefore evaluated progression-free survival (PFS) and overall survival (OS) according to tumor response and tumor shrinkage pattern in such patients.  Methods: Among 145 EGFR mutation-pos. NSCLC patients treated with EGFR-TKIs, 68 individuals were selected for anal.  Results: Of the 68 selected patients, 6 achieved a complete response (CR), 42 a partial response (PR), and 14 stable disease (SD).  Both PFS and OS were significantly longer in patients who achieved a CR or PR than in those who experienced SD.  Multivariate anal. showed that a response (CR or PR) to EGFR-TKIs was significantly assocd. with both PFS and OS.  Among the CR/PR group, the median maximal tumor shrinkage relative to baseline was 56%, and the median time to response (TTR) was 4.2 wk.  The subsets of these patients who experienced rapid tumor regression (TTR of ≤4.2 wk) or a high degree of tumor shrinkage (≥56%) did not show a more favorable PFS or OS compared with those who experienced slow tumor regression or a low degree of tumor shrinkage.  Conclusion: Response (CR or PR) may represent the optimal surrogate for efficacy among EGFR mutation-pos. NSCLC patients treated with EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhh9XFjf5TQrVg90H21EOLACvtfcHk0lgxBw-leg-xDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvVemtQ%253D%253D&md5=e10a852974cb7c80d6fdc1636a0e7df7</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1097%2FJTO.0000000000000053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0000000000000053%26sid%3Dliteratum%253Aachs%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3DSurvival%2520outcome%2520assessed%2520according%2520to%2520tumor%2520response%2520and%2520shrinkage%2520pattern%2520in%2520patients%2520with%2520EGFR%2520mutation-positive%2520non-small-cell%2520lung%2520cancer%2520treated%2520with%2520gefitinib%2520or%2520erlotinib%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2014%26volume%3D9%26spage%3D200%26epage%3D204%26doi%3D10.1097%2FJTO.0000000000000053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1056/NEJMoa044238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Janneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa044238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lgxBw-leg-xDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792%26doi%3D10.1056%2FNEJMoa044238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2eYnGs7WK85VcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekhtman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sima, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2240</span><span class="NLM_x">–</span> <span class="NLM_lpage">2247</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+tumor+specimens+at+the+time+of+acquired+resistance+to+EGFR-TKI+therapy+in+155+patients+with+EGFR-mutant+lung+cancers&doi=10.1158%2F1078-0432.CCR-12-2246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0ljXptByMyMNEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520tumor%2520specimens%2520at%2520the%2520time%2520of%2520acquired%2520resistance%2520to%2520EGFR-TKI%2520therapy%2520in%2520155%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2240%26epage%3D2247%26doi%3D10.1158%2F1078-0432.CCR-12-2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span><span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0ljXptByMyMNEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">–</span> <span class="NLM_lpage">7670</span><span class="refDoi"> DOI: 10.1073/pnas.0502860102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1073%2Fpnas.0502860102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=15897464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslOmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib&doi=10.1073%2Fpnas.0502860102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span></div><div class="casAuthors">Kwak, Eunice L.; Sordella, Raffaella; Bell, Daphne W.; Godin-Heymann, Nadia; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Driscoll, David R.; Fidias, Panos; Lynch, Thomas J.; Rabindran, Sridhar K.; McGinnis, John P.; Wissner, Allan; Sharma, Sreenath V.; Isselbacher, Kurt J.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7665-7670</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonsmall cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR) demonstrate dramatic, but transient, responses to the reversible tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva).  Some recurrent tumors have a common secondary mutation in the EGFR kinase domain, T790M, conferring drug resistance, but in other cases the mechanism underlying acquired resistance is unknown.  In studying multiple sites of recurrent NSCLCs, the authors detected T790M in only a small percentage of tumor cells.  To identify addnl. mechanisms of acquired resistance to gefitinib, the authors used NSCLC cells harboring an activating EGFR mutation to generate multiple resistant clones in vitro.  These drug-resistant cells demonstrate continued dependence on EGFR and ERBB2 signaling for their viability and have not acquired secondary EGFR mutations.  However, they display increased internalization of ligand-activated EGFR, consistent with altered receptor trafficking.  Although gefitinib-resistant clones are cross-resistant to related anilinoquinazolines, they demonstrate sensitivity to a class of irreversible inhibitors of EGFR.  These inhibitors also show effective inhibition of signaling by T790M-mutant EGFR and killing of NSCLC cells with the T790M mutation.  Both mechanisms of gefitinib resistance are therefore circumvented by irreversible tyrosine kinase inhibitors.  Our findings suggest that one of these, HKI-272, may prove highly effective in the treatment of EGFR-mutant NSCLCs, including tumors that have become resistant to gefitinib or erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW5BSM8yaZe7Vg90H21EOLACvtfcHk0liVvOYU4YGq4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslOmsr0%253D&md5=f3fb866c3673fd4dff8a3f0a8c9be65b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0502860102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0502860102%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670%26doi%3D10.1073%2Fpnas.0502860102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Kluter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grutter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raaijmakers, H. C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Otterlo, W. A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance</span> <span class="citation_source-journal">ChemBioChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2557</span><span class="NLM_x">–</span> <span class="NLM_lpage">2566</span><span class="refDoi"> DOI: 10.1002/cbic.201000352</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1002%2Fcbic.201000352" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=2557-2566&author=S.+Kluterauthor=J.+R.+Simardauthor=H.+B.+Rodeauthor=C.+Grutterauthor=V.+Pawarauthor=H.+C.+A.+Raaijmakersauthor=T.+A.+Barfauthor=M.+Rabillerauthor=W.+A.+L.+van+Otterloauthor=D.+Rauh&title=Characterization+of+irreversible+kinase+inhibitors+by+directly+detecting+covalent+bond+formation%3A+a+tool+for+dissecting+kinase+drug+resistance&doi=10.1002%2Fcbic.201000352"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201000352&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201000352%26sid%3Dliteratum%253Aachs%26aulast%3DKluter%26aufirst%3DS.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DPawar%26aufirst%3DV.%26aulast%3DRaaijmakers%26aufirst%3DH.%2BC.%2BA.%26aulast%3DBarf%26aufirst%3DT.%2BA.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3Dvan%2BOtterlo%26aufirst%3DW.%2BA.%2BL.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DCharacterization%2520of%2520irreversible%2520kinase%2520inhibitors%2520by%2520directly%2520detecting%2520covalent%2520bond%2520formation%253A%2520a%2520tool%2520for%2520dissecting%2520kinase%2520drug%2520resistance%26jtitle%3DChemBioChem%26date%3D2010%26volume%3D11%26spage%3D2557%26epage%3D2566%26doi%3D10.1002%2Fcbic.201000352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Katakami, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atagi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goto, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hida, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horai, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koboyashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebisawa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span> </span><span class="NLM_article-title">LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">3335</span><span class="NLM_x">–</span> <span class="NLM_lpage">3341</span><span class="refDoi"> DOI: 10.1200/JCO.2012.45.0981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1200%2FJCO.2012.45.0981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=23816963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KrsrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3335-3341&author=N.+Katakamiauthor=S.+Atagiauthor=K.+Gotoauthor=T.+Hidaauthor=T.+Horaiauthor=A.+Inoueauthor=Y.+Ichinoseauthor=K.+Koboyashiauthor=K.+Takedaauthor=K.+Kiuraauthor=K.+Nishioauthor=Y.+Sekiauthor=R.+Ebisawaauthor=M.+Shahidiauthor=N.+Yamamoto&title=LUX-Lung+4%3A+a+phase+II+trial+of+afatinib+in+patients+with+advanced+non-small-cell+lung+cancer+who+progressed+during+prior+treatment+with+erlotinib%2C+gefitinib%2C+or+both&doi=10.1200%2FJCO.2012.45.0981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">LUX-lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both</span></div><div class="casAuthors">Katakami, Noboyuki; Atagi, Shinji; Goto, Koichi; Hida, Toyoaki; Horai, Takeshi; Inoue, Akira; Ichinose, Yukito; Koboyashi, Kunihiko; Takeda, Koji; Kiura, Katsuyuki; Nishio, Kazuto; Seki, Yoko; Ebisawa, Ryuichi; Shahidi, Mehdi; Yamamoto, Nobuyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3335-3341</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose New mol. targeted agents are needed for patients with non-small-cell lung cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both.  Afatinib, an oral irreversible ErbB family blocker, has preclin. activity in epidermal growth factor receptor (EGFR [ErbB1]) mutant models with EGFR-activating mutations, including T790M.  Patients and Methods This was a Japanese single-arm phase II trial conducted in patients with stage IIIB to IV pulmonary adenocarcinoma who progressed after ≥ 12 wk of prior erlotinib and/or gefitinib.  Patients received afatinib 50 mg per day.  The primary end point was objective response rate (complete response or partial response) by independent review.  Secondary end points included progression-free survival (PFS), overall survival (OS), and safety.  Results Of 62 treated patients, 45 (72.6%) were EGFR mutation pos. in their primary tumor according to local and/or central lab. analyses.  Fifty-one patients (82.3%) fulfilled the criteria of acquired resistance to erlotinib and/or gefitinib.  Of 61 evaluable patients, five (8.2%; 95% CI, 2.7% to 18.1 %) had a confirmed objective response rate (partial response).  Median PFS was 4.4 mo (95% CI, 2.8 to 4.6 mo), and median OS was 19.0 mo (95% CI, 14.9 mo to not achieved).  Two patients had acquired T790M mutations: L858R + T790M, and deletion in exon 19 + T790M; they had stable disease for 9 mo and 1 mo, resp.  The most common afatinib-related adverse events (AEs) were diarrhea (100%) and rash/acne (91.9%).  Treatment-related AEs leading to afatinib discontinuation were experienced by 18 patients (29%), of whom four also had progressive disease.  Conclusion Afatinib demonstrated modest but noteworthy efficacy in patients with NSCLC who had received third- or fourth-line treatment and who progressed while receiving erlotinib and/or gefitinib, including those with acquired resistance to erlotinib, gefitinib, or both.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM0F6fZnWKTbVg90H21EOLACvtfcHk0liVvOYU4YGq4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KrsrzK&md5=1666aeb642dbc953dd9bcc818bab9098</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.45.0981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.45.0981%26sid%3Dliteratum%253Aachs%26aulast%3DKatakami%26aufirst%3DN.%26aulast%3DAtagi%26aufirst%3DS.%26aulast%3DGoto%26aufirst%3DK.%26aulast%3DHida%26aufirst%3DT.%26aulast%3DHorai%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DIchinose%26aufirst%3DY.%26aulast%3DKoboyashi%26aufirst%3DK.%26aulast%3DTakeda%26aufirst%3DK.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DNishio%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DY.%26aulast%3DEbisawa%26aufirst%3DR.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DN.%26atitle%3DLUX-Lung%25204%253A%2520a%2520phase%2520II%2520trial%2520of%2520afatinib%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%2520who%2520progressed%2520during%2520prior%2520treatment%2520with%2520erlotinib%252C%2520gefitinib%252C%2520or%2520both%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D3335%26epage%3D3341%26doi%3D10.1200%2FJCO.2012.45.0981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadranel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cong, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorence, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C. H.</span><span> </span><span class="NLM_article-title">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">528</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span><span class="refDoi"> DOI: 10.1016/S1470-2045(12)70087-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1016%2FS1470-2045%2812%2970087-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=22452896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=528-538&author=V.+A.+Millerauthor=V.+Hirshauthor=J.+Cadranelauthor=Y.+M.+Chenauthor=K.+Parkauthor=S.+W.+Kimauthor=C.+C.+Zhouauthor=W.+C.+Suauthor=M.+Z.+Wangauthor=Y.+Sunauthor=D.+S.+Heoauthor=L.+Crinoauthor=E.+H.+Tanauthor=T.+Y.+Chaoauthor=M.+Shahidiauthor=X.+J.+Congauthor=R.+M.+Lorenceauthor=J.+C.+H.+Yang&title=Afatinib+versus+placebo+for+patients+with+advanced%2C+metastatic+non-small-cell+lung+cancer+after+failure+of+erlotinib%2C+gefitinib%2C+or+both%2C+and+one+or+two+lines+of+chemotherapy+%28LUX-Lung+1%29%3A+a+phase+2b%2F3+randomised+trial&doi=10.1016%2FS1470-2045%2812%2970087-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span></div><div class="casAuthors">Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-538</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Afatinib, an irreversible ErbB-family blocker, has shown preclin. activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors.  We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.  Methods: In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncol. Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 wk of treatment with erlotinib or gefitinib.  We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care.  Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2).  Investigators, patients, and the trial sponsor were masked to treatment assignment.  The primary endpoint was overall survival (from date of randomisation to death), analyzed on an intention-to-treat basis.  This study is registered with ClinicalTrials.gov, no. NCT00656136.  Findings: Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo).  Median overall survival was 10·8 mo (95% CI 10·0-12·0) in the afatinib group and 12·0 mo (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74).  Median progression-free survival was longer in the afatinib group (3·3 mo, 95% CI 2·79-4·40) than it was in the placebo group (1·1 mo, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001).  No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group.  Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group.  The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3).  These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2.  Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group.  We recorded two possibly treatment-related deaths in the afatinib group.  Interpretation: Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 wk of previous EGFR tyrosine-kinase inhibitor treatment.  Funding: Boehringer Ingelheim Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrR4FNSnKJbVg90H21EOLACvtfcHk0lgKnsTtbgGuug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D&md5=6ddd7f552e8ab1ebb43fb699e27894f5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970087-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970087-6%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%2BM.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DZhou%26aufirst%3DC.%2BC.%26aulast%3DSu%26aufirst%3DW.%2BC.%26aulast%3DWang%26aufirst%3DM.%2BZ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DChao%26aufirst%3DT.%2BY.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DCong%26aufirst%3DX.%2BJ.%26aulast%3DLorence%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%2BH.%26atitle%3DAfatinib%2520versus%2520placebo%2520for%2520patients%2520with%2520advanced%252C%2520metastatic%2520non-small-cell%2520lung%2520cancer%2520after%2520failure%2520of%2520erlotinib%252C%2520gefitinib%252C%2520or%2520both%252C%2520and%2520one%2520or%2520two%2520lines%2520of%2520chemotherapy%2520%2528LUX-Lung%25201%2529%253A%2520a%2520phase%25202b%252F3%2520randomised%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D528%26epage%3D538%26doi%3D10.1016%2FS1470-2045%2812%2970087-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+E.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+L.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.+W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lgKnsTtbgGuug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%2BL.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Zhou, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+J.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+N.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lgKnsTtbgGuug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%2BJ.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%2BN.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Hope and disappointment: covalent inhibitors to overcome drug resistance in non-small cell lung cancer</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00475</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00475" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2-5&author=J.+Engelauthor=J.+Lategahnauthor=D.+Rauh&title=Hope+and+disappointment%3A+covalent+inhibitors+to+overcome+drug+resistance+in+non-small+cell+lung+cancer&doi=10.1021%2Facsmedchemlett.5b00475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Engel, Julian; Lategahn, Jonas; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-5</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the development of a third-generation of covalent EGFR inhibitors with excellent clin. outcomes.  However, the emergence of a newly discovered acquired drug resistance challenges the concept of small mol. targeted cancer therapy in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcxNkfyBm4vrVg90H21EOLACvtfcHk0ljxaawq0SB_EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D&md5=738e3286dd1b1d4110249e33cceec9ac</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00475%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHope%2520and%2520disappointment%253A%2520covalent%2520inhibitors%2520to%2520overcome%2520drug%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D2%26epage%3D5%26doi%3D10.1021%2Facsmedchemlett.5b00475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Thress, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paweletz, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felip, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stetson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dougherty, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markovets, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vivancos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxnard, G. R.</span><span> </span><span class="NLM_article-title">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">560</span><span class="NLM_x">–</span> <span class="NLM_lpage">562</span><span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+Janneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+mutation+mediates+resistance+to+AZD9291+in+non-small+cell+lung+cancer+harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0ljxaawq0SB_EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520AZD9291%2520in%2520non-small%2520cell%2520lung%2520cancer%2520harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Gunther, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juchum, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiebig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">Lung cancer: EGFR inhibitors with low nanomolar activity against a therapy-resistant L858R/T790M/C797S mutant</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10890</span><span class="NLM_x">–</span> <span class="NLM_lpage">10894</span><span class="refDoi"> DOI: 10.1002/anie.201603736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1002%2Fanie.201603736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A280%3ADC%252BC2s3ltFeqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10890-10894&author=M.+Guntherauthor=M.+Juchumauthor=G.+Kelterauthor=H.+Fiebigauthor=S.+Laufer&title=Lung+cancer%3A+EGFR+inhibitors+with+low+nanomolar+activity+against+a+therapy-resistant+L858R%2FT790M%2FC797S+mutant&doi=10.1002%2Fanie.201603736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant</span></div><div class="casAuthors">Gunther Marcel; Juchum Michael; Laufer Stefan; Kelter Gerhard; Fiebig Heiner</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10890-4</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The treatment of non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) inhibitors is made challenging by acquired resistance caused by somatic mutations.  Third-generation EGFR inhibitors have been designed to overcome resistance through covalent binding to the Cys 797 residue of the enzyme, and these inhibitors are effective against most clinically relevant EGFR mutants.  However, the high dependence of these recent EGFR inhibitors on this particular interaction means that additional mutation of Cys 797 results in poor inhibitory activity, which leads to tumor relapse in initially responding patients.  A new generation of irreversible and reversible mutant EGFR inhibitors was developed with strong noncovalent binding properties, and these compounds show high inhibitory activities against the cysteine-mutated L858R/T790M/C797S EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRlYaGbpc39GpZoeNcnHOQ9fW6udTcc2ebZOCGby5hAdLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s3ltFeqsA%253D%253D&md5=fb87e3c6d0c334f1811894d0341d0679</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fanie.201603736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201603736%26sid%3Dliteratum%253Aachs%26aulast%3DGunther%26aufirst%3DM.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DKelter%26aufirst%3DG.%26aulast%3DFiebig%26aufirst%3DH.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DLung%2520cancer%253A%2520EGFR%2520inhibitors%2520with%2520low%2520nanomolar%2520activity%2520against%2520a%2520therapy-resistant%2520L858R%252FT790M%252FC797S%2520mutant%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10890%26epage%3D10894%26doi%3D10.1002%2Fanie.201603736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kollipara, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahedi, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Insight into the inhibition of drug-resistant mutants of the receptor tyrosine kinase EGFR</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10909</span><span class="NLM_x">–</span> <span class="NLM_lpage">10912</span><span class="refDoi"> DOI: 10.1002/anie.201605011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1002%2Fanie.201605011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=27496389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=10909-10912&author=J.+Engelauthor=C.+Beckerauthor=J.+Lategahnauthor=M.+Keulauthor=J.+Ketzerauthor=T.+Muhlenbergauthor=L.+Kolliparaauthor=C.+Schultz-Fademrechtauthor=R.+P.+Zahediauthor=S.+Bauerauthor=D.+Rauh&title=Insight+into+the+inhibition+of+drug-resistant+mutants+of+the+receptor+tyrosine+kinase+EGFR&doi=10.1002%2Fanie.201605011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR</span></div><div class="casAuthors">Engel, Julian; Becker, Christian; Lategahn, Jonas; Keul, Marina; Ketzer, Julia; Muehlenberg, Thomas; Kollipara, Laxmikanth; Schultz-Fademrecht, Carsten; Zahedi, Rene P.; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">10909-10912</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Targeting acquired drug resistance represents the major challenge in the treatment of EGFR-driven nonsmall-cell lung cancer (NSCLC).  Herein, the authors describe the structure-based design, synthesis, and biol. evaluation of a novel class of covalent EGFR inhibitors that exhibit excellent inhibition of EGFR-mutant drug-resistant cells.  Protein x-ray crystallog. combined with detailed kinetic studies led to a deeper understanding of the mode of inhibition of EGFR-T790M and provided insight into the key principles for effective inhibition of the recently discovered tertiary mutation at EGFR-C797S.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBqcuaKxIuCbVg90H21EOLACvtfcHk0lge9IJvSbRECA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlSmt7jJ&md5=d16c5339a6f2b9ca018c56f6b3f0b8e8</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fanie.201605011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201605011%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DMuhlenberg%26aufirst%3DT.%26aulast%3DKollipara%26aufirst%3DL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DInsight%2520into%2520the%2520inhibition%2520of%2520drug-resistant%2520mutants%2520of%2520the%2520receptor%2520tyrosine%2520kinase%2520EGFR%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D10909%26epage%3D10912%26doi%3D10.1002%2Fanie.201605011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Laufer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotschenreuther, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, W.</span><span> </span><span class="NLM_article-title">Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3230</span><span class="NLM_x">–</span> <span class="NLM_lpage">3244</span><span class="refDoi"> DOI: 10.1021/jm030766k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030766k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=3230-3244&author=S.+A.+Lauferauthor=G.+K.+Wagnerauthor=D.+A.+Kotschenreutherauthor=W.+Albrecht&title=Novel+substituted+pyridinyl+imidazoles+as+potent+anticytokine+agents+with+low+activity+against+hepatic+cytochrome+P450+enzymes&doi=10.1021%2Fjm030766k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm030766k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030766k%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DWagner%26aufirst%3DG.%2BK.%26aulast%3DKotschenreuther%26aufirst%3DD.%2BA.%26aulast%3DAlbrecht%26aufirst%3DW.%26atitle%3DNovel%2520substituted%2520pyridinyl%2520imidazoles%2520as%2520potent%2520anticytokine%2520agents%2520with%2520low%2520activity%2520against%2520hepatic%2520cytochrome%2520P450%2520enzymes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D3230%26epage%3D3244%26doi%3D10.1021%2Fjm030766k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Koch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauerlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jank, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">Targeting the ribose and phosphate binding site of p38 mitogen-activated protein (MAP) kinase: synthesis and biological testing of 2-alkylsulfanyl-, 4(5)-aryl-, 5(4)-heteroaryl-substituted imidazoles</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5630</span><span class="NLM_x">–</span> <span class="NLM_lpage">5640</span><span class="refDoi"> DOI: 10.1021/jm800373t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800373t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVymtbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5630-5640&author=P.+Kochauthor=C.+Bauerleinauthor=H.+Jankauthor=S.+Laufer&title=Targeting+the+ribose+and+phosphate+binding+site+of+p38+mitogen-activated+protein+%28MAP%29+kinase%3A+synthesis+and+biological+testing+of+2-alkylsulfanyl-%2C+4%285%29-aryl-%2C+5%284%29-heteroaryl-substituted+imidazoles&doi=10.1021%2Fjm800373t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Ribose and Phosphate Binding Site of p38 Mitogen-Activated Protein (MAP) Kinase: Synthesis and Biological Testing of 2-Alkylsulfanyl-, 4(5)-Aryl-, 5(4)-Heteroaryl-Substituted Imidazoles</span></div><div class="casAuthors">Koch, Pierre; Baeuerlein, Christiane; Jank, Hartmut; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5630-5640</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three series of substituted 2-alkylsulfanyl-4-(4-fluorophenyl)imidazoles, 5-pyridinyl-, 1-methyl-5-pyridinyl-, and 5-(2-aminopyridin-4-yl)-imidazoles, were prepd. and tested for their ability to inhibit p38 MAP kinase and TNF-α release.  These compds. were tested by applying a nonradioactive p38 MAP kinase assay and by measurement of TNF-α release in human whole blood.  Potent inhibitors (IC50values in the low nanomolar range, as low as 2 nM in the enzyme assay and 37 nM in the human whole blood test) were identified by variation of substituents at the imidazole-C2-thio position as well as at the 2-aminopyridinyl functionality.  In contrast to other known kinase inhibitors, these novel imidazole derivs. with the substituents at the imidazole-C2-thio position may interact with the ribose as well as with the phosphate binding site of the p38 MAP kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodYYCjSY3UNbVg90H21EOLACvtfcHk0lge9IJvSbRECA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVymtbrK&md5=508c3e699dd65ee83a6592f2e719d17a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm800373t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800373t%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DBauerlein%26aufirst%3DC.%26aulast%3DJank%26aufirst%3DH.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTargeting%2520the%2520ribose%2520and%2520phosphate%2520binding%2520site%2520of%2520p38%2520mitogen-activated%2520protein%2520%2528MAP%2529%2520kinase%253A%2520synthesis%2520and%2520biological%2520testing%2520of%25202-alkylsulfanyl-%252C%25204%25285%2529-aryl-%252C%25205%25284%2529-heteroaryl-substituted%2520imidazoles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5630%26epage%3D5640%26doi%3D10.1021%2Fjm800373t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomassi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Termathe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer-Wrangowski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruetter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhlenbrock, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaumann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eppmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kibies, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffgaard, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heil, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menninger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz-Cuaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tinnefeld, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahedi, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kast, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Targeting drug resistance in EGFR with covalent inhibitors: a structure-based design approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">6844</span><span class="NLM_x">–</span> <span class="NLM_lpage">6863</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01082</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01082" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsrvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6844-6863&author=J.+Engelauthor=A.+Richtersauthor=M.+Getlikauthor=S.+Tomassiauthor=M.+Keulauthor=M.+Termatheauthor=J.+Lategahnauthor=C.+Beckerauthor=S.+Mayer-Wrangowskiauthor=C.+Gruetterauthor=N.+Uhlenbrockauthor=J.+Kruellauthor=N.+Schaumannauthor=S.+Eppmannauthor=P.+Kibiesauthor=F.+Hoffgaardauthor=J.+Heilauthor=S.+Menningerauthor=S.+Ortiz-Cuaranauthor=J.+M.+Heuckmannauthor=V.+Tinnefeldauthor=R.+P.+Zahediauthor=M.+L.+Sosauthor=C.+Schultz-Fademrechtauthor=R.+K.+Thomasauthor=S.+M.+Kastauthor=D.+Rauh&title=Targeting+drug+resistance+in+EGFR+with+covalent+inhibitors%3A+a+structure-based+design+approach&doi=10.1021%2Facs.jmedchem.5b01082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach</span></div><div class="casAuthors">Engel, Julian; Richters, Andre; Getlik, Matthaeus; Tomassi, Stefano; Keul, Marina; Termathe, Martin; Lategahn, Jonas; Becker, Christian; Mayer-Wrangowski, Svenja; Gruetter, Christian; Uhlenbrock, Niklas; Kruell, Jasmin; Schaumann, Niklas; Eppmann, Simone; Kibies, Patrick; Hoffgaard, Franziska; Heil, Jochen; Menninger, Sascha; Ortiz-Cuaran, Sandra; Heuckmann, Johannes M.; Tinnefeld, Verena; Zahedi, Rene P.; Sos, Martin L.; Schultz-Fademrecht, Carsten; Thomas, Roman K.; Kast, Stefan M.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6844-6863</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases represent one of the prime targets in cancer therapy, as the dysregulation of these elementary transducers of extracellular signals, like the epidermal growth factor receptor (EGFR), contributes to the onset of cancer, such as non-small cell lung cancer (NSCLC).  Strong efforts were directed to the development of irreversible inhibitors and led to compd. CO-1686, which takes advantage of increased residence time at EGFR by alkylating Cys797 and thereby preventing toxic effects.  Here, the authors present a structure-based approach, rationalized by subsequent computational anal. of conformational ligand ensembles in soln., to design novel and irreversible EGFR inhibitors based on a screening hit that was identified in a phenotype screen of 80 NSCLC cell lines against approx. 1500 compds.  Using protein x-ray crystallog., the authors deciphered the binding mode in engineered cSrc (T338M/S345C), a validated model system for EGFR-T790M, which constituted the basis for further rational design approaches.  Chem. synthesis led to further compd. collections that revealed increased biochem. potency and, in part, selectivity toward mutated (L858R and L858R/T790M) vs. nonmutated EGFR.  Further cell-based and kinetic studies were performed to substantiate the authors initial findings.  Utilizing proteolytic digestion and nano-LC-MS/MS anal., the authors confirmed the alkylation of Cys797.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNGJPIuqoVObVg90H21EOLACvtfcHk0lj2of0JGyyKrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsrvM&md5=d5264a2a99d7752af0e587f23aeb7723</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01082%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DTomassi%26aufirst%3DS.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DTermathe%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DGruetter%26aufirst%3DC.%26aulast%3DUhlenbrock%26aufirst%3DN.%26aulast%3DKruell%26aufirst%3DJ.%26aulast%3DSchaumann%26aufirst%3DN.%26aulast%3DEppmann%26aufirst%3DS.%26aulast%3DKibies%26aufirst%3DP.%26aulast%3DHoffgaard%26aufirst%3DF.%26aulast%3DHeil%26aufirst%3DJ.%26aulast%3DMenninger%26aufirst%3DS.%26aulast%3DOrtiz-Cuaran%26aufirst%3DS.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DTinnefeld%26aufirst%3DV.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DKast%26aufirst%3DS.%2BM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DTargeting%2520drug%2520resistance%2520in%2520EGFR%2520with%2520covalent%2520inhibitors%253A%2520a%2520structure-based%2520design%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6844%26epage%3D6863%26doi%3D10.1021%2Facs.jmedchem.5b01082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Tomassi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumbrink, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ketzer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhlenberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Indazole-based covalent inhibitors to target drug-resistant epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2361</span><span class="NLM_x">–</span> <span class="NLM_lpage">2372</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01626</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01626" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjt1WltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=2361-2372&author=S.+Tomassiauthor=J.+Lategahnauthor=J.+Engelauthor=M.+Keulauthor=H.+L.+Tumbrinkauthor=J.+Ketzerauthor=T.+Muhlenbergauthor=M.+Baumannauthor=C.+Schultz-Fademrechtauthor=S.+Bauerauthor=D.+Rauh&title=Indazole-based+covalent+inhibitors+to+target+drug-resistant+epidermal+growth+factor+receptor&doi=10.1021%2Facs.jmedchem.6b01626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor</span></div><div class="casAuthors">Tomassi, Stefano; Lategahn, Jonas; Engel, Julian; Keul, Marina; Tumbrink, Hannah L.; Ketzer, Julia; Muehlenberg, Thomas; Baumann, Matthias; Schultz-Fademrecht, Carsten; Bauer, Sebastian; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2361-2372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The specific targeting of oncogenic mutant epidermal growth factor receptor (EGFR) is a breakthrough in targeted cancer therapy and marks a drastic change in the treatment of non-small cell lung cancer (NSCLC).  The recurrent emergence of resistance to these targeted drugs requires the development of novel chem. entities that efficiently inhibit drug-resistant EGFR.  Herein, the authors report the optimization process for a hit compd. that has emerged from a phenotypic screen resulting in indazole-based compds.  These inhibitors are conformationally less flexible, target gatekeeper mutated drug resistant EGFR-L858R/T790M and covalently alkylate Cys 797.  Western blot anal., as well as characterization of the binding kinetics and kinase selectivity profiling, substantiates the authors' approach of targeting drug-resistant EGFR-L858R/T790M with inhibitors incorporating the indazole as hinge binder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwwmG17YkaV7Vg90H21EOLACvtfcHk0lj2of0JGyyKrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjt1WltL0%253D&md5=25e24252dc5a03ec5349359289ebd808</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01626%26sid%3Dliteratum%253Aachs%26aulast%3DTomassi%26aufirst%3DS.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DMuhlenberg%26aufirst%3DT.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DIndazole-based%2520covalent%2520inhibitors%2520to%2520target%2520drug-resistant%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D2361%26epage%3D2372%26doi%3D10.1021%2Facs.jmedchem.6b01626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Laufer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Striegel, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, G. K.</span><span> </span><span class="NLM_article-title">Imidazole inhibitors of cytokine release: probing substituents in the 2 position</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4695</span><span class="NLM_x">–</span> <span class="NLM_lpage">4705</span><span class="refDoi"> DOI: 10.1021/jm020873z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020873z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=4695-4705&author=S.+A.+Lauferauthor=H.+G.+Striegelauthor=G.+K.+Wagner&title=Imidazole+inhibitors+of+cytokine+release%3A+probing+substituents+in+the+2+position&doi=10.1021%2Fjm020873z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm020873z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020873z%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DStriegel%26aufirst%3DH.%2BG.%26aulast%3DWagner%26aufirst%3DG.%2BK.%26atitle%3DImidazole%2520inhibitors%2520of%2520cytokine%2520release%253A%2520probing%2520substituents%2520in%2520the%25202%2520position%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D4695%26epage%3D4705%26doi%3D10.1021%2Fjm020873z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Koch, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">4-Aryl-5-heteroaryl-2-thio-imidazoles: warhead for a macrocycle-based drug targeting</span> <span class="citation_source-journal">Inflammation Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">446</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2007&pages=446&author=P.+Kochauthor=S.+Laufer&title=4-Aryl-5-heteroaryl-2-thio-imidazoles%3A+warhead+for+a+macrocycle-based+drug+targeting"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoch%26aufirst%3DP.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3D4-Aryl-5-heteroaryl-2-thio-imidazoles%253A%2520warhead%2520for%2520a%2520macrocycle-based%2520drug%2520targeting%26jtitle%3DInflammation%2520Res.%26date%3D2007%26volume%3D56%26spage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Guzzo, P.; Surman, M. D.; Henderson, A. J.; Hadden, M.; Jiang, M. X.</span><span> </span><span class="NLM_article-title">Preparation of 5-pyridinone substituted indazoles as modulators of melanin-concentrating hormone (MCH1) receptor</span>. PCT Int. Appl. 2008086404 A1,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=P.+Guzzo&author=M.+D.+Surman&author=A.+J.+Henderson&author=M.+Hadden&author=M.+X.+Jiang&title=Preparation+of+5-pyridinone+substituted+indazoles+as+modulators+of+melanin-concentrating+hormone+%28MCH1%29+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGuzzo%26aufirst%3DP.%26atitle%3DPreparation%2520of%25205-pyridinone%2520substituted%2520indazoles%2520as%2520modulators%2520of%2520melanin-concentrating%2520hormone%2520%2528MCH1%2529%2520receptor%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Busch-Petersen, J.</span><span> </span><span class="NLM_article-title">Preparation of <i>N</i>-sulfonylphenyl-<i>N</i>′-(hetero)arylureas as antagonists of chemokines, in particular interleukin 8 (IL-8)</span>. U.S. Pat. Appl. 20070249672 A1,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=J.+Busch-Petersen&title=Preparation+of+N-sulfonylphenyl-N%E2%80%B2-%28hetero%29arylureas+as+antagonists+of+chemokines%2C+in+particular+interleukin+8+%28IL-8%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26atitle%3DPreparation%2520of%2520N-sulfonylphenyl-N%25E2%2580%25B2-%2528hetero%2529arylureas%2520as%2520antagonists%2520of%2520chemokines%252C%2520in%2520particular%2520interleukin%25208%2520%2528IL-8%2529%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Joo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toure, B. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sames, D.</span><span> </span><span class="NLM_article-title">C-H bonds as ubiquitous functionality: a general approach to complex arylated imidazoles via regioselective sequential arylation of all three C-H bonds and regioselective N-alkylation enabled by SEM-group transposition</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">4911</span><span class="NLM_x">–</span> <span class="NLM_lpage">4920</span><span class="refDoi"> DOI: 10.1021/jo100727j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo100727j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosFaksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2010&pages=4911-4920&author=J.+M.+Jooauthor=B.+B.+Toureauthor=D.+Sames&title=C-H+bonds+as+ubiquitous+functionality%3A+a+general+approach+to+complex+arylated+imidazoles+via+regioselective+sequential+arylation+of+all+three+C-H+bonds+and+regioselective+N-alkylation+enabled+by+SEM-group+transposition&doi=10.1021%2Fjo100727j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">C-H Bonds as Ubiquitous Functionality: A General Approach to Complex Arylated Imidazoles via Regioselective Sequential Arylation of All Three C-H Bonds and Regioselective N-Alkylation Enabled by SEM-Group Transposition</span></div><div class="casAuthors">Joo, Jung Min; Toure, B. Barry; Sames, Dalibor</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4911-4920</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Imidazoles are an important group of the azole family of heterocycles frequently found in pharmaceuticals, drug candidates, ligands for transition metal catalysts, and other mol. functional materials.  Owing to their wide application in academia and industry, new methods and strategies for the generation of functionalized imidazole derivs. are in demand.  We here describe a general and comprehensive approach for the synthesis of complex aryl imidazoles, e.g. I, where all three C-H bonds of the imidazole core can be arylated in a regioselective and sequential manner.  We report new catalytic methods for selective C5- and C2-arylation of SEM-imidazoles and provide a mechanistic hypothesis for the obsd. positional selectivity based on electronic properties of C-H bonds and the heterocyclic ring.  Importantly, aryl bromides and low-cost aryl chlorides can be used as arene donors under practical lab. conditions.  To circumvent the low reactivity of the C-4 position, we developed the SEM-switch that transfers the SEM-group from N-1 to N-3 nitrogen and thus enables prepn. of 4-arylimidazoles and sequential C4-C5-arylation of the imidazole core.  Furthermore, selective N3-alkylation followed by the SEM-group deprotection (trans-N-alkylation) allows for regioselective N-alkylation of complex imidazoles.  The sequential C-arylation enabled by the SEM-switch allowed us to produce a variety of mono-, di-, and triarylimidazoles using diverse bromo- and chloroarenes.  Using our approach, the synthesis of individual compds. or libraries of analogs can begin from either the parent imidazole or a substituted imidazole, providing rapid access to complex imidazole structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrxOPv_g_e07Vg90H21EOLACvtfcHk0lhNsIuSc8i8aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosFaksrs%253D&md5=25b4fe2a06bc6982640665f00c86ca2c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjo100727j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo100727j%26sid%3Dliteratum%253Aachs%26aulast%3DJoo%26aufirst%3DJ.%2BM.%26aulast%3DToure%26aufirst%3DB.%2BB.%26aulast%3DSames%26aufirst%3DD.%26atitle%3DC-H%2520bonds%2520as%2520ubiquitous%2520functionality%253A%2520a%2520general%2520approach%2520to%2520complex%2520arylated%2520imidazoles%2520via%2520regioselective%2520sequential%2520arylation%2520of%2520all%2520three%2520C-H%2520bonds%2520and%2520regioselective%2520N-alkylation%2520enabled%2520by%2520SEM-group%2520transposition%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2010%26volume%3D75%26spage%3D4911%26epage%3D4920%26doi%3D10.1021%2Fjo100727j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Molander, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trice, S. L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, S. M.</span><span> </span><span class="NLM_article-title">Scope of the two-step, one-pot palladium-catalyzed borylation/Suzuki cross-coupling reaction utilizing bis-boronic acid</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">8678</span><span class="NLM_x">–</span> <span class="NLM_lpage">8688</span><span class="refDoi"> DOI: 10.1021/jo301642v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo301642v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlygtLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2012&pages=8678-8688&author=G.+A.+Molanderauthor=S.+L.+J.+Triceauthor=S.+M.+Kennedy&title=Scope+of+the+two-step%2C+one-pot+palladium-catalyzed+borylation%2FSuzuki+cross-coupling+reaction+utilizing+bis-boronic+acid&doi=10.1021%2Fjo301642v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Scope of the Two-Step, One-Pot Palladium-Catalyzed Borylation/Suzuki Cross-Coupling Reaction Utilizing Bis-Boronic Acid</span></div><div class="casAuthors">Molander, Gary A.; Trice, Sarah L. J.; Kennedy, Steven M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8678-8688</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The use of bis-boronic acid for the direct synthesis of boronic acids has greatly facilitated the two-step, one-pot borylation/Suzuki cross-coupling reaction between aryl and heteroaryl halides.  With use of Buchwald's second-generation XPhos preformed catalyst, high yields of cross-coupled products were obtained for most substrates.  The method also allows an efficient two-step, one-pot synthesis, providing access to three distinct cross-coupled products after column chromatog.  The method also provides a rapid and convenient route to teraryl compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDMxPPa0A15rVg90H21EOLACvtfcHk0lhNsIuSc8i8aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlygtLjO&md5=80b369825dd060e4e3d243d3c85a9354</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjo301642v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo301642v%26sid%3Dliteratum%253Aachs%26aulast%3DMolander%26aufirst%3DG.%2BA.%26aulast%3DTrice%26aufirst%3DS.%2BL.%2BJ.%26aulast%3DKennedy%26aufirst%3DS.%2BM.%26atitle%3DScope%2520of%2520the%2520two-step%252C%2520one-pot%2520palladium-catalyzed%2520borylation%252FSuzuki%2520cross-coupling%2520reaction%2520utilizing%2520bis-boronic%2520acid%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2012%26volume%3D77%26spage%3D8678%26epage%3D8688%26doi%3D10.1021%2Fjo301642v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manuia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juarez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palakurthi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelais, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiDonato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epple, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsilje, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeill, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">534</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nature17960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1038%2Fnature17960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=27251290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=129-132&author=Y.+Jiaauthor=C.+H.+Yunauthor=E.+Parkauthor=D.+E.+Ercanauthor=M.+Manuiaauthor=J.+Juarezauthor=C.+X.+Xuauthor=K.+Rheeauthor=T.+Chenauthor=H.+K.+Zhangauthor=S.+Palakurthiauthor=J.+B.+Jangauthor=G.+Lelaisauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=P.+Y.+Michellysauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=M.+McNeillauthor=W.+S.+Luauthor=J.+Harrisauthor=S.+Benderauthor=K.+K.+Wongauthor=P.+A.+Janneauthor=M.+J.+Eck&title=Overcoming+EGFR%28T790M%29+and+EGFR%28C797S%29+resistance+with+mutant-selective+allosteric+inhibitors&doi=10.1038%2Fnature17960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span></div><div class="casAuthors">Jia, Yong; Yun, Cai-Hong; Park, Eunyoung; Ercan, Dalia; Manuia, Mari; Juarez, Jose; Xu, Chunxiao; Rhee, Kevin; Chen, Ting; Zhang, Haikuo; Palakurthi, Sangeetha; Jang, Jaebong; Lelais, Gerald; DiDonato, Michael; Bursulaya, Badry; Michellys, Pierre-Yves; Epple, Robert; Marsilje, Thomas H.; McNeill, Matthew; Lu, Wenshuo; Harris, Jennifer; Bender, Steven; Wong, Kwok-Kin; Janne, Pasi A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7605</span>),
    <span class="NLM_cas:pages">129-132</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutations in the EGFR kinase, but resistance arises rapidly, most frequently owing to the secondary T790M mutation within the ATP site of the receptor.  Recently developed mutant-selective irreversible inhibitors are highly active against the T790M mutant, but their efficacy can be compromised by acquired mutation of C797, the cysteine residue with which they form a key covalent bond.  All current EGFR TKIs target the ATP-site of the kinase, highlighting the need for therapeutic agents with alternative mechanisms of action.  Here we describe the rational discovery of EAI045, an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.  The crystal structure shows that the compd. binds an allosteric site created by the displacement of the regulatory C-helix in an inactive conformation of the kinase.  The compd. inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochem. assays.  However, as a single agent it is not effective in blocking EGFR-driven proliferation in cells owing to differential potency on the two subunits of the dimeric receptor, which interact in an asym. manner in the active state.  We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to the allosteric agent.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S), a mutant that is resistant to all currently available EGFR TKIs.  More generally, our findings illustrate the utility of purposefully targeting allosteric sites to obtain mutant-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQkr363w1dMLVg90H21EOLACvtfcHk0lhNsIuSc8i8aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D&md5=f4c2d2362eb900c64bad8550b9da0872</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnature17960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17960%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DErcan%26aufirst%3DD.%2BE.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%2BX.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%2BK.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DJ.%2BB.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DW.%2BS.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DOvercoming%2520EGFR%2528T790M%2529%2520and%2520EGFR%2528C797S%2529%2520resistance%2520with%2520mutant-selective%2520allosteric%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D534%26spage%3D129%26epage%3D132%26doi%3D10.1038%2Fnature17960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Greenberg, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tchou-Wong, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rom, W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. C.</span><span> </span><span class="NLM_article-title">Selective p38 activation in human non-small cell lung cancer</span> <span class="citation_source-journal">Am. J. Respir. Cell Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">558</span><span class="NLM_x">–</span> <span class="NLM_lpage">564</span><span class="refDoi"> DOI: 10.1165/ajrcmb.26.5.4689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1165%2Fajrcmb.26.5.4689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=11970907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFWkt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2002&pages=558-564&author=A.+K.+Greenbergauthor=S.+Basuauthor=J.+Huauthor=T.+A.+Yieauthor=K.+M.+Tchou-Wongauthor=W.+N.+Romauthor=T.+C.+Lee&title=Selective+p38+activation+in+human+non-small+cell+lung+cancer&doi=10.1165%2Fajrcmb.26.5.4689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Selective p38 activation in human non-small cell lung cancer</span></div><div class="casAuthors">Greenberg, Alissa K.; Basu, Sharmila; Hu, Jing; Yie, Ting-An; Tchou-Wong, Kam Meng; Rom, William N.; Lee, Theodore C.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">558-564</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">The mitogen-activated protein kinase (MAPK) pathways transmit signals from the cell membrane to the nucleus.  Activation of MAPK cascades may play a role in malignant transformation.  We hypothesized that enhanced expression of one or more of these pathways would occur in human lung cancers.  Using Western blot anal. of tissue homogenates from resected non-small cell lung cancers and matched non-neoplastic lung tissue, we detd. that only activated p38 was consistently increased in tumor compared with normal tissue.  In vitro kinase assays confirmed that the levels of activated MAPK correlated with the activity of the enzymes, and immunohistochem. anal. confirmed the cellular localization of the activated MAPKs.  We incubated a lung cancer cell line in a hypoxic chamber to simulate the hypoxic environment in solid lung tumors, but found no increase in p38 activation.  Contrary to our expectations, ERK and JNK, the MAPK pathways traditionally assocd. with cell growth and perhaps malignant transformation, were not consistently activated in the human lung tumor samples.  However, p38, a MAPK usually assocd. with stress responses, growth arrest, and apoptosis, was activated in all of the human lung cancer samples, suggesting an addnl. role for this pathway in malignant cell growth or transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIAmfxqEZ1wLVg90H21EOLACvtfcHk0liP0t84eiNVcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFWkt7g%253D&md5=f0d7d71351549557a4650e9774dd39e7</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1165%2Fajrcmb.26.5.4689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Fajrcmb.26.5.4689%26sid%3Dliteratum%253Aachs%26aulast%3DGreenberg%26aufirst%3DA.%2BK.%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DYie%26aufirst%3DT.%2BA.%26aulast%3DTchou-Wong%26aufirst%3DK.%2BM.%26aulast%3DRom%26aufirst%3DW.%2BN.%26aulast%3DLee%26aufirst%3DT.%2BC.%26atitle%3DSelective%2520p38%2520activation%2520in%2520human%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2002%26volume%3D26%26spage%3D558%26epage%3D564%26doi%3D10.1165%2Fajrcmb.26.5.4689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Duong-Ly, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, J. R.</span><span> </span><span class="NLM_article-title">A high-throughput radiometric kinase assay</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">1360</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span><span class="refDoi"> DOI: 10.1007/978-1-4939-3073-9_7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1007%2F978-1-4939-3073-9_7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=26501904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVems78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1360&publication_year=2016&pages=87-95&author=K.+C.+Duong-Lyauthor=J.+R.+Peterson&title=A+high-throughput+radiometric+kinase+assay&doi=10.1007%2F978-1-4939-3073-9_7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A High-Throughput Radiometric Kinase Assay</span></div><div class="casAuthors">Duong-Ly, Krisna C.; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1360</span>
        (<span class="NLM_cas:issue">Kinase Screening and Profiling</span>),
    <span class="NLM_cas:pages">87-95</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Aberrant kinase signaling has been implicated in a no. of diseases.  While kinases have become attractive drug targets, only a small fraction of human protein kinases have validated inhibitors.  Screening of libraries of compds. against a kinase or kinases of interest is routinely performed during kinase inhibitor development to identify promising scaffolds for a particular target and to identify kinase targets for compds. of interest.  Screening of more focused compd. libraries may also be conducted in the later stages of inhibitor development to improve potency and optimize selectivity.  The dot blot kinase assay is a robust, high-throughput kinase assay that can be used to screen a no. of small-mol. compds. against one kinase of interest or several kinases.  Here, a protocol for a dot blot kinase assay used for measuring insulin receptor kinase activity is presented.  This protocol can be readily adapted for use with other protein kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1VWJf_NuisLVg90H21EOLACvtfcHk0liP0t84eiNVcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVems78%253D&md5=27351bf4930bd2a5168b109436b17945</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-3073-9_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-3073-9_7%26sid%3Dliteratum%253Aachs%26aulast%3DDuong-Ly%26aufirst%3DK.%2BC.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DA%2520high-throughput%2520radiometric%2520kinase%2520assay%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2016%26volume%3D1360%26spage%3D87%26epage%3D95%26doi%3D10.1007%2F978-1-4939-3073-9_7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Anastassiadis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deacon, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devarajan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, J. R.</span><span> </span><span class="NLM_article-title">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1039</span><span class="NLM_x">–</span> <span class="NLM_lpage">1045</span><span class="refDoi"> DOI: 10.1038/nbt.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1038%2Fnbt.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=22037377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1039-1045&author=T.+Anastassiadisauthor=S.+W.+Deaconauthor=K.+Devarajanauthor=H.+Maauthor=J.+R.+Peterson&title=Comprehensive+assay+of+kinase+catalytic+activity+reveals+features+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</span></div><div class="casAuthors">Anastassiadis, Theonie; Deacon, Sean W.; Devarajan, Karthik; Ma, Haiching; Peterson, Jeffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1039-1045</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. protein kinase inhibitors are widely used to elucidate cellular signaling pathways and are promising therapeutic agents.  Owing to evolutionary conservation of the ATP-binding site, most kinase inhibitors that target this site promiscuously inhibit multiple kinases.  Interpretation of expts. that use these compds. is confounded by a lack of data on the comprehensive kinase selectivity of most inhibitors.  Here we used functional assays to profile the activity of 178 com. available kinase inhibitors against a panel of 300 recombinant protein kinases.  Quant. anal. revealed complex and often unexpected interactions between protein kinases and kinase inhibitors, with a wide spectrum of promiscuity.  Many off-target interactions occur with seemingly unrelated kinases, revealing how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases.  The results have implications for drug development and provide a resource for selecting compds. to elucidate kinase function and for interpreting the results of expts. involving kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUljWIhZGPkrVg90H21EOLACvtfcHk0liP0t84eiNVcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisL7E&md5=b2f705509b0e09afa46b01d4669f0515</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2017%26sid%3Dliteratum%253Aachs%26aulast%3DAnastassiadis%26aufirst%3DT.%26aulast%3DDeacon%26aufirst%3DS.%2BW.%26aulast%3DDevarajan%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DPeterson%26aufirst%3DJ.%2BR.%26atitle%3DComprehensive%2520assay%2520of%2520kinase%2520catalytic%2520activity%2520reveals%2520features%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1039%26epage%3D1045%26doi%3D10.1038%2Fnbt.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Krippendorff, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuhaus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lienau, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huisinga, W.</span><span> </span><span class="NLM_article-title">Mechanism-Based Inhibition: Deriving <i>K</i><sub>I</sub> and <i>k</i><sub>inact</sub> Directly from Time-Dependent IC<sub>50</sub> Values</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">–</span> <span class="NLM_lpage">923</span><span class="refDoi"> DOI: 10.1177/1087057109336751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=10.1177%2F1087057109336751" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=19675314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSjtLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=913-923&author=B.+F.+Krippendorffauthor=R.+Neuhausauthor=P.+Lienauauthor=A.+Reichelauthor=W.+Huisinga&title=Mechanism-Based+Inhibition%3A+Deriving+KI+and+kinact+Directly+from+Time-Dependent+IC50+Values&doi=10.1177%2F1087057109336751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based inhibition: deriving KI and kinact directly from time-dependent IC50 values</span></div><div class="casAuthors">Krippendorff, Ben-Fillippo; Neuhaus, Roland; Lienau, Philip; Reichel, Andreas; Huisinga, Wilhelm</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">913-923</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The potential of enzyme inhibition of a drug is frequently quantified in terms of IC50 values.  Although this is a suitable quantity for reversible inhibitors, concerns arise when dealing with irreversible or mechanism-based inhibitors (MBIs).  IC50 values of MBIs are time dependent, causing serious problems when aiming at ranking different compds. with respect to their inhibitory potential.  As a consequence, most studies and ranking schemes related to MBIs rely on the inhibition const. (KI) and the rate of enzyme inactivation (kinact) rather than on IC50 values.  In this article, the authors derive a novel relation between potentially time-dependent IC50 values and KI, kinact parameters for different types of inhibition.  This allows for direct estn. of KI and kinact values from time-dependent IC50 values, even without the need of addnl. preincubation expts.  The application of this approach is illustrated using a fluorimetric assay to access the drug-drug interaction potential assocd. with new chem. entities.  The approach can easily be implemented using std. software tools (e.g., XLfit) and may also be suitable for applications where mechanism-based inhibition is a desired mode of action (e.g., at particular pharmacol. drug targets).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSOIpe0vN8JLVg90H21EOLACvtfcHk0liYTnL-XegS0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSjtLjF&md5=93cb5f8644c7e1bdf872cf46756039cf</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1177%2F1087057109336751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057109336751%26sid%3Dliteratum%253Aachs%26aulast%3DKrippendorff%26aufirst%3DB.%2BF.%26aulast%3DNeuhaus%26aufirst%3DR.%26aulast%3DLienau%26aufirst%3DP.%26aulast%3DReichel%26aufirst%3DA.%26aulast%3DHuisinga%26aufirst%3DW.%26atitle%3DMechanism-Based%2520Inhibition%253A%2520Deriving%2520KI%2520and%2520kinact%2520Directly%2520from%2520Time-Dependent%2520IC50%2520Values%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2009%26volume%3D14%26spage%3D913%26epage%3D923%26doi%3D10.1177%2F1087057109336751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU','PDB','2JIU'); return false;">PDB: 2JIU</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i131"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00316">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_38667"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00316">10.1021/acs.jmedchem.7b00316</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Additional chemistry (schemes and description); all general methods; experimental section of materials, intermediates and precursors; metabolic stability determination in vitro (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_005.pdf">PDF</a>)</p></li><li><p class="inline">SMILES molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_002.csv">CSV</a>)</p></li><li><p class="inline">3D coordinates of proteins for docking studies: <b>31a</b> covalently docked with <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_001.pdb">PDB</a>)</p></li><li><p class="inline">3D coordinates of proteins for docking studies: <b>6a</b> covalently docked with <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_003.pdb">PDB</a>)</p></li><li><p class="inline">3D coordinates of proteins for docking studies: <b>6a</b> Glide docked with <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIU">2JIU</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_004.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_001.pdb">jm7b00316_si_001.pdb (400.95 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_002.csv">jm7b00316_si_002.csv (3.56 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_003.pdb">jm7b00316_si_003.pdb (393.06 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_004.pdb">jm7b00316_si_004.pdb (393.4 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00316/suppl_file/jm7b00316_si_005.pdf">jm7b00316_si_005.pdf (703.46 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-13%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00316" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00316" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a5f96aea122f0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
